<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"><channel><title><![CDATA[The GC Playbook]]></title><description><![CDATA[Seasoned, practical legal insight for the people who run in-house legal and finance — General Counsel, Chief Legal Officers, Heads of Legal Ops, and CFOs.

]]></description><link>https://www.thegcplaybook.law</link><image><url>https://substackcdn.com/image/fetch/$s_!paAx!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F275263ca-d184-4778-a8ff-afac21ce937f_1280x1280.png</url><title>The GC Playbook</title><link>https://www.thegcplaybook.law</link></image><generator>Substack</generator><lastBuildDate>Wed, 18 Nov 2026 16:21:04 GMT</lastBuildDate><atom:link href="https://www.thegcplaybook.law/feed" rel="self" type="application/rss+xml"/><copyright><![CDATA[John LaRocca]]></copyright><language><![CDATA[en]]></language><webMaster><![CDATA[laroccaj@substack.com]]></webMaster><itunes:owner><itunes:email><![CDATA[laroccaj@substack.com]]></itunes:email><itunes:name><![CDATA[John LaRocca]]></itunes:name></itunes:owner><itunes:author><![CDATA[John LaRocca]]></itunes:author><googleplay:owner><![CDATA[laroccaj@substack.com]]></googleplay:owner><googleplay:email><![CDATA[laroccaj@substack.com]]></googleplay:email><googleplay:author><![CDATA[John LaRocca]]></googleplay:author><itunes:block><![CDATA[Yes]]></itunes:block><item><title><![CDATA[When Your Law Firm Shuts Down — The CLO’s Playbook for the Weil Dissolution THE GC PLAYBOOK In-House Intelligence for Life Sciences Legal]]></title><description><![CDATA[FROM THE EDITOR]]></description><link>https://www.thegcplaybook.law/p/when-your-law-firm-shuts-down-the</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/when-your-law-firm-shuts-down-the</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 18 Nov 2026 12:31:07 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!-hwg!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p></p><div><hr></div><h2>FROM THE EDITOR</h2><p>Every CLO has lived through a key partner leaving in the middle of a matter. You get the call and the transition memo, and you take the new firm&#8217;s word that the conflicts check is &#8220;a formality.&#8221; It is disruptive, but it is manageable, because the old firm is still there to hand over the file.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>Weil, Gotshal &amp; Manges is a different problem. On November 10, roughly 97% of Weil&#8217;s partners voted to wind the firm down. A 95-year-old firm with about 1,200 lawyers and more than $2 billion in revenue will stop practicing. Its lawyers are dispersing to Kirkland, Gibson Dunn, Sidley, Paul Weiss, Cravath, Davis Polk, Skadden, Latham and others, a group at a time. Remaining equity partners will be deemed withdrawn by December 31.</p><p>If your company has a live matter at Weil, you have about six weeks to decide where it goes and to make sure it actually gets there. The firm doing the handing over is closing as it goes.</p><p>This issue is the checklist I would want if one of my matters were on Weil&#8217;s docket. It is also a reminder for the rest of us that the stability of a law firm is now a diligence item.</p><p><em>Sources: Bloomberg Law (Oct. 28 and Nov. 6, 2026); Reuters (Oct. 28&#8211;29, Nov. 12, 2026); Law.com/The American Lawyer (Nov. 10, 2026); ABA Journal (Nov. 13, 2026); Vargas Partners; Managing IP. Reported lateral moves are as reported and may change. I have no information about any Weil client&#8217;s matters, and nothing here is legal advice.</em></p><p><em>&#8212; John LaRocca</em></p><div><hr></div><h2>WHAT HAPPENED IN 60 SECONDS</h2><p><strong>The exodus.</strong> Nearly 60 partners left Weil or announced departures in 2026, more than half of them after August. They included:</p><ul><li><p>Corporate/M&amp;A chair Michael Aiello and five M&amp;A partners, to Cravath;</p></li><li><p>private equity co-heads Doug Warner and Chris Machera, to Paul Weiss;</p></li><li><p>securities litigation head Caroline Zalka, to Paul Weiss;</p></li><li><p>litigators Drew Tulumello and Chantale Fiebig, to Davis Polk;</p></li><li><p>regulatory partners Andrew Dean and Christopher Mulligan, to Skadden.</p></li></ul><p><strong>The failed rescue.</strong> Merger talks with Vinson &amp; Elkins and then Willkie Farr went nowhere. On October 25, Ramona Nee, elected to succeed Barry Wolf as executive partner, said she would not take the role.</p><p><strong>The decision.</strong> On October 28, the management committee recommended an &#8220;orderly wind-down,&#8221; and on November 10 the partners approved it by about 97%. The process is meant to be solvent and out of court. It is advised by AlixPartners, C Street Advisory Group and Davis Polk, and run by a three-person wind-down committee.</p><p><strong>Where the lawyers are going, as reported:</strong></p><ul><li><p>Gibson Dunn: a 120-lawyer private funds group, including co-managing partner Jonathon Soler, starting in January.</p></li><li><p>Kirkland: about 40 lawyers, including Nee, in January.</p></li><li><p>Sidley: in talks for about 200 people.</p></li><li><p>Latham and Skadden: IP lawyers.</p></li></ul><p><strong>The deadline that matters.</strong> A November 5 memo told remaining equity partners they will be deemed withdrawn by year-end. Partners who give notice now can leave immediately and keep their right to a later profit distribution. The firm said it &#8220;will continue serving clients&#8221; during the wind-down.</p><div><hr></div><h2>THE DATE THAT MATTERS IS DECEMBER 31</h2><p>The headline is the vote. The operational fact is the memo. Once equity partners are deemed withdrawn at year-end, the people who supervise your matter will have left. The firm&#8217;s incentive structure has already flipped: a partner who resigns today keeps economic rights, and one who waits gains nothing.</p><p>Expect three things between now and January:</p><p><strong>Teams will split.</strong> A group moving to one firm may not include the associate who knows your file, the paralegal who maintains your docket, or the partner who argued the last motion. Lateral packages are negotiated around books of business and practice groups, not around your matter.</p><p><strong>The infrastructure will thin.</strong> Docketing, records, litigation support, IT and billing staff are on 90-day pay. The people who can export a document review database or confirm a court deadline may leave before the lawyers do.</p><p><strong>Court and deal calendars will not wait.</strong> No tribunal pauses because counsel&#8217;s firm is dissolving. A response date, an expert deadline, a closing condition or a regulatory filing that falls in December is your problem, not Weil&#8217;s.</p><div><hr></div><h2>THE CLIENT CHOOSES</h2><p>The first principle is simple and is often forgotten in a lateral scramble. <strong>The matter belongs to the client, not to the departing lawyer and not to the dissolving firm.</strong> The ethics rules and bar guidance on departing lawyers consistently treat the choice of counsel as the client&#8217;s. The firm and the lawyer must tell you what is happening, and your files must follow your instructions.</p><p>That has a practical consequence. Do not let the transition memo make the decision for you. A letter saying &#8220;Partner X is joining Firm Y and your matter will move with her&#8221; is a proposal. Before you accept it, answer three questions:</p><ol><li><p><strong>Is the team that knows the matter actually moving together?</strong> Get names, not group descriptions.</p></li><li><p><strong>Can the receiving firm take the matter?</strong> Conflicts, protective-order eligibility and, for some matters, court or regulatory approval all come first.</p></li><li><p><strong>Is this the right moment to re-compete the matter?</strong> A forced transition is also a natural point to revisit staffing, rates and fee structure. That is not opportunism; you are signing a new engagement letter either way.</p></li></ol><div><hr></div><h2>THE TRANSITION LIST: SEVEN WORKSTREAMS</h2><h3>1. Litigation: Substitution and Deadlines</h3><p>In most courts, counsel cannot simply leave a case. Withdrawal requires leave of court unless substitute counsel appears. Bankruptcy and other court-supervised engagements may require a new retention application.</p><p>For each Weil litigation matter, confirm:</p><ul><li><p>who will file the substitution and by when;</p></li><li><p>that no deadline falls inside the transition window without a named owner;</p></li><li><p>that the docketing calendar has been exported and reconciled against the court docket itself, not against Weil&#8217;s internal system.</p></li></ul><h3>2. Protective Orders and Prosecution Bars</h3><p>This is the life sciences issue. See the box below.</p><h3>3. Conflicts at the Receiving Firm</h3><p>The receiving firm will run its own conflicts check on your matter, and the result may surprise you. A firm with a large life sciences practice may represent your competitor, the generic filer in your next Hatch-Waxman case, or the counterparty in your licensing dispute.</p><p>Ask for the result in writing before you sign the engagement letter, including:</p><ul><li><p>any ethical screens required for incoming lawyers;</p></li><li><p>any advance waivers the firm will ask you to give.</p></li></ul><p>Do not give a broad advance waiver to solve a transition problem.</p><h3>4. Transactions: Opinions, Agents and the Long Tail</h3><p>For deals, the risk is in the obligations that outlast the closing:</p><ul><li><p>legal opinions Weil delivered or is scheduled to deliver;</p></li><li><p>escrow-agent, paying-agent or notice-recipient roles naming the firm or a Weil lawyer;</p></li><li><p>post-closing roles in milestone, CVR or earnout disputes, and indemnity claims where Weil&#8217;s lawyers hold the institutional knowledge;</p></li><li><p>pending regulatory filings (HSR, CFIUS, foreign merger control) where Weil is counsel of record.</p></li></ul><p>Each needs a named replacement and, where a contract or filing designates the firm, a written amendment or notice.</p><h3>5. Files, Data and Privilege</h3><p>Your file is more than the document management system. Inventory and transfer:</p><ul><li><p>the DMS file;</p></li><li><p>email correspondence;</p></li><li><p>document review databases hosted by e-discovery vendors under Weil&#8217;s contracts;</p></li><li><p>deal data-room access;</p></li><li><p>expert and consultant work product;</p></li><li><p>litigation-hold data Weil preserved on your behalf.</p></li></ul><p>Three rules apply:</p><ul><li><p><strong>Transfer privileged material only to counsel of record.</strong> Use an agreed method and a chain of custody.</p></li><li><p><strong>Get vendor-hosted data moved before Weil&#8217;s vendor contracts lapse.</strong> Otherwise a review platform can go dark mid-matter.</p></li><li><p><strong>Get written confirmation of what was returned, what was transferred and what was destroyed,</strong> signed by someone with authority at the wind-down committee level.</p></li></ul><h3>6. Money</h3><p>Reconcile before year-end:</p><ul><li><p>final invoices;</p></li><li><p>unbilled work in progress;</p></li><li><p>unapplied retainers and credits;</p></li><li><p>any alternative-fee, capped-fee or success-fee arrangement.</p></li></ul><p>Ask how a fixed or contingent fee will be apportioned between Weil and the receiving firm. Do not pay twice for the same transition work.</p><p>There is also a question for the partners rather than for you, but it affects you. Who is entitled to profits on &#8220;unfinished business&#8221;? New York&#8217;s highest court (<em>In re Thelen LLP</em>, 2014) and the California Supreme Court (<em>Heller Ehrman LLP v. Davis Wright Tremaine</em>, 2018) both held that pending hourly matters are not partnership property of a dissolved firm. Weil&#8217;s partnership agreement and the ten former partners who have reportedly retained counsel over the firm&#8217;s assets will sort out the rest. Your concern is narrower: make sure no partner dispute delays your file or your final bill. Have your counsel confirm current law in the relevant jurisdictions before relying on either case.</p><h3>7. Malpractice Tail and Insurance</h3><p>Claims arising from work Weil performed may surface after the firm is gone. Ask the wind-down committee to confirm in writing:</p><ul><li><p>the professional liability tail coverage;</p></li><li><p>its limits;</p></li><li><p>the notice address for claims.</p></li></ul><p>Record the answer in the matter file. You will not get a second chance to ask.</p><div><hr></div><h2>BOX1: THE PROTECTIVE ORDER PROBLEM</h2><p><em>For life sciences CLOs with Hatch-Waxman, BPCIA or other confidential-information litigation at Weil</em></p><p>Patent cases between brand and generic or biosimilar companies run on protective orders that limit the other side&#8217;s confidential information to designated outside counsel. Many of those orders:</p><ul><li><p><strong>name or require disclosure of individual attorneys</strong> who may see &#8220;outside counsel eyes only&#8221; material;</p></li><li><p><strong>impose patent prosecution bars</strong> on anyone who sees technical confidential information. Courts evaluate these under <em>In re Deutsche Bank Trust Co. Americas</em> (Fed. Cir. 2010);</p></li><li><p><strong>tie access to the attorney&#8217;s firm,</strong> with notice and objection periods before new people may see designated material.</p></li></ul><p>When a Weil team moves, the same lawyers continue under a new firm name. The order may still require new designations, notice to the other side and time for objections. The other side&#8217;s information already in Weil&#8217;s systems must be handled, returned or destroyed exactly as the order specifies.</p><p><strong>The receiving firm&#8217;s prosecution practice becomes your problem.</strong> If the new firm prosecutes patents in the same technical field for other clients, opposing counsel may object to your lawyers&#8217; access. At minimum, they will use the moment to renegotiate.</p><p><strong>Ask now:</strong></p><ol><li><p>Does each of our protective orders require notice or consent before a lawyer&#8217;s change of firm takes effect?</p></li><li><p>Does the receiving firm have a patent prosecution practice in the relevant field, and how will the bar be maintained?</p></li><li><p>Who at Weil certifies the return or destruction of the other side&#8217;s material, and when?</p></li></ol><p>The cost of a missed step here is not a scheduling issue. It is a motion to disqualify your trial team in the year your exclusivity is decided.</p><div><hr></div><h2>BOX 2: THE LETTER TO SEND THIS WEEK</h2><p><em>Request in writing from Weil (copying the wind-down committee) and from the proposed receiving firm:</em></p><ul><li><p><strong>Matter list.</strong> Every open matter, with the responsible partner, the team members and each person&#8217;s destination firm.</p></li><li><p><strong>Deadlines.</strong> All court, agency and contractual deadlines through March 31, 2027.</p></li><li><p><strong>Data inventory.</strong> All client data held at Weil or by its vendors, with the planned transfer method and date.</p></li><li><p><strong>Protective orders.</strong> Each order affected, with the notice and consent steps required.</p></li><li><p><strong>Deal roles.</strong> All opinions, agent roles and notices naming Weil or a Weil lawyer.</p></li><li><p><strong>Money.</strong> A final billing reconciliation covering billed, unbilled, retainers and AFAs.</p></li><li><p><strong>Insurance.</strong> The tail coverage and the claims-notice contact.</p></li><li><p><strong>Receiving firm conflicts.</strong> Written results, including any screens or waivers sought.</p></li><li><p><strong>One name.</strong> A single transition coordinator at each firm, accountable to you.</p></li></ul><div><hr></div><h2>THE BROADER LESSON: FIRM STABILITY IS A DILIGENCE ITEM</h2><p>Weil did not collapse because of a malpractice verdict or a fraud. Its revenue grew less than 3% in 2025 while the largest firms grew more than 13%. It fell from ninth to twentieth in profits per partner over six years. In a market where the most sought-after partners can command more than $25 million a year, it lost the partners who held the client relationships. Stroock dissolved in 2023, and Dewey &amp; LeBoeuf and Howrey ended in bankruptcy before that. The pattern is not new. The scale is.</p><p>For the legal department, that means three changes to how outside counsel is managed:</p><p><strong>Hire the lawyer, document the firm.</strong> Most CLOs already know their relationship is with a person. Make the contract reflect it: outside counsel guidelines should require prompt notice of any departure of the responsible partner, any merger negotiation and any firm-level event affecting staffing.</p><p><strong>Watch the signals.</strong> Partner departures in a practice group, failed merger talks, leadership succession problems and lagging financial performance are all public and are all reported. Someone on your team should be reading them for every firm handling a bet-the-company matter.</p><p><strong>Do not put a company-defining matter in one firm without a plan B.</strong> For your largest litigation and most significant transactions, know which firm you would move to, whether it is conflicted, and how long the move would take. You will not need the plan often. When you do, you will need it within weeks.</p><div><hr></div><h2>THREE WORKSTREAMS</h2><h3>IMMEDIATE &#8212; If You Have Weil Matters</h3><p>Send the letter in the box this week. Build a single tracker covering every Weil matter: destination firm, substitution status, protective-order steps, data transfer, deal roles, final billing and tail coverage. Set December 15 as your internal deadline, not December 31. The last two weeks of the year will be the worst time to find a missing step.</p><p><strong>BUSINESS IMPACT:</strong> The transition will happen whether you manage it or not. If you do not manage it, the lateral market will decide where your matter goes, your docket will be reconstructed from memory, and opposing counsel will choose when to raise the protective order.</p><div><hr></div><h3>NEAR-TERM &#8212; Add a Firm-Event Clause to Your Outside Counsel Guidelines</h3><p>Amend outside counsel guidelines and engagement letters to require written notice within five business days of:</p><ul><li><p>the departure of a responsible partner;</p></li><li><p>merger or combination negotiations;</p></li><li><p>a dissolution or wind-down vote;</p></li><li><p>a material change in professional liability coverage.</p></li></ul><p>Require a transition plan on request. Require the firm to cooperate with file and data transfer at no charge.</p><p><strong>BUSINESS IMPACT:</strong> The clause costs nothing to add at renewal. It turns news you would otherwise learn from a trade publication into an obligation the firm owes you.</p><div><hr></div><h3>STRATEGIC &#8212; Map Your Panel Concentration</h3><p>List your top ten matters by business impact and the firm handling each. For each, identify:</p><ul><li><p>the backup firm;</p></li><li><p>whether it is conflicted;</p></li><li><p>how long a move would take.</p></li></ul><p>Review the list annually alongside firm-health signals. Report it to the general counsel&#8217;s leadership team or the audit committee as part of legal risk reporting.</p><p><strong>BUSINESS IMPACT:</strong> Concentration risk is a term every CFO understands. Applying it to outside counsel is the kind of operational discipline that changes how the C-suite views legal. It is the shift Issue #18 described.</p><div><hr></div><blockquote><p><em>&#8220;[The firm] will continue serving clients with the dedication and excellence that have defined it.&#8221;</em></p><p><em>&#8212; Weil, Gotshal &amp; Manges statement, as reported by Bloomberg Law (Oct. 28, 2026)</em></p><p>Make sure that sentence is true for your matters by December 15.</p></blockquote><div><hr></div><p>Ive prepared a Law Firm Exit and Transition Toolkit. It can be found at https://laroccaadvisory.gumroad.com/l/ydsysd.</p><p></p><div><hr></div><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!-hwg!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!-hwg!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!-hwg!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/224801520?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!-hwg!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!-hwg!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9e9e7959-3a50-432d-aac4-b90a8c613a24_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><p></p><h2>ABOUT THE AUTHOR</h2><p><em>John LaRocca is a New York and New Jersey-barred attorney with 37 years of legal experience, including approximately 26 years as GC or CLO at specialty pharma and biotech companies including Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. His transactions include the Aerie/Alcon acquisition (~$930M) and Y-mAbs/SERB acquisition ($412M, 105% premium). He runs LaRocca Advisory Services, a fractional CLO practice for PE-backed specialty pharma and commercial-stage biotech. Subscribe at laroccaj.substack.com.</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Wrong File — What Amgen’s Vectibix Warning Letter Teaches About the Form 2253 Record]]></title><description><![CDATA[THE GC PLAYBOOK In-House Intelligence for Life Sciences Legal]]></description><link>https://www.thegcplaybook.law/p/the-wrong-file-what-amgens-vectibix</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-wrong-file-what-amgens-vectibix</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 15 Nov 2026 12:31:19 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!IwDF!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2>FROM THE EDITOR</h2><p>At the end of a previous issue, I said I would cover the unsolicited-request defense. The facts went somewhere else, and I think somewhere more useful.</p><p>On October 27, FDA posted an August 12 warning letter to Amgen about a promotional video for Vectibix, its colorectal cancer drug. The letter says the video makes convenience claims and &#8220;entirely omits risk information,&#8221; even though the drug carries a boxed warning. It is addressed to Amgen&#8217;s Chairman and CEO and arrived in a year when OPDP has been sending untitled letters at a steady clip and warning letters almost never.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>Amgen&#8217;s public answer was not that FDA had read the video wrong. It was that FDA had been sent the wrong video. A spokesperson said an incorrect file &#8220;was inadvertently submitted to FDA that did not contain the required risk information.&#8221; Amgen added that the file was never publicly disseminated, the version actually used included appropriate safety information, and the correct file has since been submitted.</p><p>I have no way to test that explanation, and this issue assumes it is true. That is exactly why it matters. If Amgen is right, one of the largest biotech companies in the world received a public, CEO-addressed warning letter for misbranding, and the cause was the wrong file reaching FDA. That is a process failure in the department CLOs own, not a judgment call about promotional claims.</p><p><em>Sources: FDA Warning Letter to Amgen Inc., MARCS-CMS 739641 (Aug. 12, 2026; posted Oct. 27, 2026); Reuters and Becker&#8217;s Hospital Review reporting (Oct. 27&#8211;28, 2026); Covington &amp; Burling and The FDA Law Blog on 2026 OPDP enforcement. I have not seen Amgen&#8217;s response to FDA, and nothing here is a finding about what happened inside Amgen. Nothing here is legal advice.</em></p><p><em>&#8212; John LaRocca</em></p><div><hr></div><h2>THE LETTER IN 60 SECONDS</h2><p><strong>What FDA reviewed.</strong> A Vectibix (panitumumab) video, material code USA-954-81023, that Amgen had submitted to FDA on Form FDA 2253.</p><p><strong>What the video said.</strong> Under the header &#8220;For adult patients with wild-type RAS mCRC,&#8221; it showed &#8220;60 minutes or less of infusion time,&#8221; &#8220;No premedication&#8221; next to a crossed-out IV bag, and colon imagery.</p><p><strong>What it left out.</strong> According to FDA, all of the following:</p><ul><li><p><strong>Risk information.</strong> The video had none, including nothing from the boxed warning for dermatologic toxicity or the warnings for infusion reactions and pulmonary fibrosis/interstitial lung disease.</p></li><li><p><strong>The approved regimens.</strong> These are first-line with FOLFOX, or monotherapy after progression on fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy.</p></li><li><p><strong>The limitations of use.</strong> Vectibix is not indicated for RAS-mutant mCRC (except with sotorasib in KRAS G12C-mutated disease) or where RAS status is unknown.</p></li></ul><p><strong>The legal theory.</strong> Misbranding under FD&amp;C Act sections 502(a) and 502(n) (21 U.S.C. 352(a), (n)) and 21 CFR 202.1(e)(3)(ii)&#8211;(iii) and (e)(5). The prohibited act is introducing a misbranded drug into interstate commerce under section 301(a).</p><p><strong>What FDA asked for.</strong> Within 15 working days:</p><ul><li><p>stop the violative communications;</p></li><li><p>list every other Vectibix promotional piece with similar representations, with its 2253 submission date;</p></li><li><p>provide a plan to discontinue them;</p></li><li><p>provide a plan for corrective communications through the same media, at the same frequency and duration, to the same audiences.</p></li></ul><p>Alternatively, Amgen could explain why it believes it is not in violation.</p><p><strong>Who signed and who received it.</strong> It was signed by the Director of OPDP&#8217;s Division of Advertising &amp; Promotion Review 1 and addressed to Robert Bradway, Chairman and CEO.</p><p><strong>Timing.</strong> The letter was dated August 12 and posted October 27. Amgen&#8217;s &#8220;wrong file&#8221; statement came after the posting.</p><div><hr></div><h2>WHY THIS IS A WARNING LETTER AND NOT AN UNTITLED LETTER</h2><p>OPDP&#8217;s 2026 record makes this letter stand out. Covington&#8217;s quarterly tracker counted 10 OPDP untitled letters and no warning letters in the second quarter. By late July, The FDA Law Blog had counted 21 untitled letters for the year. Those letters cluster around a familiar set of themes:</p><ul><li><p>the full indication buried in fine print;</p></li><li><p>minimized risk;</p></li><li><p>convenience claims (a July letter objected to a TOBI Podhaler video suggesting use &#8220;in the car&#8221;);</p></li><li><p>video visuals that pull attention from the major statement.</p></li></ul><p>Vectibix fits the convenience theme exactly. Infusion time and the absence of premedication are classic convenience claims. What moved this matter up a level is the claim FDA could make about the file it had: the video contained no risk information at all for a drug with a boxed warning, and FDA called those risks potentially fatal. An untitled letter says &#8220;this is misleading.&#8221; A warning letter says &#8220;this is serious enough that we may go to court,&#8221; and this one says so: failure to correct &#8220;may result in legal action without further notice,&#8221; including seizure and injunction.</p><p>On the face of the file FDA reviewed, that escalation is defensible. A promotional video with zero risk information for a boxed-warning oncology product is about as clean a violation as OPDP sees. The problem, if Amgen is right, is that the file was not the promotion.</p><p>One point to put in perspective: OPDP warning letters are routinely addressed to the company&#8217;s CEO. The addressee here is not, by itself, a signal of personal-liability theory the way the CEO-addressed Empower letter was in Issue #13. What it does mean is that the CEO&#8217;s name sits on a public FDA document alleging the company misled physicians about a cancer drug&#8217;s safety. The CEO will ask the CLO how that happened.</p><div><hr></div><h2>WHAT FORM 2253 ACTUALLY IS</h2><p>Most CLOs know the 2253 as a regulatory-operations task: the form that goes with promotional materials to FDA. It is more than that, and this letter shows why.</p><p>For a biologic, 21 CFR 601.12(f)(4) requires the applicant to submit specimens of advertising and promotional labeling at the time of initial dissemination, accompanied by Form FDA 2253 (the drug analogue is 21 CFR 314.81(b)(3)(i)). The submission is not a request for review and is not pre-clearance. It is the company&#8217;s own signed record to FDA of what it put into the market.</p><p>That has three consequences.</p><p><strong>FDA reviews the submission, not the market.</strong> OPDP does not usually go looking for your video on a conference booth monitor. It reviews what you filed, along with complaints and surveillance. When the file and the field version differ, FDA will act on the file, because the file is the company&#8217;s representation of what it disseminated.</p><p><strong>The submission is the evidence.</strong> The letter does not say FDA saw the video in use. It cites the 2253-submitted material by its code. Under the Act, the violation is introducing a misbranded drug into commerce. When FDA&#8217;s only evidence of what was introduced is what the company told FDA it introduced, the company has handed FDA its case.</p><p><strong>The company&#8217;s own certification is the obstacle to the defense.</strong> &#8220;The file we submitted is not the file we used&#8221; is a factual defense. But it begins with an admission that the company&#8217;s signed regulatory submission was inaccurate. That is not a comfortable posture with the agency that regulates every product you sell.</p><div><hr></div><h2>THE LIMITS OF THE WRONG-FILE DEFENSE</h2><p>Assume Amgen&#8217;s explanation is entirely correct. It still answers only part of the letter.</p><p><strong>It answers the risk-omission charge.</strong> If the disseminated video carried important safety information, FDA&#8217;s central concern was not present in the market.</p><p><strong>It may not answer the indication charge.</strong> FDA also faulted the video for omitting the approved regimens and the limitations of use around RAS status. Amgen&#8217;s public statement addressed risk information. It did not say whether the disseminated version presented the full indication and the RAS limitations. The headline &#8220;For adult patients with wild-type RAS mCRC&#8221; may well appear in both versions. If the field version shared the same benefit presentation and differed only by adding safety information, part of FDA&#8217;s objection may survive. The CLO&#8217;s first question in any wrong-file situation is: what exactly is the difference between the two files, and which of FDA&#8217;s charges does that difference actually answer?</p><p><strong>It does not stop the posting.</strong> FDA dated the letter August 12 and posted it October 27. The public record does not show what Amgen told FDA in its 15-working-day response, or whether FDA has evaluated it. What the record does show is that the public learned of the &#8220;wrong file&#8221; explanation from a spokesperson after FDA&#8217;s version was already online. The company&#8217;s account and the regulator&#8217;s account reached investors in the order the regulator chose. That is the dynamic I previously described under the FDA&#8211;SEC information-sharing MOU, playing out in a promotional case.</p><p><strong>It complicates the corrective-communication request.</strong> FDA asked for corrective messages through the same media, to the same audiences, for the same duration as the original. If the violative file was never disseminated, there is no audience to correct. That is a sound argument, but it has to be made to FDA with evidence. That evidence is the dissemination record, the approved-final asset, the distribution logs, and the submission audit trail. If the company cannot produce that package quickly, the argument is only an assertion.</p><div><hr></div><h2>HOW A WRONG FILE GETS FILED</h2><p>I don&#8217;t know what happened at Amgen. In my experience, the ways a wrong file reaches FDA are few and predictable, and every one of them is a process gap rather than a judgment call:</p><ul><li><p><strong>One material code on several versions.</strong> A job code like USA-954-81023 is assigned when the piece enters review and stays on the draft, the post-comment revision and the approved final. Whoever pulls the file for submission pulls by code and gets the wrong version.</p></li><li><p><strong>Agency handoff.</strong> The creative agency renders the final cut with the ISI end-card or super, and also delivers a &#8220;clean&#8221; cut without it for other edits. Both carry the same file name.</p></li><li><p><strong>Video-specific ISI.</strong> For video, important safety information often lives in a separate track, end slate or scrolling super added late. The approved version has it; the earlier render used for timing or review does not.</p></li><li><p><strong>Submission compiled by someone outside review.</strong> Regulatory operations or a submissions vendor assembles the eCTD package from a shared drive. Nobody who sat in the MLR (medical-legal-regulatory) review checks the file that actually goes out.</p></li><li><p><strong>No binding between &#8220;approved&#8221; and &#8220;submitted.&#8221;</strong> The review system shows the piece as approved. The submission system shows a file was sent. Nothing confirms they are the same bytes.</p></li></ul><p>Each of these has a simple fix. Most companies have not made it, because until a letter like this one, the 2253 felt like paperwork.</p><div><hr></div><h2><em>BOX: BEFORE THE 2253 GOES OUT</em></h2><p><em>Six controls for the promotional review and submission process</em></p><p><em><strong>One version, one identifier.</strong> The approved final gets its own identifier or version suffix, distinct from every draft. Submission pulls by that identifier.</em></p><p><em><strong>Lock the approved file.</strong> Capture the approved asset&#8217;s file hash (a digital fingerprint, such as SHA-256) at MLR sign-off. The submission compiler checks that hash before filing. If it does not match, the submission stops.</em></p><p><em><strong>Two-person check on video and audio.</strong> For any non-print piece, someone who participated in MLR review views the exact submission file end to end, including the ISI track or super. That person attests to it in writing.</em></p><p><em><strong>Agency deliverable rules.</strong> Agency contracts require a single labeled &#8220;APPROVED FINAL&#8221; rendition per material code, with no unlabeled alternates. Delivery logs identify which file is the dissemination master.</em></p><p><em><strong>Dissemination log.</strong> The commercial team records which file was used where (booth, field force, website, congress, paid media) and when. If FDA ever cites a file you did not use, this log is your defense.</em></p><p><em><strong>Periodic reconciliation.</strong> Each quarter, sample 2253 submissions and compare the filed asset against the disseminated asset. Treat any mismatch as a deviation with a root-cause investigation.</em></p><div><hr></div><h2>THE 15-WORKING-DAY RESPONSE</h2><p>When an OPDP warning letter arrives, the CLO has three weeks to make decisions that will shape the public record for years. Five questions to settle in the first 48 hours:</p><ol><li><p><strong>Is FDA&#8217;s description of the material accurate?</strong> Pull the 2253 package FDA cites and the disseminated version. Compare them frame by frame before anyone drafts a word.</p></li><li><p><strong>Which charges does each fact answer?</strong> Map every FDA objection (risk omission, indication, limitations of use, claims) against each version. Do not let a strong answer to one charge carry the others.</p></li><li><p><strong>Do we comply, contest or both?</strong> The letter offers a route for a company that believes it is not in violation. Using that route requires evidence: a dissemination log, the approved asset, distribution data and the submission audit trail. Decide early whether you can build that package in 15 working days.</p></li><li><p><strong>What is the &#8220;similar materials&#8221; universe?</strong> FDA asks for every promotional piece with similar representations and its 2253 submission date. That inventory is an admission if it is over-inclusive and a credibility problem if it is under-inclusive. Assign one owner.</p></li><li><p><strong>Who needs to know before posting?</strong> Warning letters are posted, and you will not control when. Investor relations, corporate communications, the disclosure committee and the board&#8217;s compliance or audit chair should know the facts and the company&#8217;s position before the letter appears on FDA&#8217;s site, not after.</p></li></ol><div><hr></div><h2>THREE WORKSTREAMS</h2><h3>IMMEDIATE &#8212; Reconcile Your 2253 Record</h3><p>Pull a sample of 2253 submissions from the last 12 to 24 months, weighted toward video, audio and digital assets for boxed-warning products. Compare each submitted file to the disseminated version. Document the result, whether matches or mismatches, under privilege where appropriate.</p><p><strong>BUSINESS IMPACT:</strong> If a mismatch exists, you want to find it before OPDP does. A self-identified and corrected submission error is a quality event. An FDA-identified one is a public warning letter with your CEO&#8217;s name on it.</p><div><hr></div><h3>NEAR-TERM &#8212; Close the Gap Between &#8220;Approved&#8221; and &#8220;Submitted&#8221;</h3><p>Implement the six controls in the box. The two that matter most are the file-hash lock at MLR sign-off and the two-person view-through for non-print assets. Amend agency statements of work so that delivery of an unlabeled alternate render is a breach. Assign one owner for the submission step, not one owner per handoff.</p><p><strong>BUSINESS IMPACT:</strong> The fix costs a few hours per material. The failure costs a warning letter, a corrective-messaging campaign, a response to FDA prepared on a 15-working-day clock, and a news cycle in which the company explains that its own submission was wrong.</p><div><hr></div><h3>STRATEGIC &#8212; Write the OPDP Response Playbook Before You Need It</h3><p>Prepare a standing protocol for any OPDP letter. It should cover:</p><ul><li><p>the 48-hour fact pull;</p></li><li><p>the charge-by-charge mapping;</p></li><li><p>the decision on whether to comply, contest or both;</p></li><li><p>the similar-materials inventory method;</p></li><li><p>the corrective-communication argument when material was never disseminated;</p></li><li><p>the pre-posting notification list (IR, communications, disclosure committee, board).</p></li></ul><p>Rehearse it once on a past untitled letter.</p><p><strong>BUSINESS IMPACT:</strong> OPDP is sending letters at least twice a month in 2026. The question is no longer whether your company receives one. It is whether your first 48 hours are spent finding files or making decisions.</p><div><hr></div><blockquote><p><em>&#8220;The video creates a misleading impression about the drug&#8217;s FDA-approved indication and use.&#8221;</em></p><p><em>&#8212; FDA Office of Prescription Drug Promotion, Warning Letter to Amgen Inc. (Aug. 12, 2026)</em></p></blockquote><div><hr></div><p>I&#8217;ve compiled a checklist to manage FDA submissions and their aftermath. https://laroccaadvisory.gumroad.com/l/ouimkw</p><p></p><h2>COMING NEXT</h2><p>On November 10, Weil, Gotshal &amp; Manges partners voted 97% to dissolve the firm. For in-house legal departments with live matters there, the question is no longer which firm is winning the lateral market. It is where their files are going, who controls privilege during the transition, and what happens to a protective order that names lawyers who now work somewhere else. Issue #19 is the CLO&#8217;s playbook for when your law firm shuts down.</p><div><hr></div><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!IwDF!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!IwDF!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!IwDF!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/f860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1183988,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/224798750?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!IwDF!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!IwDF!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff860d0f2-6920-48c3-b4f1-29b327e5a8e5_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><p></p><h2>ABOUT THE AUTHOR</h2><p><em>John LaRocca is a New York and New Jersey-barred attorney with 37 years of legal experience, including approximately 26 years as GC or CLO at specialty pharma and biotech companies including Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. His transactions include the Aerie/Alcon acquisition (~$930M) and Y-mAbs/SERB acquisition ($412M, 105% premium). He runs LaRocca Advisory Services, a fractional CLO practice for PE-backed specialty pharma and commercial-stage biotech. Subs</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Skinny Label Wins — What Hikma v. Amarin Means for the CLO]]></title><description><![CDATA[Justice Jackson's opinion drew a line the patent bar will spend years mapping.]]></description><link>https://www.thegcplaybook.law/p/the-skinny-label-wins-what-hikma</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-skinny-label-wins-what-hikma</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 11 Nov 2026 12:31:00 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!t4kB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2>FROM THE EDITOR</h2><p>The skinny-label fight is over.</p><p>On June 4, the Supreme Court ruled 9-0 that Amarin had not plausibly alleged that Hikma actively induced infringement of its cardiovascular patents. On October 21, Amarin dropped the suit. The case that produced the Federal Circuit&#8217;s most aggressive theory of induced infringement &#8212; the one that made every generic filer with a section viii carve-out reconsider its press release strategy &#8212; ended at the pleading stage.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>The lesson is not that skinny labels are safe. The lesson is that the pleading standard is the first battlefield, and that what a generic company says about its product matters as much as what its label omits. Justice Jackson&#8217;s opinion drew a line the patent bar will spend years mapping.</p><p>This issue walks through that line and what it means for the CLO on both sides of a patent expiry.</p><p><em>Sources: Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 (U.S. June 4, 2026); law firm analysis from Choate Hall &amp; Stewart, Proskauer, Nixon Peabody, and Foley Hoag; Law360 reporting on the October 21 dismissal (terms paywalled). Nothing here is legal advice.</em></p><p><em>&#8212; John LaRocca</em></p><div><hr></div><h2>THE CASE IN 60 SECONDS</h2><p>Amarin sells Vascepa, an omega-3 drug approved to lower triglycerides in adults with severe hypertriglyceridemia &#8212; the unpatented use &#8212; and to reduce cardiovascular risk in adults already on a statin &#8212; the patented use. Hikma filed for a generic with a section viii carve-out: it adopted the unpatented triglyceride indication and carved the CV indication out of its label entirely.</p><p>Amarin sued under 35 U.S.C. &#167; 271(b), arguing that Hikma induced physicians to prescribe its generic for the patented CV use. Amarin&#8217;s theory rested on four categories of conduct: Hikma described its product as &#8220;generic Vascepa&#8221; in press releases; it cited Vascepa&#8217;s total sales figures (the bulk of which came from the CV indication) in investor materials; its label retained clinical study information about CV outcomes; and its website described the product in broad therapeutic terms without restricting it to the severe hypertriglyceridemia indication.</p><p>The Federal Circuit held those allegations were enough to survive a motion to dismiss. The Supreme Court disagreed, 9-0.</p><div><hr></div><h2>WHAT THE COURT HELD</h2><p>Justice Jackson&#8217;s opinion turned on the word &#8220;active.&#8221; Section 271(b) requires that the defendant <em>actively</em> induce infringement. That requires an affirmative act, not an omission, not silence, not standard industry language that an observer might interpret as encouragement.</p><p>The Court structured the analysis around what a complaint must plausibly allege under <em>Twombly</em> and <em>Iqbal</em>. For inducement, the plaintiff must allege facts making it plausible (not merely possible) that the defendant took active steps to encourage the infringing use.</p><p>Amarin&#8217;s allegations failed that test on each count:</p><p><strong>&#8220;Generic Vascepa.&#8221;</strong> Calling a product a generic equivalent of the branded drug is standard industry practice, with an obvious alternative explanation: the company is accurately describing its regulatory status. That obvious alternative defeats the inducement inference.</p><p><strong>Sales figures in investor materials.</strong> Citing total Vascepa sales as a market reference does not plausibly allege that Hikma was encouraging doctors to prescribe for the CV indication. The speculative chain in which the investor reads it, infers the CV use, eventually influences a prescription, is possible but not plausible.</p><p><strong>Retained clinical study information.</strong> Hikma&#8217;s label kept CV outcomes data because FDA regulations require the generic label to mirror the brand label except for the carved-out use. Following a statutory obligation is not an active step toward infringement.</p><p><strong>Broad website language.</strong> A category description without specific instruction to prescribe for the patented indication is too vague to constitute active encouragement.</p><p>The Court added a note on the structure of the analysis: the question is not whether a physician <em>could</em> read these materials as instructions to infringe. The question is whether Hikma <em>actively encouraged</em> the infringing use. Those are different questions. Reversing them was the Federal Circuit&#8217;s error.</p><div><hr></div><h2>WHAT &#8220;ACTIVE&#8221; MEANS NOW</h2><p>The Court did not hold that implicit inducement is impossible. It said inducement need not be express &#8212; a defendant can induce through implicit encouragement &#8212; but that encouragement must be &#8220;affirmative&#8221; and &#8220;clear to the relevant audience.&#8221;</p><p>That standard has two practical consequences.</p><p>First, omissions do not qualify. A generic company that carves out a patented use and says nothing about it has not induced infringement. There is no obligation to affirmatively disclaim the carved-out indication; at least not at the pleading stage.</p><p>Second, the content of affirmative communications still matters. The Court &#8220;decline[d] to put generic manufacturers between a rock and a hard place,&#8221; but it did not issue a blank check. A press release that explicitly promotes the carved-out use, a sales force trained on the patented indication&#8217;s patient population, a website that cross-references the patented benefit are a different set of facts. The case ended because Amarin&#8217;s complaint did not allege them. The holding does not say they would be insufficient if properly alleged.</p><div><hr></div><h2>THE SECTION VIII PATHWAY AFTER JUNE 4</h2><p>The section viii carve-out is the route a generic filer takes when it acknowledges that a patent covers a use, carves that use out of its label, and files its ANDA relying only on the unpatented indication. The carve-out tells FDA: I am not seeking approval for the patented use, so I am not required to certify invalidity or non-infringement.</p><p>The Federal Circuit&#8217;s pre-<em>Hikma</em> framework &#8212; particularly <em>GlaxoSmithKline v. Teva</em> &#8212; had made the section viii pathway precarious. Under that framework, ordinary commercial conduct could survive a motion to dismiss and proceed to discovery. Discovery cost was itself a deterrent to filing.</p><p><em>Hikma</em> changes the calculus at the pleading stage. A complaint must allege specific facts showing affirmative encouragement of the patented use. Standard commercial language, investor disclosures, and label compliance do not get the brand plaintiff to discovery.</p><p>For the brand CLO: the first question after a section viii filing is not whether the generic&#8217;s label omits the patented use. It is whether the generic&#8217;s pre-launch and post-launch communications contain affirmative, specific encouragement of the carved-out indication. That investigation has to start before the generic launches &#8212; after launch, the communications are already in the market.</p><div><hr></div><h2>THE LIFE SCIENCES CLO AND THE PATENT CLIFF</h2><p>The <em>Hikma</em> opinion matters most to the CLO at the company staring at a patent cliff &#8212; the period in which a key patent expires, an ANDA filer emerges, and commercial erosion begins.</p><p>The CLO&#8217;s window between a section viii filing and generic launch is typically short. Five questions to answer in that window:</p><ol><li><p><strong>What uses are patented, and which ones drive active prescriptions?</strong> The patent-indication overlap is not always obvious from the claims. A patented method claim covering cardiovascular risk reduction can cover a population that also uses the drug for severe hypertriglyceridemia.</p></li><li><p><strong>Does the ANDA filer&#8217;s proposed label retain clinical study data or cross-references that could constitute implicit encouragement?</strong> The <em>Hikma</em> holding was that statutory compliance explained the retention. If the label includes data beyond what FDA&#8217;s mirroring requirement demands, that is a different question.</p></li><li><p><strong>What is the ANDA filer saying publicly about the product&#8217;s market opportunity?</strong> Investor presentations, earnings call transcripts, and analyst day slides are in the public record from the moment of filing. Pull them before the litigation team drafts the complaint.</p></li><li><p><strong>Is the sales force trained on the carved-out indication?</strong> Training materials are discoverable and are the most direct evidence of active inducement. A <em>Hikma</em>-compliant complaint will need them.</p></li><li><p><strong>If we proceed to litigation, what specific facts support the inducement theory?</strong> Post-<em>Hikma</em>, the complaint needs to identify specific communications that constitute affirmative encouragement. Market share and commercial ambiguity are not enough. Know this before filing.</p></li></ol><div><hr></div><h2>BOX: THE LAUNCH COMMUNICATION CHECKLIST</h2><p><em>For CLOs overseeing a generic or biosimilar launch with a section viii carve-out</em></p><p>The <em>Hikma</em> standard protects ordinary commercial language. These six items are where the line is:</p><p><strong>Press releases.</strong> Does any release describe the product&#8217;s market opportunity by reference to a use the label has carved out? Review before issuance.</p><p><strong>Investor calls.</strong> Have the commercial team and IR reviewed earnings call scripts and Q&amp;A guidance for references to the patented indication&#8217;s patient population?</p><p><strong>Sales force training.</strong> Do training materials reference clinical outcomes data tied to the patented use? This is the highest-risk category &#8212; a training manual is specific, internal, and directly attributable to the company.</p><p><strong>Website and promotional materials.</strong> Does any promotional material reference the carved-out indication&#8217;s label history, clinical data, or patient population without specifically limiting it to the approved use?</p><p><strong>Medical information responses.</strong> Does the medical affairs function have written guidance on how to respond to unsolicited requests about the patented use?</p><p><strong>Post-launch monitoring.</strong> Is there a process to track physician-facing statements and review them on a rolling basis for affirmative reference to the patented indication?</p><div><hr></div><h2>THE CASE YOUR LITIGATION COUNSEL NEEDS TO HEAR</h2><p>For the brand CLO facing a section viii filing, three points that <em>Hikma</em> directly changes:</p><p><strong>The complaint must allege specific facts.</strong> Market share and commercial success data are insufficient. The complaint needs to identify specific communications &#8212; the press release language, the sales call documentation, the training material &#8212; that constitute affirmative encouragement of the patented use. A complaint pleaded on information and belief, without those facts, will not survive a motion to dismiss.</p><p><strong>Investigation has to start before launch.</strong> The filer&#8217;s pre-launch investor materials, commercial team communications, and FDA correspondence are not in the public record. A preliminary injunction motion requires the same factual specificity as the complaint. The investigation window is the period between ANDA filing and launch.</p><p><strong>The patent-indication map matters as much as the label.</strong> If multiple patents cover different aspects of the patented use, the complaint needs to allege inducement of each. A broad inducement theory resting on the full commercial footprint of the branded drug does not survive <em>Hikma</em> if each patent covers a specific method claim.</p><div><hr></div><h2>THREE WORKSTREAMS</h2><h3>IMMEDIATE &#8212; Audit Section viii Filings Against Your Patent Portfolio</h3><p>For any ANDA or 505(b)(2) filing with a section viii carve-out pending or recently resolved: map the ANDA filer&#8217;s commercial communications against the <em>Hikma</em> standard now, before the next earnings cycle adds new investor materials to the record. The analysis should cover investor presentations, the company website, and any commercial team statements attributable to the filer&#8217;s sales organization.</p><p><strong>BUSINESS IMPACT:</strong> Section viii filers that have already launched are building a commercial record. The older the launch, the harder it is to plead specific inducement facts that post-date the <em>Twombly</em> standard. The audit clock starts at filing, not at launch.</p><div><hr></div><h3>NEAR-TERM &#8212; Train the Commercial Team on Section viii Boundaries</h3><p>For the CLO overseeing a generic or biosimilar launch: draft guidance for commercial, medical affairs, and IR covering what the <em>Hikma</em> standard protects and what it does not. Address press releases, investor calls, medical information responses, and sales force training materials as separate categories &#8212; each has a different risk profile and a different review owner.</p><p><strong>BUSINESS IMPACT:</strong> One investor call reference to a carved-out indication&#8217;s patient population, without adequate qualification, creates the specific fact a brand complaint needs. The training gap is the litigation risk.</p><div><hr></div><h3>STRATEGIC &#8212; Revisit Your Section viii Label Strategy</h3><p>The label is the starting point, not the endpoint. If your company has relied on a section viii carve-out for a product already on the market, review whether post-launch commercial communications have created a gap between the carved-out label and the product&#8217;s actual commercial positioning. That gap is what a well-pleaded inducement complaint will target.</p><p><strong>BUSINESS IMPACT:</strong> A legacy launch with inadequate commercial communication controls carries greater exposure than a new launch designed around the <em>Hikma</em> standard. The retrospective audit is the higher-stakes exercise because the communications are already in the market.</p><div><hr></div><blockquote><p><em>&#8220;The question is not whether a physician could read these materials as instructions to infringe. The question is whether the defendant actively encouraged infringement through its own statements.&#8221;</em></p><p><em>&#8212; Justice Jackson, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (June 4, 2026)</em></p></blockquote><div><hr></div><div><hr></div><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!t4kB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!t4kB!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!t4kB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1183988,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/223830280?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!t4kB!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!t4kB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F80b3fab4-e8e7-47c4-93b4-150cc8549613_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><h2>ABOUT THE AUTHOR</h2><p><em>John LaRocca is a New York and New Jersey-barred attorney with 37 years of legal experience, including approximately 26 years as GC or CLO at specialty pharma and biotech companies including Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. His transactions include the Aerie/Alcon acquisition (~$930M) and Y-mAbs/SERB acquisition ($412M, 105% premium). He runs LaRocca Advisory Services, a fractional CLO practice for PE-backed specialty pharma and commercial-stage biotech. Subscribe at laroccaj.substack.com.</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The 42% Problem — Why Your CEO Thinks Legal Contributes Nothing (And What to Do About It)]]></title><description><![CDATA[It is about how you are organizing the department, and whether the CEO sees legal as an enabler or a tollbooth.]]></description><link>https://www.thegcplaybook.law/p/the-42-problem-why-your-ceo-thinks</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-42-problem-why-your-ceo-thinks</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 08 Nov 2026 12:31:18 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!oJ7A!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2>FROM THE EDITOR</h2><p>The Thomson Reuters Institute&#8217;s 2026 State of the Corporate Law Department Report dropped a number that should stop every CLO cold: 86% of GCs say legal is a significant contributor to the business. Only 17% of other C-suite executives agree. Forty-two percent say legal contributes little or nothing.</p><p>That is not a data anomaly. That is a structural problem, and it is yours to solve.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>I spent 26 years at the GC/CLO level in specialty pharma and biotech. I have been in that room, at that table, defending the department&#8217;s value to a CEO who wanted a head count reduction and a CFO who thought outside counsel billing was the only number that mattered. I know exactly how that conversation feels. What I want to tell you in this issue is what I wish someone had told me earlier: the perception gap is not about the work you are doing. It is about how you are organizing the department, and whether the CEO sees legal as an enabler or a tollbooth.</p><p>The analysis in this article draws on the Thomson Reuters 2026 State of the Corporate Law Department Report, the CLOC 2026 State of the Industry Report, Taylor Root&#8217;s 2026 US In-House Legal Restructuring Survey, and publicly available data on in-house legal hiring and department structure trends. No client information.</p><div><hr></div><h2>THE 42% PROBLEM</h2><p>Here is what the data actually says.</p><p>Regulatory compliance workload in in-house legal departments rose 63% last year. Cybersecurity workload rose 58%. Budget and headcount growth are flat. Outside counsel spending expectations dropped from 58% of departments projecting increases to 37%. Only 32% of departments expect attorney headcount growth this year.</p><p>You are being asked to do more with less while the regulatory environment is producing more complexity, not less. If you are a pharma or biotech CLO, that is not abstract &#8212; you have lived through 232 tariffs, an FDA-SEC information-sharing MOU, three warning letters in a week targeting different contractor types, and a compounding enforcement theory that did not exist 18 months ago. The law is moving.</p><p>The C-suite does not see any of that as legal&#8217;s contribution. They see it as noise. And the reason they see it as noise is that most legal departments are still organized to absorb problems, not to prevent them. The tollbooth model, legal reviews things after the business brings them, produces exactly the perception the survey describes: legal as the department that slows things down and says no.</p><p>The 42% are not wrong about what they are experiencing. They are wrong about what it would take to change it.</p><div><hr></div><h2>WHAT RESTRUCTURING ACTUALLY LOOKS LIKE</h2><p>The Taylor Root 2026 survey documents what the departments fixing this perception gap are doing differently. Three structural shifts are worth your attention.</p><p><strong>Embedding, not reviewing.</strong> The departments closing the C-suite perception gap are placing lawyers inside business units: in the commercial team, in the clinical team, in the supply chain function before decisions get made. The embedded lawyer can surface legal risk before the contract is signed, before the product decision is made, before the FDA submission is finalized. In other words, at the point where it is cheapest to address.  The GC who reviews things after the fact is a tollbooth. The lawyer embedded in the business team is an asset.</p><p>This is a structural change, not a cultural one. It requires headcount decisions and reporting-line clarity that most organizations have not made.</p><p><strong>Specialists over generalists.</strong> The same survey shows demand for in-house specialists &#8212; data privacy, IP, regulatory affairs, government investigations &#8212; outpacing supply. Generalist-heavy departments are running short on the precise skills the business needs at the moments of highest risk. The fix is not hiring more generalists; it is building a staffing model that uses outside counsel or flexible counsel for routine volume and keeps in-house headcount concentrated on the highest-stakes specialty work.</p><p>For pharma and biotech CLOs, this maps directly onto the regulatory environment. The FDA-SEC MOU (see TGP, 11/1/26) is not a generalist problem, it requires someone who can run a simultaneous disclosure and enforcement analysis. The Section 232 tariff exposure (see, TGP, 11/4/26) is not a generalist problem, it requires customs, contracts, and regulatory expertise operating in the same room. If your department is organized around generalist coverage, you will be reactive on both.</p><p><strong>Metrics that the CEO can read.</strong> Legal departments restructuring for C-suite credibility are building performance metrics, i.e. turnaround times, matter volume, budget variance, risk outcome tracking, and presenting them in business terms. This is not about proving that legal is busy. It is about demonstrating that legal is managing risk in a way the CFO and CEO can track. The difference between &#8220;we reviewed 847 contracts this quarter&#8221; and &#8220;we identified and remediated 23 tariff exposure provisions in supply agreements before the September 29 rate effective date&#8221; is the difference between overhead and contribution.</p><div><hr></div><h2>THE LIFE SCIENCES TIMING QUESTION</h2><p>The Pharmaphorum analysis of GC-hire timing in life sciences raises a question that every pre-commercial and growth-stage biotech CLO should think through carefully: not when to bring on the GC, but what the GC&#8217;s mandate looks like once they arrive.</p><p>The article&#8217;s finding is correct but incomplete. It correctly identifies the trigger-event model &#8212; hire the GC at clinical trial launch, or at a significant financing round, or at an IPO. What it does not address is what happens to the mandate after those events are behind you. The GC hired for the IPO is not necessarily the right organizational model for a commercial-stage company facing active FDA enforcement, a supply chain under tariff pressure, and an activist investor landscape in which 34% of concluded life sciences campaigns since January 2024 preceded the company&#8217;s acquisition or dissolution.</p><p>The mandate has to evolve, and the department structure has to evolve with it. Here is what that progression looks like in practice:</p><p><strong>Pre-IND / Series A:</strong> Outside counsel-heavy. A fractional GC or interim GC focused on IP protection, early licensing, and investor documentation makes more sense than a full-time hire. The CLOC data supports this &#8212; flexible counsel use is growing fastest in companies at this stage, partly because the work is episodic and partly because the talent is expensive.</p><p><strong>Clinical stage / Series B-C:</strong> First permanent GC hire. The mandate at this stage is primarily clinical trial agreements, vendor contracts, IP prosecution oversight, and regulatory submissions. The department is typically one or two lawyers and a paralegal, with outside counsel handling anything requiring deep specialty expertise.</p><p><strong>Commercial stage / pre- or post-IPO:</strong> This is where the department structure either evolves or breaks. The commercial-stage CLO faces a fundamentally different risk profile than the clinical-stage GC: active FDA oversight, payer and pricing risk, securities law obligations, employment law at scale, and M&amp;A either as buyer or target. The department that handled Phase 2 trials is not sized or structured for this. The CLO who does not make the case for restructuring at this inflection point will be managing the 42% problem two years later.</p><div><hr></div><h2>THE CASE YOUR CEO NEEDS TO HEAR</h2><p>The C-suite perception gap will not close by doing better legal work. It will close by changing how the work is organized and how its value is communicated.</p><p>The case has three parts:</p><p><strong>Prevention has a dollar value.</strong> A single FDA warning letter costs between $5M and $50M in remediation, depending on severity. A securities disclosure failure that becomes an SEC enforcement referral &#8212; which is now structurally easier given the FDA-SEC MOU &#8212; carries both direct financial exposure and reputational cost. A CVR definition that gets litigated by a PE buyer who controls the milestone calculations is a loss you will not see coming. Each of these is a legal problem that was preventable. The embedded legal model identifies the exposure before it becomes the cost.</p><p><strong>Outside counsel is not a substitute for in-house judgment.</strong> The non-delegation doctrine that FDA applied in the AI compliance warning letter (see TGP, 10/11/2026) applies equally to legal oversight: the company&#8217;s judgment obligation does not transfer to outside counsel, however capable. When the CEO says &#8220;we have outside counsel for that,&#8221; the right response is a clear account of what outside counsel does not know &#8212; the company&#8217;s regulatory history, the pending FDA inspection, the CFO&#8217;s read on the pipeline, the board&#8217;s risk tolerance. That institutional knowledge lives in-house or it does not exist.</p><p><strong>The department structure is a strategic decision.</strong> Embedding lawyers in business units, building a specialist-heavy model, investing in legal operations and metrics &#8212; these are capital allocation decisions, not departmental preferences. The CLO who presents them as such, with a business case in the CEO&#8217;s terms, is the CLO who closes the perception gap. The CLO who presents them as a request for more resources is the CLO who gets a head count reduction.</p><div><hr></div><h2>BOX: THE RESTRUCTURING DIAGNOSTIC</h2><p>Before you redesign the department, answer these six questions:</p><ol><li><p><strong>What is your matter volume by category, and where is it growing?</strong> Regulatory compliance and cybersecurity are the two fastest-growing categories nationally. What are they in your company?</p></li><li><p><strong>Where does legal learn about problems?</strong> If the answer is &#8220;when someone brings it to us,&#8221; you are running a tollbooth model. If the answer is &#8220;we are embedded in the team that makes the decision,&#8221; you are running a prevention model.</p></li><li><p><strong>How is outside counsel being used?</strong> Routine volume work handled by outside counsel at $600/hour is a budget problem. Specialty work handled by outside counsel that the in-house team then manages is a model.</p></li><li><p><strong>What can the CEO read in your quarterly report?</strong> If the answer is a list of matters and billing, that is an overhead report. If the answer is risk outcomes and business enablement, that is a contribution report.</p></li><li><p><strong>Who is the second lawyer?</strong> If the answer to the question &#8220;what happens if the GC leaves&#8221; is &#8220;we call outside counsel,&#8221; you do not have a legal department. You have a GC.</p></li><li><p><strong>What is the stage-specific risk profile for the next 18 months?</strong> The department should be sized and structured for where the company is going, not where it has been.</p></li></ol><div><hr></div><h2>WORKSTREAM 1 &#8212; IMMEDIATE: Run the Perception Diagnostic</h2><p>Survey your C-suite peers anonymously on two questions: Does legal contribute to business outcomes? Does legal make decisions faster or slower? The answers will tell you whether you have a structural problem or a communication problem. They are different interventions.</p><p><strong>BUSINESS IMPACT:</strong> The 42% perception finding is a CLO retention risk and a budget risk. C-suites that do not believe legal contributes significantly make different head count decisions than ones that do.</p><h2>WORKSTREAM 2 &#8212; NEAR-TERM: Map the Matter Volume and Restructure Around It</h2><p>Pull your last 12 months of matter volume by category, by origin (who brought the matter), and by time-to-resolution. Identify the three categories with the highest volume growth rate. Those are the candidates for embedding or specialist coverage. Present the restructuring case in budget terms.</p><p><strong>BUSINESS IMPACT:</strong> Departments that have done this restructuring are reporting faster decision-making and reduced outside counsel spend on routine matters, with in-house capacity freed for strategic work.</p><h2>WORKSTREAM 3 &#8212; STRATEGIC: Build the CLO Dashboard</h2><p>Build a quarterly CLO dashboard in business terms: risk events identified and remediated (with estimated avoided cost); transaction support (with deal value and timeline); regulatory matters (with enforcement exposure quantified); outside counsel spend vs. in-house headcount cost ratio. Present it to the board, not just the CEO.</p><p><strong>BUSINESS IMPACT:</strong> The board presentation of a CLO dashboard is the most direct structural intervention on the C-suite perception gap. It changes the audience and the accountability frame simultaneously.</p><div><hr></div><blockquote><p><strong>&#8220;86% of GCs say legal is a significant contributor to the business. 42% of other C-suite executives say legal contributes little or nothing. That gap does not close by doing better legal work. It closes by organizing the work differently.&#8221;</strong></p></blockquote><div><hr></div><p><em>I&#8217;ve created a CLO Department Restructuring Toolkit for readers interested in applying these cocepts to their functions. It can be found at https://laroccaadvisory.gumroad.com/l/igejy</em></p><h2>COMING NEXT</h2><p>We are turning to the SCOTUS finale on the skinny label &#8212; <em>Hikma v. Amarin</em>, decided June 4, 9-0, Justice Jackson writing. The Court held that a section viii carve-out plus ordinary marketing does not plausibly plead inducement; liability requires affirmative, purposeful steps to encourage infringement. Amarin dropped its suit in October. What the decision means for every generic strategy built around carve-out labels &#8212; and what your outside counsel&#8217;s inducement analysis should look like now.</p><div><hr></div><p></p><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!oJ7A!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!oJ7A!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!oJ7A!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/fc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1142812,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/223814110?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!oJ7A!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!oJ7A!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffc0ce0db-d460-4620-81c6-68b1551420fe_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><h2>ABOUT THE AUTHOR</h2><p><strong>John LaRocca</strong> is the founder of LaRocca Advisory Services, a fractional CLO practice serving PE-backed specialty pharma and commercial-stage biotech. He has served as GC/CLO at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals (acquired by Alcon, ~$930M), and Y-mAbs Therapeutics (acquired by SERB, $412M at a 105% premium). He is a member of the New York and New Jersey bars and holds a J.D. and B.A. from Columbia University. He lives in Montclair, NJ.</p><p><em>The GC Playbook publishes weekly on Substack.</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Read the Proclamation, Not the Headline]]></title><description><![CDATA[Section 232 Pharma Tariffs and Your Contracts]]></description><link>https://www.thegcplaybook.law/p/read-the-proclamation-not-the-headline</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/read-the-proclamation-not-the-headline</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 04 Nov 2026 12:30:59 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!9Oo5!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2><strong>FROM THE EDITOR</strong></h2><p>For months the generic-drug tariff has been described as a schedule: zero percent until mid-2028, then 100 percent, then 200. That schedule came from a July 21 presidential statement. A statement is not a proclamation and it is not an annex. It is not part of the legal instrument that imposes the tariff, so it is not a source of rates you can write into a contract.</p><p>The operative document is Proclamation 11020, signed April 2, 2026 under Section 232 of the Trade Expansion Act of 1962. It imposes tariffs on patented pharmaceuticals, their active ingredients and key starting materials. Generics and biosimilars are outside it &#8220;at this time.&#8221; The staged generic schedule does not appear in the proclamation or its annexes.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>That changes who needs to read it. This is a branded-company and licensee problem first, and a generic-company watch item second. This issue lays out what the text does and what your contracts need to say about it.</p><p><em>John LaRocca</em></p><p></p><h2><strong>WHAT THE PROCLAMATION DOES</strong></h2><p><strong>The baseline.</strong> 100 percent ad valorem on patented pharmaceuticals and associated active ingredients listed in Annex I.</p><p><strong>What &#8220;patented&#8221; means.</strong> As the Federal Register publication of the proclamation is summarized, a product is covered only if it has a valid, unexpired US patent and is listed in FDA&#8217;s Orange Book or Purple Book. The operative product scope is set by Annex I. Off-patent products, and products not so listed, fall outside the tariff.</p><p><strong>Country rates.</strong> 15 percent for the European Union, Japan, Korea, Switzerland and Liechtenstein, unless a lower rate applies. 10 percent for the United Kingdom, falling to zero as required by a US-UK pharmaceutical pricing agreement, with a Federal Register notice if it reaches zero. The US-UK agreement was finalized on April 2, 2026, the day the proclamation was signed, so the UK rate is on a path to zero.</p><p><strong>Company rates.</strong> Companies with a Commerce-approved onshoring plan, or expected to have one soon, pay 20 percent, rising to 100 percent on April 2, 2030. Companies with an onshoring plan and a most-favored-nation pricing agreement with HHS pay zero until January 20, 2029. The proclamation ratifies company-specific agreements listed in Annex II and lets the Commerce Secretary enter similar ones.</p><p><strong>Zero-rate categories.</strong> Orphan-only drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, chemical, biological, radiological and nuclear countermeasures, animal health products, and other specialty products Commerce identifies. The condition: the product comes from a jurisdiction with a current or forthcoming trade and security framework agreement, or meets an &#8220;urgent United States health need.&#8221;</p><p><strong>US-sourced API.</strong> Products made with US-sourced active pharmaceutical ingredient are exempt. A finished drug made abroad from US-origin API is not subject to the additional duty. For sourcing and supply agreements this is a lever: where the API can come from a US source, the tariff exposure on the finished product can fall away.</p><p><strong>Effective dates.</strong> July 31, 2026 for companies in Annex III. September 29, 2026 for everyone else.</p><p><strong>Generics.</strong> Excluded, with their ingredients and biosimilars, &#8220;at this time.&#8221; Commerce must report to the President within a year on whether circumstances warrant action on generics. That is the tail risk for generic makers. It is a report requirement, not a rate.</p><p><strong>Stacking and administration.</strong> If the ordinary duty is below the Section 232 rate, the two together equal the Section 232 rate; if the ordinary duty is higher, only the ordinary duty applies. Where more than one rate applies, the lowest governs. Drawback is available. Foreign trade zone admissions generally must be privileged foreign status.</p><h2><strong>THE SEPTEMBER 23 NOTICE: WHAT IT ADDED</strong></h2><p>Commerce&#8217;s Bureau of Industry and Security published implementing guidance on September 23 (91 FR 60360). It lists eligible jurisdictions for the zero rate (including the European Union, India, Japan, South Korea, Switzerland and Liechtenstein, Taiwan, and the United Kingdom, among others), opens an urgent-need approval process by email to pharma232@bis.doc.gov with one product per application, and adds a zero-rate heading for pharmaceutical articles used solely for clinical trials, research and development, or other non-commercial purposes. It also corrected five items in Annex I and removed five tariff codes from Annex IV.</p><p>Two practical points. The urgent-need path is case by case, with Commerce consulting USTR and HHS, so it is a request, not an entitlement. And the clinical-trial heading matters to every sponsor importing investigational supply: confirm your customs broker is using it.</p><h2><strong>WHERE THE LEGAL RISK SITS</strong></h2><p><strong>1. The rate depends on facts about the product and the company.</strong> The same active ingredient can face different rates depending on the finished product it goes into. A company&#8217;s rate depends on whether it has an onshoring plan or an MFN agreement. A legal department that treats &#8220;the tariff rate&#8221; as a single number will write contracts that cannot allocate the real cost.</p><p><strong>2. Zero and reduced rates are conditional.</strong> Onshoring plans are approved, monitored and reported on by Commerce, and Commerce may require external audits of the reports. If the executive branch finds a company committed fraud or deliberately misled the government about onshoring commitments, the Secretary may reimpose tariffs prospectively and retroactively. Separately, the Secretary may increase rates for failure to meet company commitments, with notice in the Federal Register; that provision does not expressly address retroactivity. A tariff exposure that depends on continuing compliance with a government agreement is a covenant, and should be treated like one.</p><p><strong>3. The exemption categories are narrow and fact-dependent.</strong> &#8220;Orphan-only&#8221; means every approved indication is orphan-designated. A product that adds a non-orphan indication loses the exemption, but the loss is delayed until the non-orphan indication is approved. Until then the product remains eligible. That makes the timing of a label expansion a tariff event: a sponsor planning a non-orphan supplemental application should model the rate that will apply from approval and plan supply and pricing before the approval date, not after it. Cell and gene therapy, ADC, and plasma categories depend on how Commerce and CBP classify the product.</p><p><strong>4. Patent status drives tariff status.</strong> Because coverage requires a valid, unexpired US patent and Orange Book or Purple Book listing, patent expiry and delisting change a product&#8217;s tariff status. Product lifecycle events, including exclusivity loss and the entry of generics, therefore carry a customs consequence that supply and license agreements should anticipate.</p><p><strong>5. Announcements are not law.</strong> The July 21 statement shows the risk of treating a presidential statement as a rate schedule. Contracts should key duty allocation to the proclamation, its annexes, and Federal Register notices, and should say so. A clause that refers to &#8220;announced tariffs&#8221; invites a dispute over what was announced.</p><p><strong>6. The Supreme Court ruling does not decide this tariff.</strong> In <em>Learning Resources, Inc. v. Trump</em> (February 2026), the Supreme Court held that the International Emergency Economic Powers Act does not authorize the President to impose tariffs, and the emergency duties imposed under that statute fell. Proclamation 11020 rests on a different statute, Section 232 of the Trade Expansion Act of 1962, which carries its own procedures. The ruling therefore does not, by its terms, reach the pharmaceutical tariff. It does show that tariff authority is litigated, and that the legal basis for a duty can change after contracts are signed. Another point: the proclamation notes that pharmaceuticals are exempt from other special tariffs, and that this could change if the administration replaces the duties the Court struck down. Draft the change-in-law clause to cover a replacement or additional duty, and not only a change to Proclamation 11020.</p><h2><strong>BOX: SIX QUESTIONS FOR YOUR SUPPLY AND LICENSE AGREEMENTS</strong></h2><p>1. <strong>Who is importer of record, and who bears Section 232 duty?</strong> Silence defaults to the importer, which may not be the party that controls the sourcing decision.</p><p>2. <strong>Is there a change-in-law or tariff reopener?</strong> A fixed price with no reopener leaves the supplier or the buyer holding a 15 to 100 percent swing. Define the trigger by reference to the proclamation, annexes and Federal Register notices, not announcements, and cover replacement or added duties.</p><p>3. <strong>Does the contract say which rate the price assumes?</strong> Tie price to a defined duty rate or to the buyer&#8217;s status under an onshoring or MFN agreement.</p><p>4. <strong>What happens if a party loses its conditional status?</strong> If your supplier&#8217;s or partner&#8217;s reduced rate depends on a Commerce plan, a compliance failure is a pricing event for you. Require notice.</p><p>5. <strong>Who bears retroactive increases?</strong> Allocate in advance, including audit cooperation.</p><p>6. <strong>Can US-sourced API change the answer?</strong> Where the finished product can be made with US-sourced API, say who decides and who captures the saving. Also confirm clinical supply agreements use the research heading.</p><h2><strong>WHAT CHANGES IN DEAL DILIGENCE</strong></h2><p>Onshoring plans and MFN agreements are commitments made to the government, and the proclamation does not say what happens to them in a transaction. It is silent on whether an assignment or a change of control affects an MFN agreement. In an acquisition, that silence is the diligence item: ask what the target has signed, read the agreement itself for assignment and change-of-control terms, confirm with Commerce and HHS how they would treat the transaction, and make the answer a closing condition or a price adjustment where the tariff rate depends on it. Also ask what milestones remain and what the reporting and audit exposure is. For asset deals, ask whether the agreement attaches to the entity or the product. For a carve-out, revisit the transition services and supply terms, since the separated business may lose the parent&#8217;s tariff status.</p><h2><strong>WORKSTREAM 1 &#8212; IMMEDIATE: Classify Your Own Exposure</strong></h2><p>Map every imported product, active ingredient and starting material against Annex I and the zero-rate categories. Record for each: patent and Orange/Purple Book status, origin country, whether US-sourced API is used or available, which rate applies, and who is importer of record. Do not rely on a broker&#8217;s summary without checking.</p><p><strong>BUSINESS IMPACT:</strong> The cost of a wrong classification is tariffs plus penalties plus a corrected price in contracts that assumed a different number.</p><h2><strong>WORKSTREAM 2 &#8212; NEAR-TERM: Amend Contracts That Run Past a Rate Change</strong></h2><p>Prioritize agreements with fixed pricing, long terms, or foreign contract manufacturers. Add duty allocation, a tariff reopener keyed to legal instruments, notice of loss of conditional status, and cooperation on audits.</p><p><strong>BUSINESS IMPACT:</strong> A reopener negotiated now costs a conversation. A reopener negotiated after a rate change costs leverage.</p><h2><strong>WORKSTREAM 3 &#8212; STRATEGIC: Treat Government Commitments as Covenants</strong></h2><p>If your company has, or is negotiating, an onshoring plan or MFN agreement, give it the same governance as a material contract: an owner, a milestone calendar, board visibility, and a disclosure review. For generics, watch the Commerce report on generics due within a year of the proclamation.</p><p><strong>BUSINESS IMPACT:</strong> A tariff rate that depends on keeping a promise to the government is only as stable as the compliance program behind the promise.</p><p style="text-align: center;"><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">&#8220;A tariff rate that depends on keeping a promise to the government is a covenant. Treat it like one.&#8221;</span></em></p><p style="text-align: center;"><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested readers I have created a Section 232 Pharma Tarriff Contract Drafting Toolkit. It can be found at https://laroccaadvisory.gumroad.com/l/nvuwok.</span></em></p><p style="text-align: center;"></p><p style="text-align: center;"></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!9Oo5!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!9Oo5!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!9Oo5!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1031487,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/222841513?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!9Oo5!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!9Oo5!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F12df4b61-0dd9-4ef1-983d-c578336a892b_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"></p><h2><strong>ABOUT THE AUTHOR</strong></h2><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><p style="text-align: center;"><em>&#169; 2026 LaRocca Advisory Services | laroccaj.substack.com</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Regulator Now Talks to Your Investors]]></title><description><![CDATA[What the FDA&#8211;SEC MOU Does to Your Disclosure Program]]></description><link>https://www.thegcplaybook.law/p/the-regulator-now-talks-to-your-investors</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-regulator-now-talks-to-your-investors</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 01 Nov 2026 12:30:56 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!ASru!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2><strong>FROM THE EDITOR</strong></h2><p> Over the previous additions of The GC Playbook I have written about FDA enforcement as something the company manages: the 483 response, the warning letter reply, the quality agreement with the contractor. In each, the working assumption was that the company controls the story. It decides what to disclose, when, and how to describe it.</p><p>On August 31, 2026, that assumption got weaker. The SEC and FDA signed a Memorandum of Understanding that sets up a formal channel for sharing nonpublic information about FDA-regulated products and the companies behind them. On October 2, FDA&#8217;s Transparency Roadmap added a second change: a plan to publish redacted Forms 483, inspection observation lists and establishment inspection reports, and clinical study reports for approved applications.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>Put the two together and the regulator&#8217;s version of events can reach your investors, and your securities regulator, without passing through you. This issue is about what that does to the work of the legal department.</p><p><em>John LaRocca</em></p><h2><strong>WHAT THE MOU SAYS</strong></h2><p>The SEC announced the MOU on August 31, 2026. SEC Chairman Paul Atkins and Acting FDA Commissioner Kyle Diamantas signed it. It took effect immediately and runs three years; either agency may end it on 30 days&#8217; notice. Four features matter to a general counsel.</p><p><strong>Scope.</strong> It covers nonpublic information about FDA-regulated products and the firms and individuals who make, distribute or sell them. Sharing can be proactive or on request. Its stated concern is representations to investors about the status of FDA review, product approvals, clinical results, manufacturing compliance, and marketing activity.</p><p><strong>Direction.</strong> The main flow is FDA to SEC. The MOU&#8217;s own examples, as described in law firm alerts, include FDA meeting minutes, Complete Response Letters, and correspondence with review divisions. The standard categories of FDA material are the obvious candidates for sharing and for SEC inquiry: warning letters, Form 483 observations, import alerts, and clinical hold letters. I have not seen the MOU list each of those by name, so treat that list as the practical reading of &#8220;nonpublic information about regulated firms,&#8221; not a quotation.</p><p><strong>Plumbing.</strong> Each agency names points of contact. On the SEC side they sit in the Division of Enforcement and the Division of Corporation Finance&#8217;s disclosure review program. On the FDA side they sit in the Office of the Chief Counsel and the Office of Inspections and Investigations. The agencies plan standardized request and transmittal templates. That is the difference between a favor between colleagues and a process.</p><p><strong>Limits.</strong> FDA&#8217;s sharing rests on 21 C.F.R. &#167; 20.85, which carves out trade secrets and confidential commercial information. SEC sharing back to FDA rests on 17 C.F.R. &#167; 240.24c-1 and needs confidentiality assurances. The SEC may not pass FDA-sourced information beyond its own staff without FDA&#8217;s written permission. Shared information is not treated as public, and the MOU says sharing does not waive privilege. If a FOIA request, subpoena or congressional inquiry seeks the shared material, each agency must promptly notify the other.</p><p>What the MOU does not do, as far as the summaries show, is create rights for companies. It is an operating agreement between two agencies. I found no language giving a company notice that its information was shared.</p><h2><strong>WHAT THE TRANSPARENCY ROADMAP ADDS</strong></h2><p>The October 2 roadmap is the public half of the same shift. FDA says it will build on existing datasets by proactively publishing redacted Form 483s, lists of inspection observations and establishment inspection reports where appropriate, with trade secrets and confidential commercial information redacted. It plans to publish clinical study reports for approved applications. Through rulemaking, it aims to disclose the fact that major applications (NDAs, BLAs, ANDAs) were submitted, and says it will consider company disclosure timing when releasing redacted documents.</p><p>Two cautions. First, the roadmap gives no dates for the 483, study report, or submission-disclosure commitments, and to my knowledge the submission rule has not been proposed. Second, FDA already publishes redacted Complete Response Letters (since July 2025) and said in September 2025 that it would publish future ones in real time. The direction of travel is established; the pace is not.</p><h2><strong>THE SHIFT FOR THE GC: THREE VERSIONS OF THE SAME EVENT</strong></h2><p>Take a routine event, a Form 483 after a plant inspection. Before these changes there were two versions: the one in FDA&#8217;s file and the one in the company&#8217;s 10-Q, earnings script and press release. The gap between them was rarely tested, because only the company held both.</p><p>Now there can be three: FDA&#8217;s file, the company&#8217;s public description, and what the SEC&#8217;s disclosure reviewers and enforcement staff can see side by side. A statement that the company &#8220;continues to believe its manufacturing operations are in compliance&#8221; reads differently when the reviewer holds the observation list.</p><p>That is the exposure. The company&#8217;s lawyers did not become less careful. The cost of checking them went down.</p><h2><strong>A WORKED EXAMPLE: THE REPEAT-ISSUE LETTER</strong></h2><p>The Baxter warning letter of September 29 shows the pattern. The letter on the Round Lake, Illinois sterile plant cites segregation failures, microbial control, laboratory controls and weak investigations. It says management oversight is inadequate across sites and told Baxter to assess its global operations. It also alleges that a summer cefazolin recall happened only after FDA made contact. It flags consequences including federal contract eligibility, export certification and a hold on new applications.</p><p>Nothing in this article asserts that Baxter&#8217;s disclosures were inadequate. I have not compared them to the letter. The point is structural. A letter that says &#8220;inadequate management oversight across sites&#8221; and links the recall to FDA contact is a document a disclosure reviewer would want to line up against risk-factor language, the description of quality systems in the 10-K, and any statements about the timing of the recall decision. Under the MOU, that comparison is something the SEC can request from FDA, not only something the company chooses to hand over.</p><h2><strong>FIVE QUESTIONS FOR YOUR OWN DEPARTMENT</strong></h2><p><strong>1. Who sees every piece of FDA correspondence, and who decides whether it is disclosure-relevant?</strong></p><p>In many companies regulatory affairs receives the 483, warning letter, CRL, or meeting minutes and quality owns the response. Securities counsel sees it only if someone forwards it. The MOU makes that gap a control weakness. Name the owner and the timeline, in writing.</p><p><strong>2. Can you tie every public regulatory statement to a document?</strong></p><p>Pull the last four quarters of earnings scripts and filings and for each statement about FDA status, timelines, inspection outcomes, or recall decisions, identify the source document in your files. If you cannot, assume a reviewer will ask.</p><p><strong>3. What does your 483 response now say to a second audience?</strong></p><p>Responses already go to FDA. If 483s and observation lists become public, the response commitments are read by investors too. Draft with that audience in mind, without softening what the quality team must say to FDA.</p><p><strong>4. How do trading windows and 10b5-1 plans connect to the regulatory calendar?</strong></p><p>FDA-held information about a pending CRL or inspection outcome is the kind of thing insiders may know before the market. Confirm the insider list includes regulatory affairs and quality staff who receive such correspondence, and that blackout triggers include regulatory events, not only earnings.</p><p><strong>5. What is your protocol when a subpoena, FOIA request, or SEC inquiry arrives?</strong></p><p>The agencies must notify each other of third-party demands for shared information. A company facing parallel FDA and SEC contact should assume each agency may learn what the other has. Decide in advance who coordinates privilege and who speaks to each agency.</p><h2><strong>WORKSTREAM 1 &#8212; IMMEDIATE: Build the Correspondence-to-Disclosure Pipeline</strong></h2><p>Create one intake point for every nonpublic FDA communication (483s, warning letters, untitled letters, CRLs, clinical hold letters, import alerts, meeting minutes) with a same-week review by securities counsel and a written disclosure-relevance call. Keep the call and the reasoning in the file.</p><p><strong>BUSINESS IMPACT:</strong> If an SEC reviewer asks why a 483 was not discussed in a filing, the answer should be a dated memo showing a considered judgment, not a search for who knew.</p><h2><strong>WORKSTREAM 2 &#8212; NEAR-TERM: Reconcile Filings Against the Regulatory Record</strong></h2><p>Run the four-quarter statement-to-document tie-out described above, starting with manufacturing compliance and approval-timeline language. Fix risk factors that describe FDA risks as hypothetical when an observation or letter already exists.</p><p><strong>BUSINESS IMPACT:</strong> A hypothetical risk factor for a risk that has already occurred is the form of disclosure problem that cross-checking against FDA files exposes quickly.</p><h2><strong>WORKSTREAM 3 &#8212; STRATEGIC: Prepare for Publication of Your Own 483s</strong></h2><p>Assume that redacted 483s and inspection reports will eventually be public. Decide your redaction requests in advance: which content is a trade secret or confidential commercial information, who marks it, and how you will tell FDA. Draft the next 483 response knowing investors, competitors and plaintiffs may read it.</p><p><strong>BUSINESS IMPACT:</strong> Companies that have already sorted their confidential material can respond to a publication notice in days. Companies that have not will argue about it under deadline.</p><p style="text-align: center;"><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">&#8220;The company&#8217;s lawyers did not become less careful. The cost of checking them went down.&#8221;</span></em></p><p style="text-align: center;"><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested readers I have created an FDA Disclosure Readiness Toolkit. You can find it at https://laroccaadvisory.gumroad.com/l/mfsust</span></em></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!ASru!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!ASru!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ASru!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ASru!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ASru!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!ASru!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/dc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1142812,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/222834056?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!ASru!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ASru!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ASru!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ASru!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc971099-fd48-43bd-8098-2b75501d1a36_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h2><strong>ABOUT THE AUTHOR</strong></h2><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><p style="text-align: center;"><em>&#169; 2026 LaRocca Advisory Services | laroccaj.substack.com</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Settling After the Loss — What the Liquidia/UTHR Agreement Actually Does]]></title><description><![CDATA[This article is about what happens after you lose.]]></description><link>https://www.thegcplaybook.law/p/settling-after-the-loss-what-the</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/settling-after-the-loss-what-the</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 28 Oct 2026 11:30:38 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!A9dz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h1></h1><div><hr></div><h2>FROM THE EDITOR</h2><p>My October 22 article ended with a tease about Liquidia launching YUTREPIA into the PAH and PH-ILD markets at risk, losing the Hatch-Waxman trial, and facing an injunction motion. I told you the at-risk launch was the GC&#8217;s most concentrated legal exposure.</p><p>In this article I talk about how the exposure was resolved. On September 30, the Delaware court upheld two of United Therapeutics&#8217; &#8216;327 patent claims &#8212; the ones Liquidia had conceded it infringed. Liquidia&#8217;s stock fell approximately 57 percent in a single session. Thirteen days later, on October 13, the parties filed an 8-K and announced a global settlement.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>This article is about what happens after you lose.</p><p>The Liquidia settlement is a GC primer on a sequence that the Hatch-Waxman litigation calendar produces regularly but that rarely gets examined as a legal document: adverse judgment, rapid negotiation, settlement agreement that does what the court order would not quite do, and a disclosure sequence that puts 13 days between a market-moving event and its resolution. The legal work in those 13 days is the article.</p><p>One note on sourcing: the $380.7M figure in this article comes from Liquidia&#8217;s accounting in the 8-K filing. The 8-K itself does not state that total; it reports each payment obligation separately. The merger of those obligations into a single number requires arithmetic across the document, which I have done and which should be confirmed against the full settlement agreement when it is filed.</p><p><em>John LaRocca</em></p><div><hr></div><h2>THE LITIGATION CONTEXT</h2><p>Liquidia launched YUTREPIA (treprostinil) inhalation powder into the pulmonary arterial hypertension (PAH) market in January 2024, and into the pulmonary hypertension associated with interstitial lung disease (PH-ILD) market shortly after. The launch was at risk &#8212; meaning Liquidia filed its NDA under the 505(b)(2) pathway and began commercial sales before patent litigation with United Therapeutics was resolved.</p><p>At-risk launch is the most aggressive posture available to a drug company in Hatch-Waxman litigation. It means you have concluded, on advice of counsel and after analysis of the litigation record, that the probability-weighted value of early market entry exceeds the probability-weighted cost of an adverse judgment plus injunction. That calculation requires legal analysis of both the merits (how strong are the remaining asserted patents?) and the remedy question (is an injunction automatic, or does equity review apply?).</p><p>For Liquidia, the calculus appeared favorable when the launch decision was made. By September 30, 2026, two patent claims on the &#8216;327 patent had been upheld in Delaware &#8212; claims that Liquidia had conceded it infringed. The concession meant the litigation was never about whether YUTREPIA infringed those claims. It was about whether those claims were valid. The court concluded they were.</p><p>With validity established and infringement conceded, the exposure calculus changed entirely. What remained was the injunction motion &#8212; and United Therapeutics was seeking one.</p><div><hr></div><h2>WHAT THE SETTLEMENT DOES</h2><p>The global settlement filed October 13 resolves every pending dispute between the parties, including the &#8216;327 patent litigation, disputes with distributors and PBM counterparties, and related third-party claims. It does not read like a simple patent license. It reads like a business arrangement designed to allocate the litigation&#8217;s commercial consequences among all the parties who held a piece of the exposure.</p><p><strong>The payment structure, as reported in the 8-K:</strong></p><ul><li><p>$175.0 million to United Therapeutics, net, within 30 business days of the settlement date</p></li><li><p>$145.4 million more to United Therapeutics in two installments through April 30, 2027</p></li><li><p>$21.75 million from Sandoz (a distributor counterparty) into escrow</p></li><li><p>$19.05 million from Henderson (an additional related party) into escrow</p></li><li><p>$19.45 million from PBM counterparties into escrow</p></li></ul><p>The aggregate, computing across all obligations, is approximately $380.7 million in total consideration flowing from the Liquidia ecosystem to United Therapeutics and related parties. For Liquidia itself, the direct payment obligation is $320.4 million &#8212; a number that must be understood against the company&#8217;s cash position and lender covenants, addressed below.</p><p><strong>The indication carve-out:</strong></p><p>Liquidia agreed to file with FDA to remove the PH-ILD indication from the YUTREPIA label. YUTREPIA will continue to be marketed for PAH. The PH-ILD commercial program ends.</p><p>This is a structural distinction that deserves attention. United Therapeutics did not obtain, through the settlement, a court injunction barring YUTREPIA&#8217;s sale. What it obtained was a contractual commitment &#8212; enforceable between the parties &#8212; that Liquidia will seek FDA approval of a label change that removes the contested indication from the product&#8217;s approved uses. The settlement closes a chapter of YUTREPIA&#8217;s commercial history not through a court order but through a regulatory filing.</p><p><strong>The conditioned releases:</strong></p><p>The mutual releases in the settlement do not take effect at signing. They are conditioned on FDA&#8217;s approval of the label amendment removing PH-ILD from the YUTREPIA label. Until FDA acts, the parties&#8217; legal claims remain technically live.</p><div><hr></div><h2>THE FDA-CONDITIONED RELEASE &#8212; WHY THIS MATTERS</h2><p>Patent settlement agreements are regularly structured to include conditions &#8212; regulatory approvals, milestone events, antitrust clearances &#8212; that must occur before the agreement becomes fully effective. But using FDA label approval as the triggering condition for mutual releases is a specific choice that deserves unpacking.</p><p>The conventional structure for an indication carve-out in patent litigation is an injunction or a consent decree: the court orders the defendant to stop commercializing the product for the infringing indication, and that order is self-executing. The settlement structure here is different. Liquidia is not under a court order. Liquidia has made a contract. The contract says Liquidia will file for the label change. The label change will happen only after FDA acts &#8212; which could take months.</p><p>From United Therapeutics&#8217; perspective, the conditioned release structure protects against a scenario in which Liquidia commits to a label change but FDA delays or declines to process it on the expected timeline. If FDA does not approve the label change, the release does not take effect, and UTHR retains its legal claims. The settlement is, in this sense, contingent on a regulatory outcome that neither party fully controls.</p><p>From Liquidia&#8217;s perspective, the conditioned release creates a period of legal limbo: the company has agreed to the settlement, paid or committed to pay the consideration, committed to stop promoting YUTREPIA for PH-ILD, and is waiting for FDA to process the label amendment before its claims against UTHR are formally released. During that period, YUTREPIA remains approved for both indications, but Liquidia has committed contractually not to promote one of them.</p><p>For GCs who handle settlement negotiations, the FDA-conditioned release model is worth understanding as a tool. It allows the parties to reach commercial finality on behavior (stop promoting) before obtaining legal finality on releases (FDA action), which is often the sequence that makes a deal possible when regulatory timing is uncertain.</p><div><hr></div><h2>THE LENDER CONSENT AND COVENANT RESET</h2><p>One provision in the settlement that does not appear in typical patent litigation summaries: HCR Collateral Management, Liquidia&#8217;s lender, was a party to &#8212; or at minimum a necessary counterparty to &#8212; the settlement. As a condition of the settlement, HCR raised Liquidia&#8217;s minimum cash covenant from $15 million to $45 million.</p><p>This is a significant restructuring of the credit agreement concurrent with the settlement. To understand why it matters: a minimum cash covenant is the floor below which the borrower&#8217;s cash balance cannot fall without triggering a covenant default. At $15 million, Liquidia had a relatively thin covenant cushion. At $45 million, the lender has tripled the floor &#8212; meaning Liquidia must maintain three times the pre-settlement minimum cash balance at all times while the credit agreement is outstanding.</p><p>The lender reset serves two functions. First, it protects HCR against the risk that Liquidia&#8217;s cash position deteriorates as the settlement payments flow out over the next six months &#8212; the $320.4 million in direct Liquidia obligations will reduce cash materially, and the lender wanted a higher minimum balance as a buffer against further deterioration. Second, it signals to the capital markets that the lender remains comfortable with the credit, has reviewed the settlement, and has agreed to remain in place at a restructured covenant level.</p><p>For GCs involved in any litigation that generates a significant cash payment obligation, the interaction between the settlement and the credit agreement is a parallel legal track that must run concurrently with settlement negotiation. A settlement that the lender will not consent to is not a settlement. A settlement that the lender consents to only on terms that impose new constraints on the borrower changes the company&#8217;s financial flexibility from the moment it closes.</p><div><hr></div><h3><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">BOX: THE AT-RISK LAUNCH DECISION &#8212; WHAT THE GC NEEDS BEFORE THE PRODUCT SHIPS</span></em></h3><p><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The Liquidia settlement illustrates the endpoint of an at-risk launch that goes badly. The GC&#8217;s work is to ensure the company understood the risk profile before the product shipped &#8212; and that the company is positioned to manage the consequence.</span></em></p><p><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Five things the GC needs to have in place before a Hatch-Waxman at-risk launch:</span></em></p><p><em><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">1. A litigation risk assessment that models the adverse case.</span></strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);"> Not just &#8220;we think we&#8217;ll win.&#8221; A specific analysis of what the judgment looks like if the asserted claims are upheld, what the injunction standard is in the relevant jurisdiction, and what the full commercial damage exposure is (lost profits to the patentee, reasonable royalty, potentially treble damages if the launch is found willful).</span></em></p><p><em><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">2. A lender analysis.</span></strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);"> Does the credit agreement contemplate an adverse judgment of this magnitude? Is a covenant default triggered by a judgment, an injunction, or just a cash payment? The lender needs to be in the conversation before the product ships, not after the court rules.</span></em></p><p><em><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">3. A remediation plan for the adverse case.</span></strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);"> What does the settlement look like if you lose? Who are the counterparties who need to be at the table (distributors, PBMs, third-party rebate administrators)? What contractual infrastructure needs to be in place so that a settlement negotiation can move in days, not weeks, when the judgment comes down?</span></em></p><p><em><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">4. A disclosure framework.</span></strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);"> The adverse judgment is a material event. The 8-K must go out promptly. The settlement, if reached quickly, is a second material event. The legal team needs to have the disclosure framework ready &#8212; the drafts, the review chain, the board communication &#8212; so that disclosure is not delayed while the settlement is being negotiated.</span></em></p><p><em><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">5. An indication carve-out plan.</span></strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);"> If the product has multiple indications, what does a partial resolution look like? An indication carve-out &#8212; as Liquidia executed through a label amendment commitment &#8212; is a settlement tool that may be unavailable if it was not anticipated in the commercial infrastructure. How are the revenue streams for each indication tracked separately? Can the company market to one indication cleanly after the settlement?</span></em></p><div><hr></div><h2>THE DISCLOSURE SEQUENCE</h2><p>The September 30 judgment and the October 13 settlement are both material events. The gap between them &#8212; 13 calendar days &#8212; is where Reg FD and Exchange Act Section 13 disclosure obligations intersect with the practical reality of settlement negotiation.</p><p>Liquidia disclosed the September 30 adverse judgment in a Form 8-K filed promptly after the decision. The stock fell approximately 57 percent. That disclosure was straightforward: a material adverse litigation outcome, promptly disclosed, with a clear market impact.</p><p>The October 13 settlement 8-K is the more legally interesting document. It discloses: (a) the resolution of the litigation, (b) the payment structure and aggregate obligation, (c) the indication carve-out and label amendment commitment, and (d) the lender covenant reset. Each of those items is material. Each was available as a disclosure item only after the settlement agreement was signed &#8212; because until then, they were pending negotiations that fell within the attorney-client privilege and the protection of settlement discussions.</p><p>The 13-day window is not a disclosure failure. It is the negotiation period. A company that has suffered an adverse judgment faces pressure to settle as quickly as possible, because an injunction motion remains live and the lender&#8217;s patience is not unlimited. The GC&#8217;s task during those 13 days is to close the settlement &#8212; with all its counterparties, including distributors and PBM parties who had their own exposure &#8212; fast enough that the injunction is not pursued and the company is not in default.</p><p>For public company GCs, the Liquidia sequence is a model of how patent litigation and disclosure obligations interact in compressed time. The lesson is not that 13 days is too long. The lesson is that the 13-day window has to be used to finish a complex, multi-party agreement &#8212; and the GC who has not pre-built the counterparty relationships and document infrastructure before the adverse judgment arrives is negotiating under deadline pressure with no leverage and a stock that has already moved.</p><div><hr></div><h2>WHAT THE GC ON EACH SIDE NEEDED TO GET RIGHT</h2><p><strong>Liquidia (defendant) side:</strong></p><p>The task was to convert a litigation loss into a business outcome: preserve the PAH business, eliminate the injunction risk on the PH-ILD business, pay the settlement over a timeline that the lender will accept, and close the releases against a settlement counter-party who had just won in court and had limited incentive to be generous.</p><p>Structurally, the GC needed to get four things done simultaneously: negotiate the payment terms with UTHR; coordinate the escrow obligations with Sandoz, Henderson, and the PBM counterparties; obtain lender consent and negotiate the covenant reset; and manage the disclosure obligations to the capital markets at each stage. Those are four parallel tracks that all had to close within 13 days.</p><p>The indication carve-out &#8212; preserving PAH while surrendering PH-ILD &#8212; was likely the key commercial value capture from the settlement. YUTREPIA&#8217;s PAH market position, which is not covered by the &#8216;327 patent claims that were upheld, is preserved. The company exits the settlement as a commercial business, not a company under injunction.</p><p><strong>United Therapeutics (plaintiff) side:</strong></p><p>UTHR had won. The question was whether winning in court would produce more value than a settlement. An injunction, if granted, would have cleared YUTREPIA from the PH-ILD market immediately &#8212; but injunctions in pharmaceutical patent cases are not automatic under eBay Inc. v. MercExchange, and litigation to enforce the injunction adds cost and timeline. A settlement that achieves the same commercial result &#8212; YUTREPIA out of PH-ILD &#8212; while generating $175 million upfront and $145.4 million more over six months, avoids the injunction enforcement risk and generates certain cash consideration.</p><p>The conditioned release was UTHR&#8217;s tool for ensuring the label change actually happens. Until FDA acts, UTHR retains its legal claims. The settlement is, from UTHR&#8217;s perspective, a deal that generates more certain value than an injunction proceeding &#8212; and conditions finality on the regulatory outcome that was the commercial point of the case.</p><div><hr></div><h2>WORKSTREAM 1 &#8212; IMMEDIATE: Build Your At-Risk Launch Legal Infrastructure Before the Product Ships</h2><p>The Liquidia settlement is the outcome of an at-risk launch plan that did not survive contact with an adverse judgment on a patented indication. Before the next at-risk launch in your portfolio, the legal team needs a documented framework that answers five questions:</p><p>What is the specific adverse-case analysis, including injunction standard and commercial damage exposure? What is the lender&#8217;s position if the adverse case materializes? Who are the third-party counterparties whose cooperation a rapid settlement will require? What does the disclosure framework look like for both the judgment and the settlement? And &#8212; most importantly &#8212; what is the indication carve-out plan if the product has multiple indications and only one is contested?</p><p>Those five questions are not asked enough during at-risk launch planning, because the launch decision is a commercial and litigation risk assessment, and the commercial team wins the argument. The GC&#8217;s job is to ensure that if the launch goes badly, the company has a path to resolution that preserves the business.</p><p><strong>BUSINESS IMPACT:</strong> The 13-day negotiation window between an adverse judgment and a settlement is only achievable if the infrastructure was built before the product shipped. A GC who builds the framework is positioned to close the settlement. A GC who is building the framework after the stock has fallen 57 percent is behind the timeline.</p><div><hr></div><h2>WORKSTREAM 2 &#8212; NEAR-TERM: Model the Lender Interaction in Any Litigation-Adjacent Transaction</h2><p>The HCR covenant reset is a reminder that the company&#8217;s lenders are never passive observers in material litigation. Lenders read 8-Ks. They model cash flows against covenant floors. They are forming a view about whether to consent, exercise remedies, or renegotiate terms well before they take any visible action.</p><p>Map the lender&#8217;s covenants against any adverse litigation scenario before the scenario materializes. Know, in advance, which covenants are triggered by a judgment versus a cash payment, what the notice and cure periods are, and who at the lender relationship is the right counterparty for an early conversation about a developing litigation risk.</p><p>The companies that negotiate lender covenant resets on favorable terms are the ones whose GC had the conversation with the lender relationship manager before the 8-K was filed, not after. The lender who reads about the adverse judgment in the financial press and receives a consent request in the same week is a lender operating from a defensive posture. The lender who has been in the conversation is a partner.</p><p><strong>BUSINESS IMPACT:</strong> A covenant default triggered by a litigation judgment is a separate legal crisis layered on top of the litigation itself. The GC who manages the lender relationship proactively converts that crisis into a negotiation. The GC who does not manage it converts it into a default waiver process that consumes legal resources and management bandwidth at the worst possible moment.</p><div><hr></div><h2>WORKSTREAM 3 &#8212; STRATEGIC: Understand the Multi-Party Settlement Architecture in Hatch-Waxman Litigation</h2><p>The Liquidia settlement involves not just Liquidia and United Therapeutics but also Sandoz, Henderson, and PBM counterparties &#8212; each contributing to escrow as part of the global resolution. That architecture reflects a reality that at-risk launch analyses often underweight: when a drug launches at risk through a commercial distribution network, every party in that network has litigation exposure.</p><p>Distributors who shipped the product may face conversion claims. PBMs who processed claims for the infringing indication have their own exposure under theories that range from aiding and abetting to direct participation. Third parties who manufactured, distributed, or facilitated the commercial program are not bystanders to the patent case &#8212; they are counterparties whose consent and contribution a global settlement will require.</p><p>The GC who has mapped those relationships and understood the legal theory of each party&#8217;s exposure before the launch is in a position to structure a settlement that closes all the exposure in a single agreement. The GC who discovers those relationships after the adverse judgment is managing a much more complex negotiation.</p><p><strong>BUSINESS IMPACT:</strong> A global settlement that closes all exposure is worth more than a bilateral settlement that leaves distributor and PBM claims live. Building the commercial and legal infrastructure to achieve a global settlement requires understanding, before launch, who the relevant parties are and what their exposure is.</p><div><hr></div><blockquote><p><em>&#8220;The 13-day window between an adverse judgment and a settlement is only achievable if the infrastructure was built before the product shipped. The GC who builds the framework is positioned to close the settlement.&#8221;</em></p></blockquote><div><hr></div><div><hr></div><p></p><p></p><p></p><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!A9dz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!A9dz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!A9dz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/ab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1030731,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/221839320?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!A9dz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!A9dz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fab44d72d-0f8f-47af-a949-551b2bf930b7_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h2>ABOUT THE AUTHOR</h2><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Pretextual — FDA's New Compounding Enforcement Theory and What It Means for Your Business FROM THE EDITOR ]]></title><description><![CDATA[Is it Evidence f an Enforcement Shift?]]></description><link>https://www.thegcplaybook.law/p/pretextual-fdas-new-compounding-enforcement</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/pretextual-fdas-new-compounding-enforcement</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 25 Oct 2026 11:30:35 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!T-8T!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2>FROM THE EDITOR</h2><p>The analysis in this article is based on FDA&#8217;s September 18, 2026 warning letter to Empower Pharmacy, Empower&#8217;s public statements, and publicly available information about the surrounding enforcement environment. Empower has not yet responded publicly to the warning letter&#8217;s substantive allegations, and the company&#8217;s response &#8212; when it comes &#8212; may contest or clarify the agency&#8217;s characterization of its operations. This article analyzes what the warning letter says and what its legal theory means for the GC community. It does not establish that the allegations are accurate.</p><p>With that sourcing note stated, the article.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>On September 18, 2026, FDA issued a warning letter to Empower Pharmacy &#8212; the company&#8217;s third. The letter was addressed to the company&#8217;s CEO by name. It contained a phrase that had never appeared in an FDA compounding enforcement document before: &#8220;pretextual compounding.&#8221;</p><p>That phrase is the article.</p><p>FDA did not borrow &#8220;pretextual compounding&#8221; from its own regulatory vocabulary. It appears to have drawn the phrase from arguments that Eli Lilly and Novo Nordisk had been making in federal court against 503A compounders who were manufacturing products that copied approved GLP-1 drugs in large quantities. FDA looked at what the private plaintiffs were arguing, concluded it described the conduct the agency was concerned about, and put the phrase in a regulatory enforcement document.</p><p>When the regulator starts borrowing the plaintiff&#8217;s bar&#8217;s language and putting it in warning letters, something has changed in the enforcement posture. This article explains what changed, what the warning letter actually says, and what it means for any company that sells to, buys from, or operates in the 503A/503B compounding space.</p><p><em>John LaRocca</em></p><div><hr></div><h2>THE ENFORCEMENT THREAD</h2><p>Empower Pharmacy is a Houston-based 503A compounding pharmacy &#8212; one of the country&#8217;s largest. A 503A pharmacy compounds medications for individual patients pursuant to a prescription, as opposed to a 503B outsourcing facility, which can compound in larger quantities without patient-specific prescriptions.</p><p>The FDA warning letter of September 18, 2026 is the company&#8217;s third. The first and second letters addressed sterility and manufacturing practice concerns following prior inspections. The September 18 letter &#8212; which FDA issued following a November 2025 inspection of Empower&#8217;s Houston facility &#8212; escalates significantly. It addresses not just manufacturing deficiencies but the legal theory under which FDA contends Empower&#8217;s entire GLP-1 compounding program is operating.</p><p>That distinction matters. A warning letter addressing manufacturing practices is a compliance remediation problem. A warning letter challenging the legal basis for a compounding program raises a different question: FDA is asserting that the activity itself &#8212; not just how the activity is being conducted &#8212; may fall outside the statutory exemption that permits it. Whether that assertion is correct is a question the company&#8217;s response and, potentially, subsequent proceedings will address.</p><p>The broader context: FDA&#8217;s shortage-based authorization for GLP-1 compounding under the Federal Food, Drug, and Cosmetic Act was tied to semaglutide and tirzepatide appearing on the Drug Shortage list. FDA removed semaglutide from the shortage list earlier in 2026 and has indicated that the tirzepatide shortage designation is under review. As that authorization narrows, FDA&#8217;s enforcement posture has hardened across the 503A compounding sector generally. This letter is one data point in that broader pattern.</p><div><hr></div><h2>THE PRETEXTUAL COMPOUNDING STANDARD</h2><p>Section 503A of the Federal Food, Drug, and Cosmetic Act permits a licensed pharmacist or physician to compound a drug for an identified individual patient pursuant to a prescription. 503A compounded drugs are exempt from the Act&#8217;s new drug approval requirements, the requirement for adequate directions for use, and FDA&#8217;s current good manufacturing practice regulations &#8212; a significant regulatory carve-out.</p><p>That carve-out is conditioned on several requirements, two of which are central to the September 18 letter.</p><p>First, a 503A pharmacy cannot compound drugs &#8220;regularly or in inordinate amounts&#8221; that are essentially copies of commercially available drug products. Second, when a drug copies an approved product, the prescribing practitioner must provide a statement that the commercially available product does not meet the patient&#8217;s needs &#8212; a &#8220;significant difference&#8221; determination &#8212; and the compounded product must be clinically different in a meaningful way.</p><p>According to the warning letter, FDA&#8217;s position is that Empower&#8217;s GLP-1 compounding program fails on both counts. On the &#8220;regularly or in inordinate amounts&#8221; prohibition, the letter points to production volumes that FDA characterizes as inconsistent with patient-specific prescription compounding for identified individual patients. On the significant-difference requirement, the letter identifies two specific alleged failures: prescribers using identical pre-generated significant-difference statements (which FDA interprets as suggesting the statements are platform-generated rather than individually authored), and significant-difference determinations that FDA contends do not identify a specific patient need that the commercially available product cannot meet.</p><p>The word &#8220;pretextual&#8221; appears in FDA&#8217;s characterization of the conduct the agency believes it is seeing: the regulatory exempt pathway, FDA contends, is being used as a pretext for large-scale manufacturing of products that copy commercially available approved drugs, rather than as a genuine patient-specific compounding operation. The 503A exemption was designed to permit individual patient care; FDA&#8217;s theory is that using it as a gateway to scale pharmaceutical manufacturing falls outside what Congress intended the exemption to cover.</p><p>That framing is new in FDA enforcement documents. FDA has challenged specific compounding practices for years. What it had not previously done was characterize a compounding program as pretextual at the theory level &#8212; asserting that the structural premise of the program&#8217;s claim to the 503A exemption is defective. Whether that theory holds up, and whether Empower&#8217;s response demonstrates that the facts have been characterized inaccurately, are open questions.</p><div><hr></div><h2>WHERE THE LANGUAGE CAME FROM</h2><p>The phrase &#8220;pretextual compounding&#8221; does not appear to have originated at FDA. It appears in federal court filings.</p><p>Eli Lilly and Novo Nordisk each filed litigation against 503A compounders selling products that copied their GLP-1 therapies. Among the arguments those plaintiffs made: the compounders&#8217; 503A claims were pretextual because no pharmacist was actually compounding individualized medications for specific patients. The 503A exemption requires patient-specific prescriptions and individual patient care; the plaintiffs&#8217; argument was that large-scale manufacturing using the exemption as a shield was not what the statute was designed to permit.</p><p>FDA&#8217;s warning letter uses similar framing. Whether the agency deliberately adopted private plaintiffs&#8217; language, independently arrived at the same characterization, or the convergence is coincidental is not established by the document itself. What is clear is that the phrase now appears in a regulatory enforcement document, and that its meaning in that context &#8212; an agency allegation that a statutory exemption is being misused &#8212; carries enforcement consequences different from those of a private lawsuit.</p><p>For GC practice, the mechanism is worth noting regardless of how the Empower matter ultimately resolves. Private litigation against a regulated company or industry generates legal theories that the regulator may read and, in some cases, adopt. When sophisticated private plaintiffs develop arguments that challenge a practice the regulator also views skeptically, the regulator&#8217;s subsequent enforcement documents sometimes reflect those arguments. The Lilly and Novo suits produced a partial dismissal in 2026 &#8212; some claims survived, others did not &#8212; and the outcome of those suits does not determine the enforceability of FDA&#8217;s warning letter theory. But the convergence between private litigation theory and agency enforcement framing is a pattern that GCs in regulated industries should track.</p><div><hr></div><h2>THE CEO LIABILITY DIMENSION</h2><p>The September 18 warning letter was addressed to Arta Shaun Noorian, CEO of Empower Pharmacy, by name and title.</p><p>FDA warning letters are typically addressed to the company. When they are addressed to an individual officer by name, the agency is signaling something about personal exposure &#8212; that the identified person may face individual accountability for the violations described, separate from the company&#8217;s liability.</p><p>The legal basis for personal liability in FDA enforcement derives from United States v. Park, 421 U.S. 658 (1975). Under the Park doctrine, a corporate officer who has the authority and responsibility to prevent or correct a violation of the Act can be held criminally liable for the violation &#8212; without proof that the officer had actual knowledge of the violation or acted with criminal intent. The standard is position and responsibility, not knowledge or intent.</p><p>The Park doctrine has been a background feature of FDA enforcement for decades. Its direct application is most common in criminal prosecutions. A warning letter addressed to a CEO by name puts the officer on notice that FDA is tracking personal responsibility &#8212; that if the violations are not corrected, and if FDA pursues criminal enforcement, the CEO&#8217;s individual exposure is on the table. This is true regardless of whether the company ultimately contests and prevails on the underlying violations; the signal the naming convention sends is about the agency&#8217;s framing of accountability at the time the letter is issued.</p><p>For any GC whose company is in a regulated industry subject to FDA jurisdiction, the personal CEO liability dimension of this letter carries a structural lesson. The GC who creates a compliance infrastructure in which the CEO is informed about material FDA regulatory risks when they are identified &#8212; not after the warning letter arrives &#8212; serves two purposes: it is genuinely better governance, and it creates a record demonstrating that when violations occurred, the officer acted responsibly within the limits of what was known. That record is the most available defense against Park liability.</p><div><hr></div><h3><em><span data-color="#1155cc" style="color: rgb(17, 85, 204);">THE 503A SIGNIFICANT-DIFFERENCE REQUIREMENT &#8212; WHAT FDA&#8217;S ALLEGATIONS TARGET</span></em></h3><p><em><span data-color="#1155cc" style="color: rgb(17, 85, 204);">The significant-difference determination is the compounding pharmacy&#8217;s most legally consequential document under 503A when the product copies a commercially available drug. It is also, based on the Empower warning letter, the element FDA contends is inadequate in high-volume compounding operations.</span></em></p><p><em><span data-color="#1155cc" style="color: rgb(17, 85, 204);">Under FDA&#8217;s reading of 503A, when a compounding pharmacy compounds a drug that is essentially a copy of a commercially available approved product, the prescribing practitioner must attest that the commercially available product does not meet the specific patient&#8217;s needs. FDA&#8217;s allegations in the Empower letter focus on three compliance failures it contends it observed:</span></em></p><p><em><strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);">Pre-generated statements.</span></strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);"> FDA alleges that identical significant-difference statements appeared across multiple prescriptions &#8212; which FDA interprets as inconsistent with genuine individualized clinical determinations. Whether the company&#8217;s response will demonstrate that the statements reflected common clinical scenarios rather than automated generation remains to be seen.</span></em></p><p><em><strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);">Inadequate clinical grounding.</span></strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);"> FDA contends that statements in the record did not identify specific patient needs that the commercially available product could not meet. This is a factual allegation that the company&#8217;s clinical documentation may address.</span></em></p><p><em><strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);">Third-party platform generation.</span></strong><span data-color="#1155cc" style="color: rgb(17, 85, 204);"> FDA&#8217;s letter raises the concern that significant-difference statements may have been produced by third-party platforms rather than authored by prescribers. This is an allegation about process; the company&#8217;s response may contest it or provide context that FDA did not have at inspection.</span></em></p><p><em><span data-color="#1155cc" style="color: rgb(17, 85, 204);">The compliance lesson for any GC reviewing 503A operations is straightforward regardless of how Empower&#8217;s matter resolves: the significant-difference determination protocol &#8212; who generates it, how it is documented, whether prescriber attestations are individualized and clinically specific &#8212; is where FDA&#8217;s enforcement attention is concentrating. A compliance audit of that protocol is warranted in any high-volume 503A operation.</span></em></p><div><hr></div><h2>WHERE THE THREAD STANDS NOW</h2><p>Two developments after the September 18 warning letter extend the enforcement pattern:</p><p><strong>Apothecary Pharma Class II recall (October 8, 2026).</strong> FDA and Apothecary Pharma announced a Class II recall of 22 lots of compounded tirzepatide products. A Class II recall involves products that may cause temporary or reversible adverse health consequences. The Apothecary recall is unrelated to Empower&#8217;s warning letter &#8212; Apothecary is a different 503A pharmacy &#8212; but it occurred within weeks of FDA&#8217;s Empower action. Whatever the individual facts of each situation, the enforcement environment around compounded GLP-1s is not a single-company story.</p><p><strong>FDA patient advisory (October 2026).</strong> FDA issued a public advisory warning patients against using compounded GLP-1 products, citing risks associated with dosing accuracy, sterility, and product identity. The advisory is directed at patients, not companies, but its content reflects FDA&#8217;s stated regulatory position: compounded GLP-1 products carry risks that commercially approved products do not.</p><p>The September 18 warning letter, the Apothecary recall, and the FDA patient advisory form a three-point pattern at the sector level: a major enforcement action against a large 503A compounder, a safety recall from a different 503A compounder, and a public advisory warning patients away from compounded GLP-1s generally. Whether that pattern reflects coordinated enforcement strategy or convergent individual actions, the GC of any company with 503A exposure should be tracking it.</p><div><hr></div><h2>WHAT THE GC NEEDS TO UNDERSTAND</h2><p>The Empower warning letter and the surrounding enforcement pattern have implications beyond the compounding pharmacy sector. Three categories of companies need GC-level attention to this development.</p><p><strong>Companies that supply 503A compounders.</strong> API suppliers, equipment vendors, testing labs, and distribution partners who serve 503A compounding pharmacies should understand the scope of those relationships and the FDA exposure that could accompany them if the enforcement ramp reaches criminal prosecution. The supply relationship is not automatically a shield against individual exposure.</p><p><strong>Healthcare systems and prescription platforms that channel prescriptions to 503A compounders.</strong> The significant-difference documentation allegation in the Empower letter &#8212; specifically, the use of pre-generated statements from third-party platforms &#8212; points at the prescription-generation infrastructure that high-volume compounding operations use. If a telemedicine platform or prescription management system generates the significant-difference statements attached to compounding prescriptions, that platform&#8217;s own compliance exposure in a hardening enforcement environment is a question its GC should be examining.</p><p><strong>Any regulated company watching FDA&#8217;s enforcement doctrine develop.</strong> The pretextual compounding theory is, at the level of regulatory doctrine, an assertion that a statutory exemption has limits &#8212; that a company cannot use an exemption as a business model if the underlying activity is not what the exemption was designed to permit. That doctrinal move is not unique to compounding. Regulated companies in any sector operating under statutory exemptions should review their compliance posture against the question FDA is implicitly asking: is the use of this exemption genuinely consistent with its purpose? Whether or not the theory succeeds against Empower, it is now in an FDA enforcement document, and the GC community needs to understand it.</p><div><hr></div><h2>WORKSTREAM 1 &#8212; IMMEDIATE: Audit Your 503A Exposure Map</h2><p>If your company has any relationship with the 503A compounding sector &#8212; as a supplier, a customer, a distribution partner, or a prescription-channeling platform &#8212; the first legal task is an exposure map. Who are your compounding counterparties? What products do you supply to them or receive from them? What volume of those products involves commercially available approved drugs? What does your contractual allocation of FDA compliance obligations look like?</p><p>This is a defensive audit, not a remediation project. The point is not to terminate relationships with compounding pharmacies. The point is to understand, before FDA&#8217;s enforcement actions reach your counterparties, what the exposure profile is and what your disclosure and response framework looks like.</p><p><strong>BUSINESS IMPACT:</strong> Companies that understand their 503A exposure map before a warning letter arrives at a counterparty are in a materially better position than companies that discover their exposure when the enforcement news breaks. The difference is preparation time &#8212; and preparation time is the most valuable resource in a regulatory enforcement sequence.</p><div><hr></div><h2>WORKSTREAM 2 &#8212; NEAR-TERM: Map the Personal Liability Doctrine for Your CEO and C-Suite</h2><p>The Park doctrine is not new law. Every GC in a regulated industry should already have a working knowledge of it. But the Empower letter&#8217;s direct CEO naming is a reminder that the doctrine is live and that FDA is willing to invoke it in enforcement documents.</p><p>The near-term workstream is a review of your compliance information flow: when the CEO and other C-suite officers are informed about material regulatory risks, in what form, and what documentation exists of that information flow. The GC who can demonstrate that the CEO was informed about a compliance risk, received a remediation recommendation, and responded appropriately has built a factual record that is the best available defense against Park liability. The GC who cannot demonstrate that information flow has not built that record.</p><p>This is a compliance governance review: does your company&#8217;s regulatory reporting structure ensure that the right people know about the right risks at the right time, and does your documentation infrastructure support that?</p><p><strong>BUSINESS IMPACT:</strong> The personal liability dimension of FDA enforcement is the dimension most likely to generate board-level concern and executive-level attention to compliance investment. The GC who uses the Empower letter to open a structured conversation about C-suite regulatory reporting is using an external event to advance an internal governance improvement that benefits the company regardless of whether FDA enforcement ever reaches it.</p><div><hr></div><h2>WORKSTREAM 3 &#8212; STRATEGIC: Track the Regulatory Doctrine Adoption Pipeline</h2><p>The pretextual compounding story is a specific instance of a regulatory phenomenon worth tracking: enforcement doctrine that originates in private litigation and later appears in agency enforcement documents. The Lilly/Novo litigation theories and FDA&#8217;s warning letter language converge around the same characterization. The migration of analytical framing from courtroom to agency enforcement document &#8212; whatever its precise mechanism &#8212; happened faster than most companies in the 503A space anticipated.</p><p>The strategic workstream is a systematic approach to monitoring private litigation against your industry &#8212; not just as legal risk in its own right, but as a potential leading indicator of regulatory enforcement framing. Private plaintiffs with sophisticated legal teams develop theories about conduct they believe is unlawful. Those theories, when they resonate with the regulatory record the agency has independently compiled, sometimes appear later in agency enforcement documents.</p><p>For the compounding sector specifically: the Lilly and Novo suits continue. There are additional defendants, additional claims, and additional briefing cycles ahead. Each brief is a potential data point. The GC of any company with 503A exposure should be tracking those filings with that lens in mind.</p><p><strong>BUSINESS IMPACT:</strong> Regulatory doctrine that migrates from private litigation typically provides a window &#8212; months, sometimes longer &#8212; between its articulation in court filings and its appearance in agency enforcement documents. That window is compliance review time. The GC who uses it is addressing risk before enforcement. The GC who misses it is addressing risk after enforcement &#8212; which is a different problem with much lower leverage.</p><div><hr></div><blockquote><p><strong>PULL QUOTE:</strong> &#8220;A warning letter challenging the legal basis for a compounding program raises a different question than one addressing manufacturing deficiencies. FDA is asserting that the structural premise of the 503A claim may be defective. Whether that assertion holds up is an open question &#8212; but the theory is now in an FDA enforcement document.&#8221;</p></blockquote><div><hr></div><h2>COMING NEXT</h2><p>Baxter International received a management oversight letter from FDA in the aftermath of the Hurricane Helene supply disruption &#8212; a letter that raises questions about the scope of FDA&#8217;s authority to require management accountability for supply chain resilience, not just for product quality. What the letter says, what it doesn&#8217;t say, and what it means for every pharmaceutical company whose supply chain runs through a single critical manufacturing site. Issue #14.</p><div><hr></div><p></p><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!T-8T!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!T-8T!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!T-8T!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/dfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1031487,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/221824763?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!T-8T!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!T-8T!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfde10d5-dd59-4420-9ad0-46a45b172fbd_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h2>ABOUT THE AUTHOR</h2><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><div><hr></div><p><em>&#169; 2026 LaRocca Advisory Services | laroccaj.substack.com</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The CVR Is the Deal]]></title><description><![CDATA[A $12 CVR is not an incidental feature. It is the deal.]]></description><link>https://www.thegcplaybook.law/p/the-cvr-is-the-deal</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-cvr-is-the-deal</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Thu, 22 Oct 2026 11:31:45 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!tpO0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<h2>FROM THE EDITOR</h2><p>The Curium-Lantheus deal closed in the press as an $8 billion take-private. That number is accurate the way a settlement described as &#8220;up to $500 million&#8221; is accurate &#8212; it is the ceiling, not the floor, and the distance between them is the document.</p><p>The distance here is $12 per share. Curium is paying $102.50 in cash at closing. The rest &#8212; up to $12 per share in contingent value rights tied to Lantheus sales milestones through 2030 &#8212; depends entirely on what happens inside a company that will no longer be public, reporting to no one with any obligation to care whether the CVR pays out.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>That tension is the GC&#8217;s work on both sides of this deal. On the Lantheus side, the CVR document is the last protective instrument for shareholders who cannot hold onto their stock. Every definition of &#8220;net sales,&#8221; every competing business covenant, every dispute resolution mechanism is a substantive legal question that determines whether $12/share is real money or a number in a press release. On the Curium side, the CVR is a contingent liability of up to $720 million or more, secured by operating covenants that bind a PE-controlled company to the commercial strategy of an asset it just acquired in order to take it off the market.</p><p>This is a deal where the economic gap between headline and closing value is as wide as any I have seen in a straightforward cash transaction. The $12 CVR is not an incidental feature. It is the deal.</p><p><em>John LaRocca</em></p><div><hr></div><h2>THE TRANSACTION</h2><p>CapVest Partners-backed Curium announced the acquisition of Lantheus Holdings (NASDAQ: LNTH) in a transaction that packages a clean cash offer with a milestone structure that will run for more than three years after closing.</p><p>The headline terms: $102.50 per share in cash plus up to $12.00 per share in contingent value rights tied to Lantheus net sales milestones through December 31, 2030. At $102.50, the cash component alone represents a 21 percent premium to Lantheus&#8217;s unaffected closing price on May 21, 2026 &#8212; the last trading day before rumors of a deal appeared in the financial press. The 60-day volume-weighted average price premium is 38 percent. Total deal value at full CVR payout is approximately $8 billion; equity value at closing, assuming the CVRs pay nothing, is approximately $6.9 billion.</p><p>Close is expected in the first half of 2027. The regulatory calendar is typical for a transaction with significant radiopharmaceutical supply chain implications: Hart-Scott-Rodino clearance, NYSE delisting mechanics, and a tender offer process that will run concurrently with the antitrust review.</p><p><strong>Lantheus</strong> is not a typical specialty pharma acquisition target. Its flagship product, PYLARIFY (piflufolastat F 18), is an FDA-approved PSMA-targeted PET imaging agent for prostate cancer &#8212; the category leader in a market that did not exist in commercial form before 2021. Its legacy product, DEFINITY (perflutren lipid microsphere), is the dominant ultrasound contrast agent in the US cardiac imaging market. The company has a radiopharmaceutical manufacturing and supply infrastructure that is genuinely difficult to replicate and a pipeline of PSMA-targeted therapeutic candidates that are pre-commercial but advancing.</p><p><strong>Curium</strong> is among the largest nuclear medicine companies in the world by volume. CapVest, its PE sponsor, acquired it in 2023. The Lantheus transaction is a consolidation of the two largest independent players in diagnostic nuclear medicine and, through Lantheus&#8217;s pipeline, a bet on PSMA-targeted therapeutic radiopharmaceuticals &#8212; a market that Bristol-Myers Squibb, Eli Lilly, and Novartis are simultaneously building from a different direction.</p><p>What Curium is buying, in simplest terms, is PYLARIFY&#8217;s current commercial trajectory, DEFINITY&#8217;s durable cash generation, and the option value in Lantheus&#8217;s therapeutic pipeline. The CVR is how the parties agreed to split the uncertainty between those three things.</p><div><hr></div><h2>WHAT A CVR ACTUALLY IS &#8212; AND WHY IT CREATES LEGAL RISK</h2><p>A contingent value right is a contractual promise by an acquirer to pay additional consideration to target shareholders if specified events occur within a defined period. In pharmaceutical M&amp;A, CVRs most often attach to pipeline milestones &#8212; regulatory approvals, phase completion, or sales thresholds for recently launched products.</p><p>The Curium-Lantheus CVR is of the sales-threshold variety: up to $12.00 per share, non-transferable, contingent on Lantheus meeting net sales milestones through December 31, 2030. The specific milestone structure &#8212; the revenue thresholds, the payment schedule, the definition of net sales &#8212; is contained in the CVR agreement itself, which is a material contract attached to the merger agreement and which Lantheus shareholders, as the CVR holders, will inherit when the merger closes.</p><p>Non-transferable means exactly what it says. A Lantheus shareholder who tenders their shares receives the $102.50 at closing and then holds a non-tradeable right to receive additional payments if milestones are hit. They cannot sell the CVR. They cannot hedge it. They sit for up to four and a half years as creditors of the acquirer on terms they did not negotiate and cannot modify.</p><p>This is where the GC&#8217;s work matters most, and where the legal record of this deal will be scrutinized if the CVR does not pay out as shareholders expected.</p><div><hr></div><h2>THE DEFINITION FIGHTS</h2><p>The most consequential drafting in any CVR agreement is the definition of the metric that triggers payment. In a sales-based CVR, that definition is &#8220;net sales&#8221; &#8212; and net sales in the pharmaceutical industry is not an accounting concept. It is a negotiated one.</p><p>The standard deductions from gross-to-net in pharmaceutical sales include:</p><ul><li><p>Chargebacks and rebates paid to government programs (Medicaid best price, 340B, VA federal ceiling price)</p></li><li><p>Managed care and commercial rebates</p></li><li><p>Distribution fees and prompt-pay discounts</p></li><li><p>Returns</p></li><li><p>Co-pay assistance and patient support programs</p></li><li><p>Allowances for uncollectible amounts</p></li></ul><p>In a product like PYLARIFY, which is sold into hospital and imaging center systems, the gross-to-net adjustment is material. Hospital GPO contracts, outpatient rebates, and government program pricing can represent a significant percentage of gross sales. The precise methodology for calculating those deductions &#8212; which programs count, how rebates are estimated and trued up, what the accounting period is &#8212; directly determines whether PYLARIFY hits the CVR milestones.</p><p>What makes this particularly pointed for the Curium deal is that PYLARIFY&#8217;s commercial trajectory is not hypothetical. The product launched in 2021, has several years of commercial history, and a reasonably well-established gross-to-net profile. But that profile was built inside a public company with its own finance function, its own contracting strategy, and its own incentives. Once Lantheus is a private subsidiary of a CapVest portfolio company, none of those incentives run directly to CVR milestone achievement. Curium controls the contracting strategy. Curium controls the pricing. Curium controls the gross-to-net calculation methodology.</p><p>The CVR agreement either constrains that discretion or it does not.</p><div><hr></div><h2>THE COMPETING BUSINESS COVENANT</h2><p>The second major drafting fight in any commercial CVR is what the acquirer is obligated to do &#8212; and not do &#8212; to give the milestone a fair opportunity to be reached.</p><p>A typical operating covenant in a sales-based CVR obligates the acquirer to use commercially reasonable efforts (or some defined variant of that standard) to promote and sell the product during the milestone period. At minimum, it prohibits the acquirer from taking actions whose principal effect is to reduce the product&#8217;s net sales below a milestone threshold while the CVR is outstanding &#8212; deliberately redirecting customers to competing products, cutting the commercial infrastructure, or abandoning contracting strategies the legacy company had in place.</p><p>For Curium, this covenant is not a formality. Curium has its own diagnostic imaging portfolio. In markets where Curium&#8217;s products and Lantheus&#8217;s products compete for the same clinical decision, Curium will face a real operational tension: maximizing the performance of its existing business or maximizing the performance of the acquired Lantheus business for CVR purposes. The covenant defines how that tension is resolved and, if it is not resolved in PYLARIFY&#8217;s favor, what the legal consequences are.</p><p>What the Lantheus GC needed in this document: a specific and enforceable standard, not a general &#8220;commercially reasonable efforts&#8221; formulation that gives the acquirer discretion to balance its own commercial portfolio against CVR obligations. The difference between &#8220;commercially reasonable efforts consistent with those historically applied by Lantheus&#8221; and &#8220;commercially reasonable efforts as determined by Curium in its business judgment&#8221; is the difference between a CVR that pays and one that litigates.</p><div><hr></div><h2>THE CALCULATION AND DISPUTE MECHANISM</h2><p>Every CVR agreement that has ever paid out less than shareholders expected has produced litigation. The instrument requires a dispute mechanism because the acquirer calculates whether its own milestone has been reached and then reports that calculation to a trustee &#8212; typically a bank &#8212; who represents the CVR holders.</p><p>CVR litigation follows a pattern. The acquirer calculates net sales, concludes the milestone was not reached (or that a lower tranche was reached), reports to the trustee, and the trustee has a defined window to object. If the trustee objects, the parties go to the resolution mechanism &#8212; typically independent auditor review with binding effect. If the trustee does not object within the window, the calculation is deemed final.</p><p>The weakest link in this chain is the trustee. CVR trustees are typically institutional trustees whose mandate is administrative, not advocacy. They verify that the calculation followed the defined methodology. They do not independently verify whether the defined methodology produces an accurate picture of what PYLARIFY actually earned. For former Lantheus shareholders who received no seat at the negotiating table for the CVR agreement and who will have no visibility into Curium&#8217;s internal accounting for the milestone period, the trustee&#8217;s capability and independence are the only substantive protections that exist.</p><p>What sophisticated CVR counsel negotiates: independent audit rights for the trustee, triggered by a shareholder demand threshold, with the acquirer bearing the cost if the audit reveals a material understatement. Without an audit right, the dispute mechanism is limited to reviewing whether arithmetic was performed correctly on numbers the acquirer supplied.</p><div><hr></div><h3>BOX: THE PE TAKE-PRIVATE DYNAMIC</h3><p>The Curium-Lantheus transaction is a PE-controlled strategic buyer acquiring a US-listed target. That combination creates an operational and governance context for the CVR that is different from a strategic-to-strategic deal.</p><p>In a public company acquirer, the executive team managing PYLARIFY post-close answers to a board with independent directors, reports to financial analysts, and operates under SEC disclosure obligations that require honest characterization of product performance. Quarterly earnings calls create a public record of what the buyer thought PYLARIFY was going to do and what it actually did.</p><p>In a PE-backed private acquirer, none of those transparency mechanisms exist. The board is the sponsor. The reporting is to LPs. There are no analyst calls about PYLARIFY&#8217;s net sales trajectory. The CVR milestone calculation, whenever it is made, will emerge from an internal accounting process that former shareholders cannot observe and, absent the contractual rights described above, cannot audit.</p><p>This is not an accusation of bad faith. It is a structural observation: the PE take-private removes the transparency infrastructure that public company status provides, and the CVR&#8217;s enforceability depends entirely on the contractual rights that remain.</p><p>European comparison: Recordati, the Italian specialty pharmaceutical company, is in the middle of its own PE take-private by CVC Capital Partners and Groupe Bruxelles Lambert. The Recordati transaction is larger &#8212; CVC and GBL launched a tender offer valued at approximately &#8364;10.73 billion ($12.47 billion) &#8212; and does not include a CVR structure of the Lantheus type, reflecting the different market context of a European delist. The common thread: PE capital is pricing pharmaceutical assets at premiums that require a view about commercial trajectories no public market was willing to fully discount.</p><div><hr></div><h2>THE 10-MONTH SIGN-TO-CLOSE WINDOW</h2><p>Curium announced the deal and expects to close it in the first half of 2027 &#8212; approximately 10 to 12 months from sign to close. For a radiopharmaceutical transaction, that window is not unusually long, but it creates a defined legal exposure that the Lantheus GC and Curium&#8217;s counsel both had to plan around.</p><p>During the sign-to-close period, Lantheus remains a public company. It continues to report quarterly financial results, manage its commercial pipeline, and answer analyst questions about PYLARIFY&#8217;s performance. Every disclosure Lantheus makes during this period is simultaneously a public statement about the target&#8217;s value, a basis for any renegotiation that adverse developments might prompt, and a baseline against which the CVR milestones will eventually be measured.</p><p>The sign-to-close period also introduces interim operating covenant risk. Lantheus agreed, as part of the merger agreement, to operate the business in the ordinary course of business consistent with past practice between signing and closing. This covenant limits Lantheus&#8217;s ability to modify pricing strategies, enter new long-term contracts, restructure its commercial organization, or adjust its gross-to-net accounting methodology &#8212; even if those changes might be beneficial for the business independent of the transaction.</p><p>For the Lantheus GC, the ordinary course covenant is a constraint on legal authority that runs for 10 or more months. Material decisions about product strategy, contracting, and customer terms require acquirer consent. The process for seeking and obtaining that consent &#8212; particularly in a radiopharmaceutical market that moves fast &#8212; is a practical management challenge that begins the day the merger agreement is signed.</p><div><hr></div><h2>WHAT THE GC ON EACH SIDE NEEDED TO GET RIGHT</h2><p><strong>Lantheus (target) side:</strong></p><p>The Lantheus GC had one primary document obligation that determined the value of the transaction for shareholders: the CVR agreement. The merger agreement&#8217;s cash terms were fixed. The CVR terms were negotiated. Every dollar of the $12 CVR&#8217;s actual probability of payment was determined by the precision of that document.</p><p>Five provisions that needed to be airtight: the net sales definition and gross-to-net methodology (including whether the methodology is locked at signing or can evolve); the operating covenant standard (specific, historical-conduct-anchored, and enforceable); the competing product covenant (does it address Curium&#8217;s existing portfolio?); the audit right and dispute mechanism (with trustee capability to exercise it); and the CVR term structure (do all $12 pay at once on a single milestone, or is it tranched across multiple thresholds, with the later tranches contingent on earlier ones being reached?).</p><p>A CVR that addresses all five of those questions with specificity is a financial instrument. One that does not is a lawsuit.</p><p><strong>Curium/CapVest (buyer) side:</strong></p><p>The Curium GC had a different but parallel task: ensuring that the operating covenants in the CVR agreement preserved the buyer&#8217;s flexibility to manage the combined business without creating de facto board-level approval requirements for every commercial decision through 2030.</p><p>The operating covenant tension is real. A CVR that obligates Curium to use commercially reasonable efforts to hit PYLARIFY net sales milestones constrains every commercial decision Curium makes about the radiopharmaceutical business for four and a half years. Pricing strategy, customer contracting, geographic prioritization, and pipeline investment are all potentially caught within the scope of a broad operating covenant. Curium&#8217;s counsel&#8217;s job was to define those obligations narrowly enough that the company retains operational flexibility while remaining enforceable enough that the CVR does not become a dead letter that Lantheus&#8217;s financial advisors characterized incorrectly to their own board.</p><p>The GC on the buyer&#8217;s side of a CVR transaction is negotiating against its own deal team &#8212; which has every incentive to promise generous operating covenants to close the deal &#8212; and against target counsel, which has every incentive to make those covenants as specific and binding as possible. That tension, between deal urgency and legal precision, is where the document ends up defining what shareholders actually received.</p><div><hr></div><h2>WORKSTREAM 1 &#8212; IMMEDIATE: Pull the CVR Agreement and Map the Definitions</h2><p>The CVR agreement is a material contract that will be attached as an exhibit to the merger agreement filed with the SEC. When Lantheus files the transaction documents &#8212; expected within weeks of announcement &#8212; the CVR agreement becomes publicly available.</p><p>For GCs with any CVR in their company&#8217;s deal history, or any pending M&amp;A transaction that might include one, the Curium-Lantheus CVR agreement is a current-market reference document for understanding how these instruments are being drafted in 2026. Pull it when it files.</p><p>The specific questions to answer on a first read: How is &#8220;net sales&#8221; defined? What gross-to-net deductions are enumerated? Is the methodology fixed at signing or subject to revision? What is the operating covenant standard &#8212; and does it reference Lantheus&#8217;s historical commercial practices as a floor? What dispute mechanism applies, and does it include an independent audit right?</p><p><strong>BUSINESS IMPACT:</strong> A GC who can read a CVR agreement and identify whether its definitions will produce the payment the press release implied is providing value that the company&#8217;s investment bankers, who structured the instrument, may not be positioned to provide. The definitions are legal work.</p><div><hr></div><h2>WORKSTREAM 2 &#8212; NEAR-TERM: Audit Your Own CVR Exposure</h2><p>The Curium-Lantheus transaction is a prompt to review any CVR obligations currently in your own company&#8217;s capital structure &#8212; as payer or potential payee.</p><p>If your company is the acquirer with outstanding CVR obligations: confirm that your operating covenant obligations are being documented in real time, that the calculation methodology is being applied consistently, and that any deviation from the defined methodology &#8212; even one that benefits the business &#8212; is getting legal review before it occurs. CVR litigation almost always traces to a moment when the acquirer made an operationally rational decision that the CVR agreement prohibited or constrained without anyone in legal being in the room.</p><p>If your company is a potential target with a CVR in any deal discussion: treat the CVR negotiation as a separate legal engagement from the merger agreement itself. The merger agreement&#8217;s cash terms get the investment bankers, the board, and the financial advisors. The CVR agreement often does not get the same level of scrutiny &#8212; and it should. The CVR is the instrument that determines whether shareholders were fairly compensated for the portion of value that was not paid at closing.</p><p><strong>BUSINESS IMPACT:</strong> CVRs that are not enforced are not free money forgiven. They are liabilities that generate litigation three years after closing when a trustee who was inadequately resourced finds that milestones were not reached, and shareholders who received no dividend and had no audit right have the merger agreement and a CVR trustee standing between them and an answer.</p><div><hr></div><h2>WORKSTREAM 3 &#8212; STRATEGIC: Understand the PE Buyer&#8217;s Governance Model</h2><p>The Curium-Lantheus deal is the most significant articulation of the PE-controlled strategic buyer model in radiopharmaceuticals. CapVest and Curium are integrating Lantheus into a portfolio company that is itself PE-controlled. The combined entity will not have public company governance &#8212; no independent directors with fiduciary obligations to public shareholders, no SEC reporting obligations, no quarterly analyst scrutiny of PYLARIFY&#8217;s commercial trajectory.</p><p>For GCs at specialty pharma companies who may face a PE-controlled strategic acquirer in a future transaction &#8212; a category that is expanding rapidly as PE capital accumulates in the pharmaceutical space &#8212; the governance model of the acquirer is a due diligence item, not just a background fact.</p><p>Specifically: Does the acquirer&#8217;s existing PE governance structure create board-level conflicts with the operating covenants you are agreeing to? Does the acquirer have outstanding CVR obligations on other portfolio companies that create a template for how it calculates milestones? Does the PE sponsor&#8217;s investment horizon align with the CVR term &#8212; or does the sponsor&#8217;s exit window create incentives to manage the business in ways that trade off against milestone achievement?</p><p>These are questions about the counterparty&#8217;s governance and incentive structure, not about the deal&#8217;s economic terms. They belong in legal due diligence. For a public company target&#8217;s GC accepting CVR consideration from a PE-controlled acquirer, they are the diligence that determines whether the instrument is worth what the press release says it is.</p><p><strong>BUSINESS IMPACT:</strong> PE take-privates with CVR structures are not rare. Curium-Lantheus is this year&#8217;s high-profile example in a field that has produced a dozen similar transactions in the last five years. A GC practice that develops a framework for evaluating PE-controlled acquirers &#8212; governance structure, existing CVR history, sponsor investment horizon &#8212; is positioned to add value to the next transaction at the moment the counterparty is selected, not after the term sheet is signed.</p><div><hr></div><blockquote><p><strong>PULL QUOTE:</strong> &#8220;The CVR agreement is the last protective instrument for shareholders who cannot hold their stock. Every definition of &#8216;net sales,&#8217; every competing business covenant, every dispute mechanism is a legal question that determines whether $12 per share is real money or a number in a press release.&#8221;</p></blockquote><div><hr></div><p>For interested readers I have created a CVR Tool kit. It can be found on Gumroad at https://gumroad.com/products.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!tpO0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!tpO0!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!tpO0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/220760408?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!tpO0!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!tpO0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e4b2fae-cc09-47b7-8570-bb6f6af05eb3_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h2>ABOUT THE AUTHOR</h2><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Your Contract Lab’s Warning Letter Is Your Adulteration Problem ]]></title><description><![CDATA[The adulteration follows as a matter of law.]]></description><link>https://www.thegcplaybook.law/p/your-contract-labs-warning-letter</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/your-contract-labs-warning-letter</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 18 Oct 2026 11:31:21 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!Rk3F!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p><em>Three warning letters hit the FDA enforcement database in the first week of October. Each one named a different type of contractor &#8212; an independent analytical testing lab, a nonclinical CRO, and a contract drug manufacturer. Each one carried the same underlying message: the GC&#8217;s company is legally responsible for what these contractors did, regardless of what the contract says.</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p><em>That&#8217;s the non-delegable obligation doctrine, and it&#8217;s the thread running through this issue. FDA doesn&#8217;t pierce it for good contracts. It doesn&#8217;t pierce it for qualified vendors. The FD&amp;C Act puts the obligation on the sponsor, and warning letters like these are the reminder that the obligation follows the sponsor wherever it outsources.</em></p><p><em>The October cluster landed close enough together to read as a signal worth studying. This issue walks through each letter, what the legal exposure looks like for sponsors who used these contractors, and what the contract testing agreements should have said &#8212; and still can say &#8212; going forward.</em></p><p><em><strong>John LaRocca</strong></em></p><p><strong>THE OCTOBER ENFORCEMENT CLUSTER</strong></p><p>FDA&#8217;s warning letter database posted three enforcement actions in the first week of October 2026, each targeting a different link in the pharmaceutical outsourcing chain. Read together, they describe a pattern biopharma GCs need to understand: FDA treats the sponsor&#8217;s product as adulterated when the contractor fails, whether the failure occurred at a testing lab, a nonclinical CRO, or a contract drug manufacturer.</p><p><strong>Eurofins SF Analytical Laboratories (Horsham, Pennsylvania, FEI 3014704316)</strong></p><p>received a CGMP warning letter dated October 6, 2026, citing violations of 21 CFR 211.194(a) &#8212; the requirement for complete laboratory records. FDA investigators found analysts recording microbial testing results incompletely: total colony counts recorded as &#8220;too numerous to count&#8221; without documenting actual plate counts; dried and cracked pour plates recorded as meeting specifications; and zero-CFU results entered without required second analyst verification, with FDA&#8217;s investigator finding a visible colony on a plate logged as 0 CFU. FDA cited the tested products as adulterated under FD&amp;C Act Section 501(a)(2)(B).</p><p><strong>Lovelace Biomedical Research Institute (Albuquerque, New Mexico)</strong></p><p>received a GLP warning letter dated October 2026, citing violations of 21 CFR 58.35(b)(6) &#8212; the obligation of the Quality Assurance Unit to verify that final study reports accurately reflect raw data and protocols. Following an April 2025 inspection, FDA found two specific study protocols with systematic omissions: in Protocol 1, abnormal clinical observations were missing from the final report for 20 of 34 test animals; in Protocol 2, abnormal stool observations recorded during the study for all 48 animals were absent from the final report. Sponsors who relied on Lovelace nonclinical data for pending IND or NDA submissions face a material data integrity question.</p><p><strong>Silgan Unicep Packaging, LLC (Spokane, Washington, FEI 3011913386)</strong></p><p>&#8212; a Silgan Dispensing Systems subsidiary &#8212; received a CGMP warning letter dated October 5, 2026, following an inspection from March 26 to April 2, 2026. FDA found the firm averaging out-of-specification yeast and mold counts across lots to produce a passing microbiology result &#8212; a practice FDA said was inconsistent with USP &lt;61&gt; &#8212; and then releasing those lots into manufacturing. The violations cited were 21 CFR 211.192 (inadequate OOS investigation) and 21 CFR 211.22 (quality unit failures). A linked Class I recall for potential fungal contamination was already underway when the letter issued. FDA also cited the firm&#8217;s product labeling as containing disease claims without an approved NDA, triggering liability under FD&amp;C Act sections 301(d) and 505(a) for marketing unapproved new drugs.</p><p><strong>WHY THE ANALYTICAL LAB IS DIFFERENT FROM THE CDMO</strong></p><p>The Eurofins SF letter requires its own legal analysis, because the sponsor&#8217;s exposure runs through a channel most GCs underestimate: FDA does not need to find a defective product to treat the sponsor&#8217;s goods as adulterated.</p><p>Under FD&amp;C Act Section 501(a)(2)(B), a drug is adulterated if it is manufactured, processed, packed, or held under conditions that do not conform to CGMP. When Eurofins SF generated the testing data for a sponsor&#8217;s product, it was operating within the CGMP umbrella for that sponsor&#8217;s manufacturing process &#8212; analytical testing of a drug product is part of CGMP compliance, not separate from it. The plate-recording failures FDA cited are failures in that CGMP process. Every lot tested at Eurofins SF during the relevant period is presumptively adulterated, regardless of whether a single patient was harmed or a single product failed a specification.</p><p>That is the analytical lab&#8217;s unique legal relationship to the sponsor. A packaging CGMP failure at a contract manufacturer is serious, but the chain of liability runs through a contract that typically includes lot acceptance, certificate of analysis review, and identity testing by the sponsor. The analytical lab sits at the point where that verification chain ends &#8212; the sponsor relies on the lab&#8217;s data as the evidence of conformance. When the data is fabricated or incomplete, the conformance it was supposed to demonstrate never occurred.</p><p><strong>THE SPONSOR&#8217;S LEGAL POSITION</strong></p><p>FDA&#8217;s enforcement posture on contract testing is grounded in two principles that GCs should have in writing before the first lot is tested.</p><p>First, the sponsor&#8217;s CGMP obligation is non-delegable. The holder of the NDA, ANDA, or BLA is responsible for ensuring that every step in the manufacture of its product &#8212; including analytical testing performed by a contractor &#8212; conforms to CGMP. A quality agreement, however detailed, does not transfer that obligation. It creates private remedies between the parties; it does not limit FDA&#8217;s enforcement reach against the sponsor.</p><p>Second, the Responsible Corporate Officer doctrine &#8212; affirmed in United States v. Park &#8212; establishes that senior executives can be personally liable for CGMP violations within their organization&#8217;s sphere of authority, including those committed by contractors they directed or engaged. The RCO doctrine does not require the executive to have known about the violation. It requires only the authority to prevent it and the failure to do so.</p><p>For GCs, these two principles together answer the question of why the contract testing agreement matters beyond indemnification. The agreement is not just a risk-transfer document. It is the GC&#8217;s record that the sponsor exercised reasonable oversight &#8212; that it set standards, required access, demanded testing data in usable formats, and had documented remediation rights. Without that record, the sponsor&#8217;s position with FDA is that it trusted a contractor it couldn&#8217;t supervise.</p><p><strong>THE GLP APPLICATION INTEGRITY QUESTION</strong></p><p>The Lovelace letter creates a specific problem for sponsors with pending regulatory submissions that include Lovelace nonclinical data.</p><p>FDA&#8217;s GLP regulations require that studies used to support INDs, NDAs, and BLAs be conducted in compliance with 21 CFR Part 58. When FDA finds that a QAU failed to verify that final reports accurately reflect raw data &#8212; as it found at Lovelace &#8212; the evidentiary value of those studies becomes questionable. FDA has authority under 21 CFR 58.35 to disqualify a testing facility, which would render its submitted data unacceptable in pending applications without replication.</p><p>GCs with Lovelace studies in any pending submission should be asking three questions now:</p><p>1. Are any of our pending IND or NDA submissions supported by nonclinical studies conducted at Lovelace Biomedical between the April 2025 inspection date and the October 2026 warning letter?</p><p>2. Do those studies fall under the two protocols specifically cited in the warning letter &#8212; and if not, does the QAU failure FDA identified extend to other studies not yet enumerated in enforcement documents?</p><p>3. What is our documented basis for believing the data in those studies accurately reflects what actually happened to those animals?</p><p>The third question is the hard one. If the QAU wasn&#8217;t checking, the sponsor doesn&#8217;t have a record of independent verification &#8212; and rebuilding that record from raw data, assuming it exists and is recoverable, is a multi-month exercise that delays submissions on its own.</p><p><strong>WHAT THE CONTRACT TESTING AGREEMENT SHOULD HAVE SAID</strong></p><p>The October cluster is a useful checklist for auditing existing contract testing agreements. Seven provisions that should appear in any agreement with an analytical testing lab or nonclinical CRO:</p><p><strong>Explicit CGMP/GLP compliance certification &#8212; </strong>Not just a representation, but a defined obligation with a specific right to audit on 48-hour notice.</p><p><strong>Data integrity standards by name &#8212; </strong>Cite 21 CFR 211.194(a) for analytical labs; 21 CFR 58.35(b)(6) for GLP facilities. The specific CFR section should appear in the agreement so neither party treats it as implicit.</p><p><strong>Unredacted access to raw data &#8212; </strong>Not just the certificate of analysis or the final study report, but underlying instrument records, analyst logs, second-verification signatures. The Eurofins SF violations were all in the underlying records, not the final results.</p><p><strong>Mandatory disclosure of FDA observations &#8212; </strong>The contractor must notify the sponsor within 24 hours of receiving a Form 483 observation related to any sponsor product or study, and within 24 hours of receiving a warning letter.</p><p><strong>Lot hold rights &#8212; </strong>The sponsor&#8217;s right to place a hold on any lot pending resolution of an FDA observation is a right that should exist before the warning letter arrives, not one you negotiate under pressure.</p><p><strong>Survival provisions for regulatory remediation &#8212; </strong>The agreement&#8217;s data access, audit, and remediation provisions should survive termination for the period covered by any pending regulatory submission that used the contractor&#8217;s data.</p><p><strong>Qualified Person bridge &#8212; </strong>For sponsors with EU operations, the agreement should expressly identify which party&#8217;s QP takes responsibility for certification of lots tested by the contractor, with a mechanism for QP notification on any data integrity finding.</p><p><strong>THE EUROFINS NETWORK QUESTION</strong></p><p>Eurofins SF Analytical Laboratories is one subsidiary in the Eurofins Scientific network &#8212; approximately 900 laboratories across more than 60 countries. The warning letter addressed to FEI 3014704316 in Horsham, Pennsylvania covers one facility. It does not extend on its face to Eurofins subsidiaries in other locations.</p><p>GCs whose contract testing portfolio includes other Eurofins facilities face a judgment call the letter itself doesn&#8217;t answer: whether the plate-recording practices FDA cited at Horsham reflect site-specific behavior or are symptomatic of a broader analytical culture. That judgment requires a conversation with the Eurofins quality team and, ideally, a documentation review at any Eurofins facility currently testing active sponsor products.</p><p>FDA&#8217;s enforcement action at one subsidiary does not trigger automatic liability for products tested at others. But it is notice. A GC who knew about the Eurofins SF letter and took no steps to review other Eurofins relationships has a harder time explaining the omission if a different Eurofins subsidiary generates a similar finding twelve months later.</p><p><strong>WORKSTREAM 1 &#8212; IMMEDIATE</strong></p><p><strong>Map the Lot Exposure Before the Quality Team Does</strong></p><p>The first legal question after a contract testing warning letter is not &#8220;what does our agreement say&#8221; &#8212; it is &#8220;which lots were tested there.&#8221; Quality teams will build that list. The GC should see it at the same time they do, not as a report afterward.</p><p>For Eurofins SF: identify every lot of your products tested at FEI 3014704316 in Horsham during the period FDA&#8217;s investigators reviewed. That list defines the population of potentially adulterated product under 501(a)(2)(B). Once you have it, the questions become: were any of those lots distributed? Are any still in the supply chain? Was any of the testing data submitted to FDA in a pending application?</p><p>For Lovelace: identify every nonclinical study conducted at Lovelace that has been submitted to FDA in a pending IND, NDA, BLA, or sNDA. Cross-reference against the specific protocols cited in the warning letter, then make a conservative judgment about whether studies outside those protocols were conducted under the same QAU regime.</p><p>For Silgan Unicep: if any of your products use Silgan Unicep as a contract drug manufacturer, identify which lots were manufactured during the March&#8211;April 2026 inspection period and determine whether any are subject to the Class I recall already underway.</p><p><strong>BUSINESS IMPACT: </strong>The exposure map determines the scope of every decision that follows &#8212; disclosure to FDA, voluntary recall, submission hold, or none of the above. Building it slowly is the costliest possible response.</p><p><strong>WORKSTREAM 2 &#8212; NEAR-TERM</strong></p><p><strong>Audit the Contract Testing Agreement Against Seven Provisions</strong></p><p>Once you know which contractors you use and which products are affected, pull every contract testing agreement for analytical labs and nonclinical CROs. Run each one against the seven provisions described above.</p><p>The audit will likely find three categories of agreements: those that have most of the provisions and need targeted updates; those that have a CGMP/GLP representation but nothing about data access, audit rights, or FDA observation notification; and those that are effectively just purchase orders. The second and third categories are the legal exposure &#8212; relationships where FDA could argue the company didn&#8217;t exercise the oversight the non-delegable obligation requires.</p><p>The Eurofins SF and Lovelace letters are also leverage. Any analytical lab or CRO that pushes back on data access rights or audit provisions in the next six months is taking a position that will be harder to defend with an active FDA warning letter in the same industry vertical.</p><p><strong>BUSINESS IMPACT: </strong>A contract that doesn&#8217;t give you real-time access to raw data is a contract where you learn about the problem from FDA, not from the contractor. Getting to audit rights now, before the next warning letter, is cheaper than getting to them in response to one.</p><p><strong>WORKSTREAM 3 &#8212; STRATEGIC</strong></p><p><strong>Build a Contract Testing Lab Oversight Framework</strong></p><p>The October cluster is the case for a formal framework that doesn&#8217;t currently exist at most biopharma companies: tiered oversight of contract testing facilities calibrated to the regulatory risk of the product and the criticality of the testing.</p><p>Tier 1 &#8212; Critical Path Testing: Analytical labs and CROs generating data for pending NDA or BLA submissions, or testing product lots currently in distribution. Annual on-site audits, 48-hour FDA observation notification obligations, unredacted raw data access, and a GC review of the contract testing agreement annually.</p><p>Tier 2 &#8212; Supporting Testing: Labs generating stability, compatibility, or development testing for programs not yet in late-stage submission. Biennial on-site audits, FDA observation notification obligations, certificate of analysis review plus raw data access on request, and a GC review of the agreement on any scope change.</p><p>Tier 3 &#8212; Commodity Testing: Low-criticality testing where results don&#8217;t directly support regulatory submissions. Qualification documentation on file, FDA observation notification obligations, and a spot-check audit on any change of ownership or change of site.</p><p>The framework doesn&#8217;t require new contracts for all three tiers at once. It requires a documentation standard &#8212; knowing which tier every testing relationship sits in, and having a record of the oversight commensurate with that tier.</p><p><strong>BUSINESS IMPACT: </strong>A tiered oversight framework gives the GC documented evidence that the company exercised oversight proportionate to risk. That evidence is the difference between a sponsor who acted reasonably in the face of a contractor failure and a sponsor who deferred to a contractor it didn&#8217;t supervise.</p><p><em>FDA&#8217;s treatment of Eurofins SF-tested products as adulterated under 501(a)(2)(B) does not require a defective drug &#8212; it requires a defective process. The data integrity failures are the CGMP failure. The adulteration follows as a matter of law.</em></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Rk3F!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Rk3F!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!Rk3F!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1183988,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/220748608?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Rk3F!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!Rk3F!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F54a2d75f-d806-43df-9da7-7a0d1b4a4f70_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>For interested readers, I have created a <strong>Contract Testing Lab Oversight Toolkit</strong> &#8212; six practical tools a GC can use immediately. It can be found at https://gumroad.com/products.</p><p><strong>ABOUT THE AUTHOR</strong></p><p>John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Your CDMO's Warning Letter Is Your Problem]]></title><description><![CDATA[The quality agreement in your file is not a defense. It&#8217;s evidence]]></description><link>https://www.thegcplaybook.law/p/your-cdmos-warning-letter-is-your</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/your-cdmos-warning-letter-is-your</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 14 Oct 2026 11:31:00 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!gYBY!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p>Here is the fact that defines your CDMO risk: under FDA enforcement doctrine, the sponsor is legally responsible for product quality regardless of who makes the product. Your CDMO&#8217;s cGMP violation is your warning letter. Their data integrity failure is your import alert. Their inability to pass an inspection is your supply disruption &#8212; and potentially your consent decree.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>FDA&#8217;s enforcement posture toward foreign contract manufacturers has tightened materially. For-cause inspections rose approximately 250% in 2025. Import alerts on foreign facilities multiplied. In early 2026, FDA deployed its Elsa AI tool to identify high-priority inspection targets from surveillance data &#8212; which means the list of facilities in the agency&#8217;s crosshair is now larger and more data-driven than it has ever been.</p><p><strong>The legal function needs to own this exposure. Quality agreements are legal documents. Supplier qualification is a regulatory compliance obligation. And the concentration of pharmaceutical supply chains in India and China is now a national security framing that has the administration&#8217;s full attention &#8212; which means the enforcement resources are not going away.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p><strong>Your CDMO&#8217;s Warning Letter Is Your Problem</strong></p><p><em>FDA has increased for-cause inspections 250%, deployed AI to pick its targets, and made clear it holds sponsors accountable for what their contract manufacturers do. The quality agreement in your files is not a defense. It&#8217;s evidence.</em></p><p>Format: Issue Brief | Covers: CDMO Oversight | Foreign Manufacturing Enforcement | Quality Agreements | Sponsor Liability | Supply Chain Risk</p><p><em>FDA&#8217;s enforcement against foreign contract manufacturers accelerated through 2025 and into 2026. For-cause inspections rose approximately 250% in 2025. More than 120 import alerts were issued on foreign facilities. The agency deployed an AI surveillance tool to prioritize its inspection queue. And in every one of those enforcement actions, the foundational legal principle was the same: the sponsor owns the violation, even when a CDMO committed it.</em></p><p><strong>DOMAIN 1 THE ENFORCEMENT MATH</strong></p><p>The numbers from 2025 forward represent a structural shift in FDA&#8217;s foreign inspection program, not a temporary spike.</p><p>CDER issued approximately 50% more warning letters in FY2025 than the prior year. About 35% of those letters cited cGMP violations at manufacturing sites. More than 120 new import alerts were issued on foreign facilities in 2025. For-cause inspections &#8212; the inspections triggered by specific compliance concerns rather than routine scheduling &#8212; rose approximately 250% over the same period.</p><p>The enforcement geography is concentrated. India and China together account for the majority of foreign drug manufacturing supplying the U.S. market: roughly 44% of active pharmaceutical ingredient Drug Master File holders are in India, 22% are in China, and only 9% are in the United States. Over half of branded drug products and nearly 70% of generics have at least one manufacturer outside the U.S.</p><p><em>FDA is now using its Elsa GenAI tool to identify high-priority inspection targets from surveillance data. The AI is picking the inspection queue. If your CDMO&#8217;s data patterns look like the facilities that have received warning letters, they are in the model.</em></p><p>The recurring violation themes are not new, but FDA&#8217;s tolerance for them has narrowed: unvalidated test methods, uninvestigated equipment excursions, data integrity lapses including incomplete or copied records, destruction of analytical records, backdated documents, and inadequate responses to Form 483 observations. Contract testing laboratories &#8212; the labs your CDMO may use for product release testing &#8212; have received their own warning letters, including actions against labs that FDA found had falsified or destroyed records.</p><p>FDA has also finalized guidance on Remote Regulatory Assessments and is reorganizing its inspectorate to support expansion. The agency&#8217;s planned shift to more unannounced inspections at foreign facilities is an explicit policy direction, not a threat. Plan for it.</p><p><strong>DOMAIN 2 THE SPONSOR RESPONSIBILITY DOCTRINE</strong></p><p>The foundational regulatory principle governing outsourced pharmaceutical manufacturing is straightforward and consistently enforced: the sponsor is legally responsible for the quality of its product regardless of who manufactures it. FDA treats contract manufacturers as extensions of the sponsor&#8217;s own facility. That is not a metaphor. It describes how FDA assigns enforcement consequences.</p><p>When FDA issues a warning letter to a CDMO, the sponsor&#8217;s products made at that facility are typically swept into the action. When FDA places a foreign facility on import alert, the sponsor&#8217;s ability to bring product made at that facility into the U.S. halts. The CDMO&#8217;s compliance failure becomes the sponsor&#8217;s supply interruption, the sponsor&#8217;s product recall exposure, and potentially the sponsor&#8217;s consent decree obligation.</p><p>Viatris learned this in December 2024, when FDA issued a warning letter and import alert covering 11 actively distributed products made at its Indore, India facility. The import alert barred those products from U.S. entry until the warning letter was lifted. Viatris implemented a remediation plan including corrective and preventive actions and independent third-party oversight, but the enforcement consequence &#8212; the market access interruption &#8212; preceded any of that remediation.</p><p><em>The quality agreement in your files does not limit your regulatory exposure. It documents who agreed to do what. FDA&#8217;s enforcement action will name the sponsor, not the CDMO&#8217;s quality director.</em></p><p>Six Asian manufacturing firms were placed on import alert in 2025 and 2026 for refusing to allow FDA inspections. Refusal to inspect is treated as equivalent to a significant cGMP failure for import alert purposes. If your CDMO refuses &#8212; or cannot logistically accommodate &#8212; an FDA inspection, your product is affected.</p><p>The legal function&#8217;s role in this framework is not to monitor GMP compliance directly. It is to ensure that the company&#8217;s quality agreements, supplier qualification processes, and supply chain contracts create an enforceable structure that the company can demonstrate to FDA and defend in an enforcement proceeding. The distinction matters. Legal doesn&#8217;t run quality; legal owns the contractual architecture that quality operates within.</p><p><strong>DOMAIN 3 THE FOREIGN FACILITY PROBLEM</strong></p><p>The administration has framed pharmaceutical supply chain concentration in China and India as a national security issue. Executive Order 14293 directed FDA and EPA to reduce regulatory barriers to domestic manufacturing, established the FDA PreCheck Program for streamlined domestic facility approvals, and called for higher fees and more frequent inspections of foreign plants.</p><p>This framing matters for CLOs because it means enforcement resources aimed at foreign manufacturing are not subject to the usual budget and priority competition. When supply chain vulnerability is national security, inspection activity at Indian and Chinese facilities becomes a policy imperative rather than a regulatory workload question. That is a different enforcement environment than pharma has operated in over the past decade.</p><p>The data integrity problem at foreign facilities is a specific concern that has driven disproportionate enforcement. Multiple warning letters in 2025 and 2026 cited contract testing labs outside the U.S. that had destroyed analytical records or backdated documents. When FDA finds those issues at a contract lab, it invalidates data from that lab retroactively &#8212; affecting product release testing for every sponsor that used that lab.</p><p>FDA has also signaled that it examines a sponsor&#8217;s other manufacturing and testing sites when it finds problems at one. The inspection of a single facility can trigger a review of the broader network. For sponsors using multiple foreign CDMOs or contract labs in concentrated geographies, that network effect is the compounding risk &#8212; a compliance failure at one site puts the entire foreign manufacturing footprint in scope.</p><p>The talc enforcement action in June 2026 illustrated this network sweep directly: CDER sent nine cGMP letters simultaneously to talc-product manufacturers in India, China, Japan, Turkey, Canada, the Dominican Republic, and the U.S. over asbestos contamination risk. The enforcement was coordinated across jurisdictions, not sequential. When FDA decides a product-class risk is systemic, the enforcement covers the supply chain.</p><p><strong>DOMAIN 4 THE QUALITY AGREEMENT GAP</strong></p><p>Quality agreements between sponsors and CDMOs are required under FDA guidance. They are also, in the current enforcement environment, significantly underengineered for the risks they&#8217;re supposed to manage.</p><p>The recurring failure modes identified in FDA&#8217;s 2025 and 2026 warning letters &#8212; data integrity lapses, uninvestigated out-of-specification results, inadequate change control, failure to report deviations &#8212; are all areas that a quality agreement should address explicitly. Most quality agreements in the market address them at a level of generality that does not produce actual compliance behavior. The agreement says the CDMO will report deviations. It doesn&#8217;t specify what constitutes a reportable deviation, what the timeline is, what the escalation path is when a deviation is unreported, or what the sponsor&#8217;s contractual remedy is when the CDMO fails to comply.</p><p>Contract testing laboratory oversight is the specific gap that FDA&#8217;s recent enforcement has exposed most sharply. Sponsors routinely rely on their CDMO&#8217;s contract lab relationships for product release testing. The quality agreement with the CDMO may say the CDMO is responsible for its subcontractors. But the sponsor has no direct contractual relationship with the testing lab, no direct audit rights, and no direct visibility into the lab&#8217;s data integrity practices.</p><p>When FDA finds that a contract lab destroyed records or backdated data, the invalidation of that lab&#8217;s testing data is retroactive. Products released based on that data face recall exposure regardless of what the quality agreement between the sponsor and the CDMO said. The contract allocation of responsibility does not bind FDA&#8217;s enforcement action.</p><p>The import alert contingency gap is equally significant. Most quality agreements address what happens when a product fails testing. Very few address what happens when the facility receives an import alert. The notice period, the product in transit, the in-process inventory, the back-up sourcing obligation &#8212; those are operational and legal questions that need contractual answers before the alert is issued, not after.</p><p><strong>CLO WORKSTREAMS</strong></p><p>&#9632; <strong>Quality Agreement Audit. </strong>Pull every active quality agreement with a foreign CDMO or contract testing lab. Benchmark against FDA&#8217;s current enforcement themes: does each agreement specifically address deviation reporting timelines, data integrity obligations, change control notification, inspection access rights, and remediation escalation? Gaps in those areas are gaps in your regulatory defense.</p><p>&#9632; <strong>Import Alert Contingency Protocol. </strong>For each foreign facility in your manufacturing network, establish a documented contingency protocol that addresses: in-transit inventory ownership and disposition, back-up sourcing timelines, regulatory notification obligations, and sponsor communication to affected customers. The time to build that protocol is before FDA issues the alert.</p><p>&#9632; <strong>Foreign Supplier Risk Tiering. </strong>Tier your CDMOs and contract labs by geography, product criticality, and enforcement history. Facilities in India and China supplying critical products with no identified back-up source represent concentrated, compounding risk. That tier should receive priority audit attention and more robust quality agreement terms than your standard template provides.</p><p>&#9632; <strong>Contract Testing Lab Direct Oversight. </strong>Map every contract testing lab your CDMOs use for product release, stability, or method validation. Confirm your quality agreements include either direct audit rights over those labs or CDMO-imposed oversight obligations with reporting to the sponsor. The retroactive data invalidation risk at contract labs is not adequately managed by a pass-through clause in the CDMO agreement.</p><p>&#9632; <strong>Board Briefing on Supply Chain Concentration. </strong>The administration&#8217;s national security framing of pharmaceutical supply chain dependency is a board-level risk item. Brief the board on your company&#8217;s geographic concentration in foreign manufacturing, the enforcement trend data, your quality agreement coverage, and your import alert contingency posture. That briefing is also the basis for any capital allocation decision about domestic manufacturing investment.</p><p>For interested readers I created a CDMO Oversight Audit Toolkit. It can be found at https://laroccaadvisory.gumroad.com/l/unjhwk</p><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!gYBY!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!gYBY!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!gYBY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/c0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/219651678?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!gYBY!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!gYBY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc0ca770f-2e2a-4ae4-8adb-08487e14c059_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><p><strong>John LaRocca</strong> is the Founding Editor of The GC Playbook and a fractional CLO at LaRocca Advisory Group, advising PE-backed specialty pharma and biotech companies on regulatory risk, supply chain governance, and transaction readiness.</p><p><strong>laroccaj.substack.com</strong> | LaRocca Advisory Group</p><p style="text-align: center;"><strong>THE GC PLAYBOOK</strong></p><p style="text-align: center;"><em>Intelligence for pharma CLOs and GCs who can&#8217;t afford to be surprised.</em></p><p style="text-align: center;"><strong>laroccaj.substack.com</strong></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The AI Defense Didn't Work ]]></title><description><![CDATA[FDA Just Issued Its First Warning Letter Citing AI Overreliance as a cGMP Failure. Your Compliance Team Is Next.]]></description><link>https://www.thegcplaybook.law/p/the-ai-defense-didnt-work</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-ai-defense-didnt-work</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 11 Oct 2026 11:31:18 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!M04P!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p>FDA issued its first warning letter citing AI overreliance as a cGMP compliance failure in April 2026. The letter did not name the manufacturer. It did not need to. Every pharma company using AI in any compliance function read it the same way: this is the theory inspectors are now carrying into facilities.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>For two years I have watched legal functions treat AI compliance as an IT problem. The vendor selects the tool, procurement reviews the contract, and compliance writes a policy. Nobody owns the regulatory exposure in that sequence. The warning letter tells you who FDA thinks owns it: the quality unit, the company, and by extension the legal function that approved the contracts and the oversight framework.</p><p>This issue is about the specific legal work the warning letter starts. The renegotiation it forces. The documentation gap it exposes. And what needs to be in place before the next inspection, not after the next 483.</p><p><strong>The AI system failed. That is not the finding. The finding is that the company let it.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p></p><p><em>A drug manufacturer used an AI tool to generate its drug product specifications, procedures, and master production records. FDA inspected and found cGMP violations. The company&#8217;s defense: the AI failed to flag the gaps. FDA&#8217;s response: that is not a defense.</em></p><p>This is the first FDA warning letter to cite a company&#8217;s use of AI as a compliance instrument &#8212; not whether the AI itself is a regulated device, but whether the company maintained adequate human oversight of what the AI produced. The distinction matters because it applies to every pharma company using AI in any compliance function, right now.</p><p><strong>DOMAIN 1 WHAT THE WARNING LETTER ACTUALLY SAID</strong></p><p>The company&#8217;s quality unit failed to adequately review and validate AI-generated documents for accuracy and cGMP compliance before those documents governed manufacturing. When inspectors found the gaps, company representatives pointed to the AI system&#8217;s failure to flag missing requirements.</p><p>FDA&#8217;s position: the quality unit&#8217;s obligation to review and validate is non-delegable. It does not transfer to the AI vendor. It does not transfer to the algorithm. It stays with the company.</p><p>The practical problem is that AI-generated compliance documents look authoritative. They are well-formatted, internally consistent, and written in regulatory language. A quality professional reviewing a document the AI produced has to know what&#8217;s missing &#8212; which is exactly what the AI was supposed to help with. When the AI fails to flag a gap and the reviewer doesn&#8217;t catch it either, the document enters the quality system undetected.</p><p>That is the failure pattern FDA just named and cited.</p><p><em>FDA doesn&#8217;t care what the vendor promised. The company&#8217;s non-delegable obligation to review stays with the company, not the algorithm.</em></p><p><strong>DOMAIN 2 THE VENDOR AGREEMENT GAP</strong></p><p>Most enterprise AI agreements disclaim fitness for any particular purpose and cap liability at annual fees. That disclaimer protects the vendor in a contract dispute. It does not protect the pharmaceutical company in the regulatory relationship.</p><p>The vendor&#8217;s contract excludes liability for the failure pattern FDA just described. The pharmaceutical company bears the entire regulatory consequence. The gap is now a fact pattern: AI-generated compliance document, inadequate human review, cGMP violation, warning letter. Your vendor&#8217;s indemnification section covers none of that sequence.</p><p>If your AI vendor agreements were drafted before March 2025 &#8212; before FDA and EMA issued their joint guidance on AI in regulated manufacturing &#8212; they were almost certainly written without the indemnification language your company now needs. The renegotiation this warning letter forces is not optional.</p><p><strong>DOMAIN 3 HUMAN OVERSIGHT PROTOCOL</strong></p><p>The company in this warning letter probably had people who reviewed the AI outputs. They either didn&#8217;t catch what was missing, or they didn&#8217;t document that they looked. FDA doesn&#8217;t distinguish between them.</p><p>A policy saying &#8220;employees must review AI-generated documents&#8221; is not sufficient. The quality system needs to specify who reviews, what the review must cover, how the reviewer certifies the review was substantive, and what happens when an AI-generated claim cannot be independently verified. That protocol needs to exist before the next inspection.</p><p>FDA inspectors now have a named theory for AI-related cGMP failures. Every facility using AI in any compliance function &#8212; specifications, procedures, production records, batch records, investigation reports &#8212; should expect inspectors to ask how AI outputs are reviewed. &#8220;We reviewed it&#8221; is not the answer. The answer is the documented protocol and evidence it was followed.</p><p><strong>DOMAIN 4 THE RENEGOTIATION</strong></p><p>The renegotiation objectives are specific: validation documentation commitment, 21 CFR Part 11 data integrity, and a meaningful liability carve-out for regulatory-related losses caused by AI system failures. Add to that a specific indemnification provision covering FDA warning letters, consent decrees, and import alerts that result from documented failures in AI-generated compliance outputs.</p><p>That last provision is what most AI vendors will resist hardest. It is also what your company most needs. Most vendors will agree to enhanced validation commitments before they agree to regulatory indemnification &#8212; use the validation commitment as the opening position and treat indemnification as the objective.</p><p>Start with your three highest-risk systems: those generating specifications, SOPs, or production records. Those are the document types FDA cited. They are also the documents most likely to produce a 483 observation if the AI-generated content contains a gap the review process didn&#8217;t catch.</p><p></p><p><strong>CLO WORKSTREAMS</strong></p><p>Priority actions for the legal function before the next inspection.</p><p>&#9632; <strong>Compliance infrastructure inventory. </strong>Identify every AI system in your compliance infrastructure &#8212; specifications, SOPs, production records, investigation reports, change control documentation. Map what human oversight currently exists and whether it is documented in the quality system.</p><p>&#9632; <strong>Gap assessment against FDA&#8217;s fact pattern. </strong>Commission a review against the pattern FDA just described: AI-generated document, inadequate human review, undetected gap. That sequence is the inspection theory now. Assess every system against it before your next inspection date.</p><p>&#9632; <strong>Quality system documentation. </strong>The oversight protocol must be in the quality system, not just in a policy memo. Who reviews. What they must cover. How they certify the review was substantive. What happens when a claim cannot be independently verified.</p><p>&#9632; <strong>Vendor agreement audit. </strong>For every AI system in your compliance infrastructure, pull the vendor agreement and assess: validation documentation, 21 CFR Part 11 data integrity obligations, liability cap and disclaimer language, absence of regulatory indemnification. That gap is what the warning letter just confirmed.</p><p>&#9632; <strong>Renegotiation priority list. </strong>Rank your AI vendor agreements by regulatory risk. Begin renegotiations with the vendors whose systems generate specifications, SOPs, or production records &#8212; the specific document types FDA cited. Validation commitments first; indemnification is the objective.</p><p>For interested readers I have created an Ai Compliance Oversight Assessment. It can be found at https://laroccaadvisory.gumroad.com/l/sbbfnj.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!M04P!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!M04P!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!M04P!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!M04P!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!M04P!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!M04P!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/219644162?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!M04P!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!M04P!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!M04P!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!M04P!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F530e913b-5e5e-44e2-b927-901df5dc0b6a_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><p><strong>John LaRocca</strong></p><p>John LaRocca has served as general counsel and CLO in the pharmaceutical and biotech sectors for 26 years. He advises boards and executive leadership on regulatory risk, M&amp;A, and governance.</p><p><strong>laroccaj.substack.com</strong></p><p style="text-align: center;"><strong>THE GC PLAYBOOK</strong></p><p style="text-align: center;"><em>Intelligence for pharma CLOs and GCs who can&#8217;t afford to be surprised.</em></p><p style="text-align: center;"><strong>laroccaj.substack.com</strong></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Biotech Governance Gap: Why Scientific-Depth Boards Create Activist Targets and What the CLO Does About It]]></title><description><![CDATA[The CLO's role in closing that gap is not to find new board members. It is to conduct the analysis that shows the board where the gap is before the activist's 13D arrives.]]></description><link>https://www.thegcplaybook.law/p/the-biotech-governance-gap-why-scientific</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-biotech-governance-gap-why-scientific</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 07 Oct 2026 11:30:51 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!pzb3!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p>The Harvard Law School Corporate Governance blog published an analysis in March 2026 of 75 concluded activist campaigns in the life sciences sector since January 2024. The finding that matters most for CLOs advising biotech and specialty pharma boards: 34% of those campaigns preceded the company&#8217;s acquisition or dissolution. That is not a coincidence. It is the activist thesis playing out &#8212; identify a company with a governance or strategic failure, launch the campaign, force the strategic process that the board failed to pursue on its own, and capture the premium.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>The life sciences and healthcare sector drew 31 activist campaigns in 2025 &#8212; 12% of a record 255 total worldwide. Four of the six biotech targets who drew activist attention in 2025 came under pressure to refresh their boards, replace CEOs, or amend bylaws. A Diligent analysis of biotech activism identified the specific vulnerability pattern: biotech boards typically have considerable scientific depth but lack capital markets or operational expertise. That gap &#8212; a board that can evaluate a Phase 3 readout but cannot credibly defend a capital allocation decision to a sophisticated institutional investor &#8212; is the specific opening that activists enter through.</p><p>I have sat in enough board meetings to understand what this looks like from the inside. The board room where the most senior voice on a PDUFA date is a former FDA medical officer, and the most senior voice on a capital allocation decision is the CFO who also manages investor relations, is a board room that has a governance problem. The deficit is not intelligence or commitment. It is the specific combination of capital markets experience, M&amp;A execution history, and institutional investor relationship depth that makes a board credibly defensible to a sophisticated activist.</p><p><strong>The CLO&#8217;s role in closing that gap is not to find new board members. It is to conduct the analysis that shows the board where the gap is before the activist&#8217;s 13D arrives.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p></p><p><strong>The Data: What 75 Concluded Campaigns Reveal</strong></p><p>The Harvard Law Corporate Governance analysis of 75 concluded campaigns in life sciences since January 2024 produces a dataset that should be required reading for every biotech CLO. Among those 75 campaigns: 34% preceded the company&#8217;s acquisition or dissolution. 17% ended in formal settlement agreements &#8212; cooperation agreements in which the activist received board representation in exchange for a standstill. 12% achieved other objectives &#8212; share repurchases, board changes, management transitions &#8212; without a formal settlement. 11% reached partial success through informal understandings. Only 9% proceeded to a shareholder vote. 17% were abandoned without the activist achieving its stated objectives.</p><p>The 34% acquisition rate is the number that defines the activist strategy in life sciences. Elliott, Sarissa, Velan, ADAR1 Capital, and the other repeat activists in the sector are not running governance improvement campaigns. They are running strategic alternatives campaigns with governance as the entry thesis. The governance critique &#8212; insufficient capital markets expertise, excessive director tenure, CEO and chair combination &#8212; is the platform that persuades institutional investors to support an activist nomination. The acquisition or strategic process is the monetization event.</p><p><strong>The CLO who understands this treats the activism vulnerability assessment as an M&amp;A readiness assessment.</strong> The question is not whether the board can govern effectively in steady state. The question is whether the board&#8217;s composition and governance structure can withstand the specific scrutiny that an activist deploys before filing a 13D.</p><p><strong>The Three Biotech-Specific Vulnerability Factors</strong></p><p><strong>1. Scientific-Depth Boards Without Capital Markets Expertise</strong></p><p>The Diligent analysis of 2025 biotech activism identifies this as the primary governance gap that activists exploit: biotech boards are built for scientific oversight of drug development and regulatory strategy. The directors with the most credibility &#8212; former FDA officials, academic scientists with the relevant disease expertise, former pharma R&amp;D executives &#8212; are the right directors for evaluating a Phase 3 readout, a CRL response strategy, or a clinical program prioritization decision. They are the wrong directors for defending a capital allocation decision, evaluating a strategic alternatives analysis, or credibly representing the board&#8217;s M&amp;A process to an institutional investor audience.</p><p>The activist campaign built on this gap targets the board&#8217;s capital allocation decisions: the decision to advance a program that has consumed three times its original budget; the decision to build commercial infrastructure for a drug that has not yet received approval; the decision not to pursue an acquisition or partnership that would have extended the runway; or the decision to maintain a cash position rather than return it to shareholders. Each of these decisions requires capital markets expertise to defend credibly. A board that cannot put a director with direct buy-side or sell-side experience in front of an institutional investor to defend the company&#8217;s capital allocation framework is a board that is vulnerable on that specific dimension.</p><p><strong>The board composition test:</strong> can at least one board member &#8212; not the CFO, not management, but an independent director &#8212; credibly describe to a sophisticated activist investor why the company&#8217;s capital allocation decisions have been the right ones? If the answer is no, the gap is real and the campaign thesis is available.</p><p><strong>2. Cash Runway Pressure and Development-Stage Dilution Risk</strong></p><p>For development-stage biotech companies &#8212; companies pre-commercial or early commercial with a cash runway measured in quarters &#8212; the activist campaign thesis is arithmetic. Higher R&amp;D costs or unexpected clinical delays accelerate burn, reduce runway, increase dilution risk from the next financing, and strengthen the activist argument that the board should rationalize the pipeline, pursue a licensing transaction, or explore a strategic sale before the next financing dilutes existing shareholders.</p><p>The Diligent analysis describes this precisely: cash runway concerns accelerate the activist&#8217;s case for capital allocation discipline, portfolio rationalization, or strategic alternatives. At development-stage companies, this is often the decisive vulnerability factor. A board that has not publicly articulated a clear framework for pipeline prioritization against its runway timeline &#8212; including the specific clinical milestones that will trigger a strategic alternatives review &#8212; is a board that has left the activist&#8217;s thesis unanswered before the campaign launches.</p><p><strong>The advance answer:</strong> a board-level strategic alternatives policy that documents the specific conditions under which the board will formally initiate a strategic alternatives review is the governance document that closes this vulnerability before the activist demands it. The policy does not need to be public. Its existence needs to be articulable by the board&#8217;s directors to institutional investors who ask the question.</p><p><strong>3. Long-Tenured Directors and Governance-Focused Activism</strong></p><p>The Harvard analysis identifies board refreshment as a consistent activism demand: four of six biotech targets in 2025 drew pressure to refresh boards, replace CEOs, or amend bylaws. ISS governance trends for 2026 show a slight increase in the number of U.S. companies with separate chair and CEO positions &#8212; a governance norm that ISS and Glass Lewis increasingly enforce through director vote recommendations.</p><p>The long-tenured director is the specific governance profile that activates ISS&#8217;s negative recommendation framework. A director who has served for more than 12 years, chairs a key committee, and whose independence the activists can credibly characterize as compromised by tenure is a director whose continued service becomes an activist campaign argument. In the biotech context, the founding scientist-director who has served since the company&#8217;s inception, has deep scientific knowledge that is genuinely valuable, but whose tenure creates an independence optic that ISS scores negatively is a specific governance problem that the CLO should identify in the annual board composition analysis.</p><p><strong>The CLO&#8217;s Pre-Campaign Analysis</strong></p><p>The annual activism vulnerability assessment is a CLO deliverable. It answers four questions before the activist answers them publicly.</p><p><strong>Question 1: What Is the Performance Gap?</strong></p><p>One-year and three-year total shareholder return against the relevant index and peer group. If TSR trails the peer group median by more than 15% on either measure, the performance gap is identifiable in public data and the activist can quantify it for an institutional investor audience. The CLO&#8217;s role is not to solve the performance problem &#8212; that is a board and management responsibility. The CLO&#8217;s role is to ensure the board has been presented with the quantified performance gap before an activist presents it in a public letter.</p><p><strong>Question 2: What Is the M&amp;A Thesis Vulnerability?</strong></p><p>Is there an identifiable argument that the board failed to pursue available strategic alternatives &#8212; either by not pursuing acquisitions to address a pipeline gap, by not selling when a premium was available, or by not pursuing licensing transactions that would have extended the pipeline or the runway? The M&amp;A thesis campaign accounted for 64% of all Q4 2025 activist campaigns &#8212; the highest proportion in five years. A board that has not documented its analysis of strategic alternatives in board minutes &#8212; including a documented record of M&amp;A opportunities the board considered and rejected, with the business rationale &#8212; is a board that is vulnerable on this specific dimension.</p><p><strong>Question 3: Are the Structural Defenses Current?</strong></p><p>Advance notice bylaw currency is the most basic structural question. Does the company&#8217;s advance notice bylaw require the nominating shareholder to disclose its full economic interest &#8212; including derivatives and instruments that create economic exposure without voting rights &#8212; against the 2026 standard of activist disclosure sophistication? Does the acting-in-concert definition capture aggregated positions held through related entities? A bylaw last reviewed before 2021 is almost certainly inadequate against current activist disclosure practices.</p><p>Poison pill status: does the company have a current plan reviewed against current Delaware case law within the prior 12 months? A pill adopted in 2019 that has not been reviewed against the current Delaware precedent on trigger thresholds, passive investor exemptions, and acting-in-concert definitions provides less structural protection than the board believes it does.</p><p><strong>Question 4: Is the Board Composition Defensible?</strong></p><p>The specific composition questions the CLO should answer annually: average director tenure (tenure above 10 years is a specific ISS vulnerability); number of directors who have not served on another public company board (insufficient governance experience); presence of at least one director with current capital markets experience &#8212; direct buy-side or sell-side, not a former CFO of a private company; and whether any director whose independence is potentially compromised by tenure is in a position where that compromise creates a governance argument.</p><p><strong>THE KEROS AND ALKERMES COMPARISON &#8212; TWO BIOTECH ACTIVISM OUTCOMES IN 2025-2026</strong></p><p>Keros Therapeutics reached a resolution with activists ADAR1 Capital Management and Pontifax Venture Capital by repurchasing their stakes as part of a broader buyback &#8212; the activists exited the board without requiring a strategic process. Alkermes mounted a successful defense, with shareholders rejecting three board nominees from Sarissa Capital and reelecting seven incumbents. Both companies took different paths to the same destination: activists came and left without achieving board control. The CLO&#8217;s lesson from both: an advance vulnerability assessment, a current governance document review, and a proactive institutional investor engagement program are the inputs that gave both boards the position to respond to activist pressure without capitulating to it. Neither outcome was an accident.</p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">Conduct the Annual Activism Vulnerability Assessment Before November</span></strong></p><p>The proxy season begins in January. An activism vulnerability assessment completed in October gives the board twelve weeks to address identified gaps before activists file their first 13D positions for the spring proxy season. The assessment covers: TSR performance gap (1-year and 3-year against peer median); M&amp;A thesis vulnerability (documented strategic alternatives analysis in board minutes); advance notice bylaw currency against 2026 activist disclosure practices; poison pill status reviewed against current Delaware case law; and board composition defensibility &#8212; capital markets expertise, director tenure profile, ISS independence scoring, and the operating independence of audit and compensation committee structures. The assessment is a CLO deliverable. It should be presented to the board&#8217;s nominating/governance committee before the end of the fiscal year.</p><p><strong>BUSINESS IMPACT: </strong><em>A board that receives an activist&#8217;s public letter without a current vulnerability assessment is a board making governance decisions in real time under public pressure. A board that completed the assessment in October is a board that has already made the governance decisions that matter.</em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">Update the Advance Notice Bylaw and Confirm Poison Pill Currency</span></strong></p><p>For any company whose advance notice bylaw has not been reviewed by outside governance counsel since 2021, commission a review against the current standard before the next proxy season. The specific provisions requiring update: economic interest disclosure (the bylaw must require disclosure of derivatives, swaps, and instruments that create economic exposure without voting rights &#8212; the wolf-pack aggregation problem); acting-in-concert definition (must capture related-entity aggregation); nominee questionnaire requirement; and the update obligation requiring the nominating shareholder to confirm disclosure accuracy through the meeting date. For the poison pill: confirm whether a current plan is in place, when it was last reviewed against Delaware precedent, and whether the trigger threshold, passive investor exemption, grandfathering provision, and acting-in-concert definition remain defensible under current case law. Both documents should be reviewed by outside governance counsel &#8212; the same firm that would represent the company in a proxy contest &#8212; not by in-house counsel alone.</p><p><strong>BUSINESS IMPACT: </strong><em>The advance notice bylaw and poison pill determine whether an activist can mount a proxy campaign on their own timeline or the company&#8217;s timeline. The company whose governance documents are current negotiates from a position of structural advantage. The one with outdated documents does not.</em></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">Build the Board Composition Pipeline Before the Next Annual Meeting</span></strong></p><p>The most durable response to the scientific-depth / capital-markets-expertise gap is a board composition pip</p><p>eline &#8212; a documented list of director candidates with capital markets, M&amp;A execution, or institutional investor relationship backgrounds who meet the company&#8217;s independence requirements and have been vetted by the nominating/governance committee. The pipeline does not require a vacancy to exist. It requires the governance committee to have completed its work before the activist nominates its own candidates and the company is forced to respond in a proxy contest environment. The specific target profile: one director with direct buy-side (institutional asset management or hedge fund) or sell-side (investment banking or equity research) experience in the relevant sector; and one director with direct M&amp;A execution experience at the CLO, CFO, or CEO level at a company of comparable size and complexity. When the activist nominates two directors with precisely those backgrounds, the company whose board already has that expertise can make a credible case to institutional shareholders that the activist&#8217;s nominees are redundant, not additive.</p><p><strong>BUSINESS IMPACT: </strong><em>The activist&#8217;s most effective campaign strategy in biotech is nominating directors whose expertise is genuinely missing from the current board. The board that has already filled the gap removes the most compelling argument from the activist&#8217;s proxy statement before it is written.</em></p><p style="text-align: center;"><em>&#8220;34% of concluded activist campaigns in life sciences since 2024 preceded the company&#8217;s acquisition or dissolution. The activists are not running governance improvement campaigns. They are running strategic process campaigns with governance as the entry point. The CLO&#8217;s job is to close the entry before the campaign opens.&#8221;</em></p><p style="text-align: center;"><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested readers I have created a Biotech Board Governance Gap Assessment. It can be found at:https://laroccaadvisory.gumroad.com/l/hurpye</span></em></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!pzb3!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!pzb3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!pzb3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1142812,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/218544744?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!pzb3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!pzb3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f515112-b162-4656-ac8b-4484c9749c62_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"><strong>ABOUT THE AUTHOR</strong></p><p><strong>John LaRocca </strong>is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of <strong>LaRocca Advisory Group</strong>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Merger of Equals — With a Dental MDL: The Supernus / Indivior All-Stock Merger and the Litigation Tail Supernus Shareholders Are Inheriting]]></title><description><![CDATA["Merger of equals" is a transaction description, not a legal conclusion. The CLO's job is to identify where the equality ends.]]></description><link>https://www.thegcplaybook.law/p/merger-of-equals-with-a-dental-mdl</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/merger-of-equals-with-a-dental-mdl</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 04 Oct 2026 11:31:58 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!07yw!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>On August 1, 2026, Supernus Pharmaceuticals and Indivior Pharmaceuticals signed a definitive agreement to combine in an all-stock, tax-free merger of equals. The combined company will be named Supernus, Inc., trade as SUPN, and carry a pro forma revenue base of approximately $2.2 billion anchored by Indivior&#8217;s Sublocade &#8212; buprenorphine extended-release for opioid use disorder &#8212; alongside Supernus&#8217;s Qelbree for ADHD, ZURZUVAE for postpartum depression, and GOCOVRI and ONAPGO for Parkinson&#8217;s disease. Jack Khattar, Supernus&#8217;s CEO, leads the combined company. The deal is expected to close in the fourth quarter of 2026.</p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:null}" data-component-name="ButtonCreateButton"><a class="button primary" href="https://www.thegcplaybook.law/subscribe?"><span>Subscribe now</span></a></p><p>The trade press covered this as a CNS powerhouse story. The correct analytical frame is different. Before this merger closes, Indivior will declare a $1 billion special cash dividend to its existing shareholders, financed partly by a $650 million term loan from Citibank. The combined company closes with that debt already on its balance sheet. And while the Master Settlement Agreements covering Indivior&#8217;s civil opioid MDL obligations were finalized in January 2026, the Suboxone dental MDL &#8212; approximately 1,900 cases representing roughly 25,000 plaintiffs consolidated in the Northern District of Ohio &#8212; remains in its preliminary stages, with no reserve established and no loss estimate possible. That litigation transfers to the combined company at closing.</p><p>Supernus shareholders will own 43.5% of a combined company that carries $650 million of acquisition-related debt and an unquantified dental MDL exposure. The merger agreement&#8217;s representation about the status of the dental MDL, and the indemnification structure Supernus&#8217;s counsel at Saul Ewing negotiated around it, is the document that determines whether the 43.5% stake was priced correctly.</p><p><strong>&#8220;Merger of equals&#8221; is a transaction description, not a legal conclusion. The CLO&#8217;s job is to identify where the equality ends.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p><strong>The Deal Structure</strong></p><p>The transaction is structured as a forward triangular merger &#8212; Indivior&#8217;s wholly-owned subsidiary merges into Supernus, with Supernus surviving as a wholly-owned subsidiary of Indivior, which then changes its name to Supernus, Inc. The surviving legal entity on the Indivior side is the combined Supernus, Inc. For purposes of the litigation analysis, the entity that survives and carries the combined company&#8217;s obligations is the successor to Indivior&#8217;s existing legal relationships &#8212; including the litigation described below.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!07yw!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!07yw!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 424w, https://substackcdn.com/image/fetch/$s_!07yw!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 848w, https://substackcdn.com/image/fetch/$s_!07yw!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 1272w, https://substackcdn.com/image/fetch/$s_!07yw!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!07yw!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png" width="624" height="472" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/286ffec3-9de4-4e98-b10d-58075191f244_624x472.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:472,&quot;width&quot;:624,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:186937,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/218539145?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!07yw!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 424w, https://substackcdn.com/image/fetch/$s_!07yw!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 848w, https://substackcdn.com/image/fetch/$s_!07yw!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 1272w, https://substackcdn.com/image/fetch/$s_!07yw!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F286ffec3-9de4-4e98-b10d-58075191f244_624x472.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong>The Litigation Profile: What Transfers at Closing</strong></p><p>The &#8216;merger of equals&#8217; label requires context against Indivior&#8217;s litigation history. Indivior has been one of the most extensively litigated pharmaceutical companies in the U.S. over the past decade, with cumulative settlements and criminal penalties exceeding $1.3 billion. Most of that history is resolved. The portion that is not resolved is the piece that belongs in the merger agreement&#8217;s representation and warranty analysis.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!A9aj!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!A9aj!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 424w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 848w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 1272w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!A9aj!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png" width="631" height="379" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:379,&quot;width&quot;:631,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:149219,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/218539145?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!A9aj!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 424w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 848w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 1272w, https://substackcdn.com/image/fetch/$s_!A9aj!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ebfd9d7-197e-4efe-bff8-12989e2e9a16_631x379.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong>The Dental MDL: The Unquantified Tail</strong></p><p>The Suboxone Film Products Liability MDL &#8212; the dental litigation &#8212; is the unresolved item. As of April 28, 2026, approximately 1,900 cases representing approximately 25,000 plaintiffs were consolidated in multi-district litigation in the Northern District of Ohio. A tolling agreement was negotiated for Schedule A plaintiffs, permitting plaintiffs&#8217; counsel additional time to investigate whether any Indivior product was used before determining whether to file individual complaints. As of April 28, 2026, the Schedule A claimants had been reduced to approximately 5,300. The MDL cases are in their preliminary stages. No estimate of possible loss can be made. No reserve has been established specific to this litigation.</p><p><strong>The dental MDL theory:</strong> the plaintiffs allege that Suboxone Film &#8212; the sublingual buprenorphine/naloxone formulation that Indivior marketed as a safer alternative to Suboxone tablets in part because the film formulation reduced the risk of accidental pediatric exposure &#8212; caused dental decay, tooth loss, and other oral health complications. The theory is that prolonged sublingual dissolution of the film&#8217;s acidic components caused damage to tooth enamel. Indivior disputes the causal connection and has contested the litigation at every stage.</p><p>The litigation is in its earliest substantive phase &#8212; the fact sheet process is still producing case dismissals on one end, while the tolling agreement is preserving additional claims on the other. There is no date certain for trial, no bellwether schedule, and no settlement negotiation framework in the public record. For merger purposes: the combined company inherits this litigation in full, with no reserve, no estimate, and no trial date.</p><p><strong>The Pre-Closing Dividend and the Leverage Question</strong></p><p><strong>The $1 billion pre-closing special dividend is the financial feature of this deal that deserves the most attention.</strong> Indivior will fund the dividend from a $650 million term loan from Citibank and the remainder from existing cash on the balance sheet. The term loan is drawn before close. The combined company begins its post-close operating life with $650 million of acquisition-related debt plus Indivior&#8217;s existing balance sheet obligations.</p><p>The financial logic: Indivior shareholders, who will own 56.5% of the combined company post-close, receive $1 billion in cash before the deal closes &#8212; capturing value that would otherwise be locked in equity they would need to sell after close. This is a standard technique in all-stock mergers where one party has more cash on its balance sheet than the exchange ratio captures. The CLO concern is not the dividend itself &#8212; it is the combined leverage profile against the combined EBITDA in a scenario where the dental MDL produces material reserve requirements in the near term.</p><p>The $125 million in projected cost synergies are the offset: if synergies materialize on schedule, the combined company&#8217;s EBITDA capacity to service the term loan is adequate. If the dental MDL reserve obligation competes with debt service for cash in the same period, the leverage profile tightens materially.</p><p><strong>The Representation and Warranty Analysis</strong></p><p>The most consequential legal work in this deal was the merger agreement&#8217;s representation structure around the dental MDL. The standard litigation representation requires that the company has disclosed all pending and threatened legal proceedings material to the business, that the reserve and accrual for such proceedings is adequate under GAAP, and that no material adverse effect will result from the resolution of disclosed proceedings. For a litigation with no reserve and no loss estimate, the representation must be carefully drafted to avoid an unintended warranty that the absence of a reserve reflects an assessment of immateriality.</p><p><strong>The Indivior 10-Q states plainly:</strong> &#8220;Given the status and preliminary stage of litigation, no estimate of possible loss can be made at this time.&#8221; That language appears in the public filing. The merger agreement representation must be consistent with that disclosure &#8212; representing that the dental MDL is in preliminary stages, that no reserve has been established because a loss estimate cannot be made at this stage, and that the merger agreement disclosure schedule identifies the MDL accurately. A broader representation that the disclosed litigation reserves are adequate would be affirmatively inaccurate.</p><p>Goodwin Procter, as Indivior&#8217;s merger counsel, drafted the representation. Saul Ewing, as Supernus&#8217;s merger counsel, negotiated the scope. The article a CLO should actually read is the merger agreement&#8217;s disclosure schedule for the dental MDL &#8212; which is not public &#8212; not the press release description of the deal.</p><p><strong>The Governance Asymmetry</strong></p><p>The deal has an interesting governance structure that does not obviously reflect the 56.5%/43.5% economic split. Four directors from each company join the combined board. Indivior&#8217;s Tony Kingsley becomes board chair. Supernus&#8217;s Jack Khattar becomes CEO. Supernus&#8217;s Rockville, Maryland headquarters becomes the combined company&#8217;s global headquarters. The combined company uses Supernus&#8217;s name and Supernus&#8217;s Nasdaq ticker.</p><p>This structure reflects the reality of the transaction: Indivior wanted the diversification out of OUD-only exposure and used the merger to accomplish it, but the resulting company is operationally led by the Supernus team. Kingsley as board chair with Khattar as CEO creates a split that gives Indivior&#8217;s legacy shareholders governance representation at the board level without operational control. The audit committee composition &#8212; which will oversee the dental MDL reserve determination and the OUD revenue trajectory &#8212; is the governance appointment that matters most and has not been publicly announced.</p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">Analyze the Dental MDL Representation in the Merger Agreement Before Endorsing the Deal</span></strong></p><p>For any CLO advising on an acquisition where the target carries an unresolved MDL in preliminary stages with no reserve and no loss estimate, the merger agreement representation structure around that litigation is the highest-priority legal workstream. Specifically: does the representation characterize the litigation accurately as preliminary stage with no current reserve, or does it represent more broadly that disclosed litigation reserves are adequate? The latter would be inaccurate. Does the disclosure schedule identify the dental MDL with sufficient specificity &#8212; case count, plaintiff count, tolling agreement status, current posture in the MDL court &#8212; to satisfy the buyer&#8217;s due diligence obligation? Is there a specific indemnification carve-out for dental MDL losses exceeding a defined threshold? Is there a material adverse effect qualifier for the dental MDL that is specific enough to give the buyer a walk right if the MDL posture materially worsens before close? These are the questions that Saul Ewing&#8217;s representation of Supernus was built to answer. For any CLO in a comparable position &#8212; acquiring a company with an unresolved MDL in preliminary stages &#8212; these are the four specific provisions to negotiate.</p><p><strong>BUSINESS IMPACT: </strong><em>A merger agreement that closes without specific protection around an unquantified MDL gives the buyer shareholders an undisclosed risk at the moment they vote on the transaction. A well-structured representation and indemnification package creates clarity. The Supernus shareholders voting on this deal deserve both.</em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">Assess the Combined Leverage Profile Against the Dental MDL Reserve Scenario</span></strong></p><p>Before any analyst presentation of the combined company&#8217;s financial profile, model the leverage scenario in which the dental MDL produces a material reserve requirement in the same period as the $650M term loan requires service. The combined company&#8217;s $2.2 billion pro forma revenue base and the $125 million synergy projection provide the numerator. The $650M term loan debt service provides one denominator element. The dental MDL reserve &#8212; which could range from immaterial to several hundred million dollars depending on the plaintiffs&#8217; causation case &#8212; is the variable that stress-tests the leverage profile. This is the financial scenario that the audit committee of the combined company will be managing from Day 1 of close. The CLO who modeled it in advance is the CLO who owns the right conversation with the board.</p><p><strong>BUSINESS IMPACT: </strong><em>A leveraged combined company with an unquantified MDL reserve obligation is not a crisis. It is a capital allocation management challenge. The CLO who mapped it is the CLO who can manage it.</em></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">Map the Audit Committee Oversight Structure for the Dental MDL Post-Close</span></strong></p><p>The audit committee of the combined Supernus, Inc. will be responsible for the periodic assessm</p><p>ent of the dental MDL reserve and the decision of when and at what level to establish a reserve against a litigation that currently has no estimate. That decision &#8212; when to establish a reserve, at what level, and what disclosure obligation attaches to the establishment of a material reserve &#8212; is a governance function with direct securities law consequences. The CLO&#8217;s strategic workstream is confirming that the audit committee&#8217;s composition includes at least one member with experience overseeing pharmaceutical litigation reserves, that the audit committee&#8217;s access to outside MDL counsel is direct and not filtered through management, and that the board-level disclosure protocol for any material change in the dental MDL&#8217;s posture is clearly defined before the first post-close board meeting. The audit committee that makes the reserve determination for the dental MDL is making one of the most consequential financial judgments the combined company&#8217;s board will face in its first 12 months.</p><p><strong>BUSINESS IMPACT: </strong><em>Audit committee governance over pharmaceutical litigation reserves is the governance workstream that most CLOs do not focus on until the reserve decision creates a disclosure obligation. The combined Supernus board has the opportunity to build the governance structure before that decision arrives.</em></p><p style="text-align: center;"><em>&#8220;Merger of equals is a transaction description. The dental MDL is the legal reality. The CLO&#8217;s job is to map the gap between the two before the shareholders vote.&#8221;</em></p><p style="text-align: center;"></p><p style="text-align: center;"><span data-color="#0000ff" style="color: rgb(0, 0, 255);">I&#8217;ve created a Merger of Equals Legal Architecture Protocol. You can find it at: https://laroccaadvisory.gumroad.com/</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!ImDo!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!ImDo!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!ImDo!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/d79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/218539145?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!ImDo!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ImDo!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd79589cd-299f-409c-aced-2d6cd957cc6c_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button tabindex="0" type="button" class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"><strong>ABOUT THE AUTHOR</strong></p><p><strong>John LaRocca </strong>is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of <strong>LaRocca Advisory Group</strong>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:null}" data-component-name="ButtonCreateButton"><a class="button primary" href="https://www.thegcplaybook.law/subscribe?"><span>Subscribe now</span></a></p><p></p>]]></content:encoded></item><item><title><![CDATA[The Rare Disease Platform Acquisition: What the Lexeo / Mantle Deal Teaches About SAFEs, Unregistered Stock, and the 12-Year Milestone]]></title><description><![CDATA[This article covers what makes the Lexeo/Mantle deal legally distinctive and what the CLO needs to execute correctly at each step.]]></description><link>https://www.thegcplaybook.law/p/the-rare-disease-platform-acquisition</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-rare-disease-platform-acquisition</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 30 Sep 2026 11:31:57 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!igMl!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p>On September 22, 2026, Lexeo Therapeutics announced the acquisition of Mantle Therapeutics for $8.3 million upfront &#8212; $5.3 million in cash and $3.0 million in unregistered Lexeo common stock &#8212; with up to $13 million in contingent consideration payable over a 12-year milestone term. Simultaneously, Lexeo announced three research collaboration agreements with academic and industry partners to advance cerebellar-targeted gene therapy for Friedreich ataxia. Four transactions closed on the same day. The aggregate announced consideration was $21.3 million.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>This deal will not appear in the BioBucks deal tracker. It is below the threshold that moves the aggregate M&amp;A statistics. It is the kind of transaction that receives a paragraph in BioPharma Dive and a brief Globe Newswire release. It also contains four specific legal structures that CLOs at clinical-stage and pre-commercial biotech companies encounter regularly and that the GC Playbook has not addressed in depth: the SAFE cancellation at closing, the unregistered stock consideration, the long-tail milestone covenant with an explicit no-minimum-resource-commitment, and the simultaneous collaboration agreement IP architecture.</p><p>At Y-mAbs Therapeutics, I was the CLO of a rare disease company working in a small patient population with multiple therapeutic programs and a complex development environment. The legal work at a rare disease biotech does not look like the legal work at a commercial-stage specialty pharma company. The structures are different, the patient population dynamics shape the regulatory strategy differently, and the acquisition of a small private company with early-stage programs requires CLO capabilities that a company whose M&amp;A experience is limited to large strategic transactions does not automatically have.</p><p><strong>This article covers what makes the Lexeo/Mantle deal legally distinctive and what the CLO needs to execute correctly at each step.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p></p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The Rare Disease Platform Acquisition: What the Lexeo / Mantle Deal Teaches About SAFEs, Unregistered Stock, and the 12-Year Milestone</span></strong></p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Friedreich Ataxia and the Multi-Modality Platform Thesis</span></strong></p><p>Friedreich ataxia is a progressive, multisystem genetic disease caused by deficiency of frataxin &#8212; a mitochondrial protein essential for iron-sulfur cluster assembly and energy metabolism. Approximately 5,000 individuals in the United States are affected; approximately 15,000 worldwide. Cardiac complications account for up to 80% of deaths in FA patients, with an average life expectancy of 35-40 years. There is no currently approved treatment specifically for FA cardiomyopathy.</p><p>Lexeo&#8217;s lead program &#8212; LX2006, an adeno-associated virus gene therapy designed to restore frataxin expression in cardiac tissue &#8212; is in its SUNRISE-FA 2 pivotal study with topline data expected in the second half of 2027. LX2006 received Orphan Medicinal Product designation from the European Commission in July 2024 and has FDA orphan drug designation. It has demonstrated sustained improvements across multiple cardiac biomarkers with no treatment-related serious adverse events in Phase 1/2.</p><p>The Mantle acquisition expands the platform beyond cardiac gene therapy in two specific ways. First, it adds non-gene-therapy modalities &#8212; oral small molecules, protein replacement, and RNA-based approaches &#8212; that could be used by patients who received or cannot receive gene therapy. Second, it adds CNS-targeted approaches that address the neurological manifestations of FA that systemic cardiac-targeted gene therapy does not reach. Lexeo&#8217;s strategic thesis: the FA patient needs both the cardiac program (LX2006) and the neurological program (the Mantle/collaboration portfolio), and no single modality addresses both.</p><p>The multi-modality platform thesis has a specific legal architecture consequence: the CLO is not managing a single development program and a single regulatory relationship. The CLO is managing an AAV gene therapy IND, two or three small molecule development programs at different stages, a biologic (fusion protein) development program, and an oligonucleotide program &#8212; each with its own IP chain of title, regulatory path, manufacturing requirements, and collaboration agreement terms.</p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The Full Deal Structure: Consideration Components and CLO Issues</span></strong></p><p>The Lexeo/Mantle merger agreement provides for a more complex consideration structure than the headline $8.3 million figure suggests. The table below maps each consideration component to its legal instrument and the specific CLO issue it creates.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!igMl!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!igMl!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 424w, https://substackcdn.com/image/fetch/$s_!igMl!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 848w, https://substackcdn.com/image/fetch/$s_!igMl!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 1272w, https://substackcdn.com/image/fetch/$s_!igMl!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!igMl!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png" width="628" height="370" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/ff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:370,&quot;width&quot;:628,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:153297,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/217447866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!igMl!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 424w, https://substackcdn.com/image/fetch/$s_!igMl!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 848w, https://substackcdn.com/image/fetch/$s_!igMl!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 1272w, https://substackcdn.com/image/fetch/$s_!igMl!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fff4f2704-2493-4be5-a808-bbf530f96b2f_628x370.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Legal Structure 1: The SAFE Cancellation</span></strong></p><p>Simple Agreements for Future Equity &#8212; SAFEs &#8212; are the dominant early-stage biotech financing instrument. Most pre-Series A biotech companies that have raised institutional capital have outstanding SAFEs, and most CLOs at clinical-stage public companies who have never been on the sell side of an early-stage acquisition have not managed SAFE cancellation at closing.</p><p><strong>The SAFE is not equity. It is the right to receive equity on the occurrence of a specified triggering event.</strong> The standard Y Combinator SAFE converts into preferred stock at the price per share of the company&#8217;s next equity financing round &#8212; the &#8216;Next Equity Financing.&#8217; A merger is typically defined in the SAFE as a &#8216;Liquidity Event&#8217; rather than a Next Equity Financing. Under the standard SAFE liquidity event provisions, the SAFE holder receives either: (a) conversion into common stock at the price determined by dividing the Post-Money Valuation Cap by the Company Capitalization, or (b) a cash payment equal to the Purchase Amount (the amount originally invested), whichever is greater.</p><p>The specific CLO obligation before the merger agreement is finalized: every outstanding SAFE must be individually analyzed against its liquidity event provisions to determine the SAFE consideration each holder will receive at closing. The merger agreement states that SAFE consideration is &#8216;determined in accordance with the liquidity event provisions of each SAFE&#8217; &#8212; meaning the merger agreement does not itself determine what the SAFE holders receive. The Shareholder Representative, acting on behalf of all Mantle equity holders, is responsible for confirming the SAFE consideration allocation, but the CLO overseeing the transaction must confirm that the SAFE analysis is complete and that the merger agreement&#8217;s consideration mechanics are consistent with each SAFE&#8217;s actual liquidity event terms.</p><p><strong>Common errors in SAFE cancellation at acquisition:</strong> applying a single conversion price to all SAFEs when different SAFEs have different valuation caps or discount rates; failing to identify SAFEs that have MFN provisions entitling older SAFE holders to the better of their own terms and the most favorable terms subsequently granted; and failing to account for SAFEs held by parties who are also employees, which creates a tax characterization question about whether the SAFE proceeds are capital gains or ordinary income.</p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Legal Structure 2: Unregistered Stock Consideration</span></strong></p><p>The $3.0 million stock component of the upfront consideration &#8212; and any stock-denominated milestone payments over the 12-year milestone term &#8212; are issued as unregistered Lexeo common stock under Section 4(a)(2) of the Securities Act and/or Regulation D. The shares are not registered under the Securities Act. The Mantle sellers who receive them cannot sell them in the public market until either a registration statement covering their resale is declared effective, or an exemption from registration is available (typically Rule 144, which requires a holding period of six months for non-affiliates and one year for affiliates of the issuer).</p><p><strong>The negotiated terms that determine the real value of the stock consideration:</strong></p><p>&#8226; <strong>Registration rights:</strong> Does the merger agreement include registration rights for the unregistered shares? Demand registration rights (the seller can demand a registration statement) or piggyback registration rights (the seller can include their shares in a registration statement Lexeo files for other purposes) determine when the shares become freely tradeable. Registration rights with a 6-month filing deadline are materially more valuable than registration rights that allow Lexeo to delay registration indefinitely.</p><p>&#8226; <strong>Lockup period:</strong> Even if registration rights are included, many merger agreements include a lockup period during which the selling shareholders agree not to sell the registered shares. The lockup period is a negotiated concession by the sellers in exchange for certainty of closing or other terms.</p><p>&#8226; <strong>VWAP mechanics for milestone stock:</strong> The milestone payments are payable in &#8216;shares of Common Stock valued using a thirty-day trailing volume-weighted average price based on the date of achievement of such milestone.&#8217; Twelve years from closing, Lexeo&#8217;s stock price may be materially different from what it is today. The VWAP mechanic is standard for stock-denominated milestone payments &#8212; it prevents gaming of the share count by reference to a single day&#8217;s price &#8212; but the milestone payees should understand that the dollar value of the stock they receive depends on Lexeo&#8217;s stock price at the time of achievement, not at closing.</p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Legal Structure 3: The 12-Year Milestone &#8212; Reading the Covenant</span></strong></p><p>The Merger Agreement provides for up to $12 million in milestone payments over a 12-year term, payable upon achievement of &#8216;specified development and regulatory milestones relating to Mantle&#8217;s product candidates.&#8217; The Merger Agreement also states, in language that is unusually explicit for a contingent consideration structure: &#8216;Lexeo makes no guarantees that it will achieve any milestone, and the Merger Agreement does not require Lexeo to devote any particular level of resources to the development or commercialization of Mantle&#8217;s product candidates beyond the commercially reasonable efforts standard set forth in the Merger Agreement.&#8217;</p><p><strong>This language is important. Commercially reasonable efforts is the weakest effort standard available in an M&amp;A milestone structure.</strong> It does not require a minimum R&amp;D spend, a minimum headcount devoted to the program, a specified timeline for development activities, or any specific commitment to advance the program to clinical testing. It requires only that Lexeo pursue the milestones with the effort that a company of similar resources and capabilities would devote to a similar program in similar circumstances &#8212; a standard that gives Lexeo substantial discretion in how it prioritizes the Mantle programs against LX2006 and its other pipeline.</p><p>The 12-year milestone term means that some or all of the milestones remain payable for more than a decade after closing. A program that is currently in the discovery stage &#8212; LX3070 &#8212; could theoretically advance to regulatory approval within that window, but the timeline is not guaranteed and the effort standard does not require Lexeo to advance it on any particular schedule. The Mantle sellers who negotiated milestone consideration in lieu of higher upfront consideration accepted the risk that those milestones may take the full 12 years to trigger &#8212; or may never trigger.</p><p><strong>For the CLO at a company acquiring pre-commercial programs with long-tail milestone structures, the lesson is direct:</strong> the milestone payment&#8217;s commercial value to the seller is inversely proportional to the length of the milestone term and the weakness of the effort standard. A 12-year milestone with a CRE standard and no minimum resource commitment is a contingent payment that may never be made. If the CLO&#8217;s client is the seller, negotiate a shorter milestone term, a stronger effort standard, or higher upfront consideration in exchange for the contingent risk.</p><p><strong>The Four Acquired Programs: IP and Regulatory CLO Obligations</strong></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!sbrz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!sbrz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 424w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 848w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 1272w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!sbrz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png" width="622" height="325" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/f067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:325,&quot;width&quot;:622,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:110678,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/217447866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!sbrz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 424w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 848w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 1272w, https://substackcdn.com/image/fetch/$s_!sbrz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff067c723-5bcf-46a8-a1ac-b80d89e1d54b_622x325.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Legal Structure 4: The Simultaneous Collaboration Agreements</span></strong></p><p>Three research collaboration agreements were signed on the same day as the Mantle merger agreement. Each collaboration is a separate legal instrument &#8212; a research collaboration and license agreement &#8212; with its own IP terms, governance structure, and milestone economics. The simultaneous announcement of four transactions (one merger, three collaborations) is a platform-building strategy, not an accident. It is also a significant CLO workstream.</p><p><strong>The specific IP issues in each collaboration:</strong></p><p>&#8226; <strong>Background IP vs. Foreground IP:</strong> Each collaboration agreement must define what technology each party brings to the collaboration (background IP) and what technology is developed in the collaboration (foreground IP, also called &#8216;program IP&#8217; or &#8216;collaboration IP&#8217;). The allocation of ownership and licensing rights to foreground IP determines who controls the commercial development of any discovery made in the collaboration. For a cerebellar gene therapy collaboration where the academic partner contributes CNS delivery expertise and Lexeo contributes the frataxin gene payload, the question of who owns the optimized delivery vector &#8212; which may have applications beyond Friedreich ataxia &#8212; is a negotiation point with significant commercial consequences.</p><p>&#8226; <strong>Publication rights:</strong> Academic collaboration partners require the right to publish research results. The collaboration agreement must give Lexeo a review period before publication &#8212; typically 30-60 days &#8212; to identify patentable inventions in the manuscript and file patent applications before the public disclosure that would defeat the novelty requirement. A collaboration agreement whose publication rights clause allows immediate publication without a Lexeo review window is a collaboration agreement that may inadvertently destroy patentable IP in Lexeo&#8217;s own platform.</p><p>&#8226; <strong>Right of first negotiation:</strong> If the collaboration produces a result that neither party developed alone &#8212; a novel delivery system, a new therapeutic modality &#8212; the collaboration agreement should give Lexeo a right of first negotiation to license or acquire the collaboration&#8217;s output before the academic partner can offer it to a third party. The ROFN window (typically 60-90 days) and the trigger event (disclosure of the collaboration result to the partner, not publication) are the specific terms that determine whether the ROFN provides meaningful protection.</p><p>&#8226; <strong>Exclusivity scope:</strong> Is the collaboration exclusive to Friedreich ataxia, or does it restrict Lexeo&#8217;s ability to use the developed delivery technology in other rare neurological disease programs? An exclusive collaboration in a broad technology area &#8212; TfR1-targeted delivery, for example &#8212; could prevent Lexeo from using the developed technology for programs outside FA without the collaboration partner&#8217;s consent. The exclusivity scope should be defined specifically by indication, target, and modality.</p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">FRIEDREICH ATAXIA ORPHAN DRUG DESIGNATION &#8212; WHAT LEXEO ALREADY HAS AND WHAT IT NEEDS TO MAINTAIN</span></strong></p><p>LX2006 holds FDA Orphan Drug Designation for Friedreich ataxia and EMA Orphan Medicinal Product designation. These designations provide: 7 years of U.S. market exclusivity post-approval; 10 years of EU market exclusivity; clinical development cost offsets (25% U.S. tax credit, waived FDA application fees). The Mantle programs &#8212; acquired at clinical, preclinical, and discovery stage &#8212; do not automatically inherit Lexeo&#8217;s ODD. Each Mantle-derived program that seeks FDA approval in FA will require its own Orphan Drug Designation application, its own clinical development data, and its own exclusivity period. The FA indication has roughly 5,000 U.S. patients &#8212; comfortably within the ODD threshold of 200,000. The CLO managing the FA platform should confirm ODD status for each program independently and track maintenance obligations (ODD holder must report to FDA annually on development progress).</p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong>Complete the SAFE Inventory and Liquidity Event Analysis Before the Merger Agreement Is Executed</strong></p><p>Before signing any merger agreement with a private early-stage target, the CLO must ensure the complete SAFE inventory analysis is done and reflected in the merger agreement&#8217;s consideration mechanics. The SAFE inventory covers: the aggregate principal amount of each outstanding SAFE; the valuation cap and discount rate for each SAFE; the MFN provisions in any SAFE; the liquidity event formula for each SAFE (valuation-cap conversion price vs. return of Purchase Amount &#8212; which is greater?); and the tax characterization of SAFE proceeds for each holder (capital gains vs. ordinary income depends on whether the SAFE is treated as equity for tax purposes, which in turn depends on the SAFE&#8217;s structure and the issuer&#8217;s election). The Shareholder Representative will make the allocation calculations, but the CLO should confirm the methodology before the merger agreement is signed. A merger agreement whose consideration waterfall is inconsistent with the actual SAFE terms will produce allocation disputes at closing that delay the transaction and create litigation risk.</p><p><strong>BUSINESS IMPACT: </strong><em>A SAFE analysis error that surfaces at closing &#8212; when the consideration waterfall produces a different result for a SAFE holder than their instrument entitles them to &#8212; is an error that either delays closing or produces a post-closing securities law claim by the SAFE holder who received less than they were owed.</em></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong>Negotiate Registration Rights for the Unregistered Stock Consideration</strong></p><p>In any acquisition where the acquirer is a NASDAQ- or NYSE-listed company issuing unregistered stock as consideration, the CLO for the target company should negotiate registration rights as a closing condition or as a covenant in the merger agreement. Specifically: demand registration rights exercisable at any time after six months from closing, with a filing deadline for the registration statement of 60 days following the demand; an automatic shelf registration obligation if the acquirer qualifies as an S-3 registrant (most NASDAQ-listed companies do); piggyback registration rights for any public offering the acquirer conducts in the 12 months following closing; and no lockup period beyond six months from closing. The CLO for the acquirer should resist unconditional demand registration rights and negotiate a six-month lockup as the standard concession. Either way, the registration rights negotiation is not a detail &#8212; it determines when the stock consideration becomes liquid and therefore what its present value is to the sellers.</p><p><strong>BUSINESS IMPACT: </strong><em>Unregistered stock consideration with no registration rights, a one-year lockup, and a 12-year milestone stock component creates seller consideration that may be effectively illiquid for years. The sellers who accepted that structure understood its value. The CLO who did not negotiate registration rights left value on the table for their client.</em></p><p><strong><span data-color="#38761d" style="color: rgb(56, 118, 29);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong>Build the Platform IP Map and Orphan Drug Designation Maintenance Calendar</strong></p><p>After closing a multi-modality rare disease platform acquisition, the CLO&#8217;s most durable contribution is the platform IP map &#8212; a document that inventories every IP asset in the combined portfolio by program, modality, and stage; maps the ownership and licensing chain for each IP asset; identifies the freedom-to-operate analysis status for each program; and confirms the orphan drug designation status and maintenance obligations for each program. For the Lexeo platform post-Mantle, the IP map covers: LX2006&#8217;s AAV gene therapy IP chain; LX3010&#8217;s oral combination IP; LX3030&#8217;s benzamide HDAC inhibitor IP; LX3050&#8217;s TfR1-targeted protein replacement IP; LX3070&#8217;s TfR1-targeted ASO IP; and the collaboration-derived IP from each of the three research collaborations. The orphan drug designation maintenance calendar confirms: which programs have FDA ODD, which have EMA OMP, which need ODD applications, and what the annual reporting obligations are for each designation. This map does not exist at closing &#8212; the CLO builds it in the 90 days following closing.</p><p><strong>BUSINESS IMPACT: </strong><em>A rare disease platform company that does not have a current IP map and ODD maintenance calendar is a company that cannot answer the basic diligence questions a potential acquirer, partner, or co-development counterparty will ask. The CLO who builds the map in the quarter following closing provides a tool the company will use for the duration of the platform.</em></p><p style="text-align: center;"><em>&#8220;The $8.3 million upfront acquisition contains the SAFE cancellation mechanics, the unregistered stock considerations, the long-tail milestone covenant, and the collaboration IP architecture that a CLO at any clinical-stage biotech needs to understand. The size of the deal does not determine the complexity of the legal work.&#8221;</em></p><p style="text-align: center;"><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested readers I have prepared a Rare Disease Platform Acquisition Protocol. It can be found at: http://laroccaadvisory.gumroad.com/</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!UvwM!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!UvwM!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!UvwM!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/aebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1040427,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/217447866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!UvwM!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!UvwM!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faebf2e8d-d8e0-44a4-a975-42c89b40b203_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"><strong>ABOUT THE AUTHOR</strong></p><p><strong>John LaRocca </strong>is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of <strong>LaRocca Advisory Group</strong>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</p><p></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Shareholder Activism in Pharma and Biotech: The 2026 Campaign Wave, the M&A Thesis, and the CLO's Pre-Campaign Governance Protocol]]></title><description><![CDATA[Every pharma and biotech board needs a pre-campaign governance framework in place before the activist's first letter arrives.]]></description><link>https://www.thegcplaybook.law/p/shareholder-activism-in-pharma-and</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/shareholder-activism-in-pharma-and</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 27 Sep 2026 11:32:23 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!paAx!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F275263ca-d184-4778-a8ff-afac21ce937f_1280x1280.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong>FROM THE EDITOR</strong></p><p>Shareholder activism ended 2025 with more than 255 campaigns &#8212; up 40% from 2024, the third consecutive year in which more than 1,000 companies were targeted globally. Elliott Management alone launched 18 campaigns in 2025 and 12 in the first half of 2026. Starboard Value won five board seats in Q1 2026 through cooperation agreements with Fox Factory, Phillips 66, Norwegian Cruise Line, and J.M. Smucker among others. In healthcare, Kenvue &#8212; the J&amp;J consumer health spinout &#8212; was targeted simultaneously by Starboard, Third Point, and Toms Capital Management, ultimately agreeing to be acquired by Kimberly-Clark at a valuation of nearly $49 billion.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>The pharma and biotech sector&#8217;s vulnerability to activist campaigns in 2026 is structural, not coincidental. It has three specific drivers. First, patent cliff pressure: looming LOE events force boards to demonstrate a pipeline replenishment strategy, and activists who believe the board is pursuing that strategy too slowly or too expensively have a credible public thesis. Second, IRA pricing reform: the Maximum Fair Price program has compressed the commercial window for branded small molecules in a way that changes the NPV of existing assets and the logic of the M&amp;A strategy the board should pursue. Third, the M&amp;A market itself: the H1 2026 deal wave demonstrated that assets in the right therapeutic categories are genuinely scarce, and activists who believe a company&#8217;s board failed to capture that value &#8212; either by selling too cheaply, by not selling when it should have, or by overpaying for acquisitions that did not deliver &#8212; have a specific, factual campaign thesis.</p><p><strong>In 2026, M&amp;A activism accounts for 64% of all campaigns in Q4 &#8212; the highest proportion in five years. Every pharma and biotech board needs a pre-campaign governance framework in place before the activist&#8217;s first letter arrives.</strong></p><p><em>&#8212; John LaRocca</em></p><p>Founding Editor | LaRocca Advisory Group</p><p><span data-color="#0000ff" style="color: rgb(0, 0, 255);">Shareholder Activism in Pharma and Biotech: The 2026 Campaign Wave, the M&amp;A Thesis, and the CLO&#8217;s Pre-Campaign Governance Protocol</span></p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The 2026 Activism Landscape: What Changed and What Did Not</span></strong></p><p>The headline statistics from Barclays&#8217; H1 2026 Review of Shareholder Activism are consistent with a market that has not returned to baseline after the 2025 surge: 255 campaigns in 2025 (up 40% from 2024), M&amp;A-thesis campaigns rising to 64% of all Q4 2025 campaigns &#8212; the highest proportion in five years &#8212; and Elliott and Starboard together accounting for nearly three-quarters of major campaign activity in H1 2026.</p><p>What the data also shows: the sector distribution has shifted. Technology drew the most campaigns in H1 2026 at roughly 21% of all campaigns, up from 12% a year earlier. Healthcare runs second at roughly 19%. The shift of activism toward technology does not reduce healthcare&#8217;s exposure &#8212; it reflects a broader market in which every sector with identifiable underperformance gaps, M&amp;A optionality, and a board that can be characterized as insufficiently responsive is a credible target.</p><p><strong>The specific pharma and biotech activism thesis in 2026 is the M&amp;A thesis:</strong> the target company&#8217;s board has either failed to pursue the strategic alternatives that the current M&amp;A market has made available, has failed to sell at a premium it was offered, or has overpaid for an acquisition that destroyed value instead of creating it. All three of those campaign theses are specific to the 2026 pharma market&#8217;s conditions.</p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The Three Pharma-Specific Vulnerability Factors</span></strong></p><p><strong>Patent Cliff Pressure</strong></p><p>A company whose largest commercial product faces LOE within 3-5 years and whose pipeline does not have a Phase 3 program capable of replacing the revenue is a company with an identifiable strategic problem that the activist can quantify. The activist&#8217;s thesis is simple: the market has discounted the stock for the patent cliff, the board&#8217;s response has been inadequate, and the company should either pursue M&amp;A to replace the revenue or put itself up for sale. Elliott&#8217;s approach at Pfizer &#8212; where it raised its holding to 8.5 million shares while publicly criticizing the company&#8217;s underperformance &#8212; is the current model for large-cap pharma activism driven by patent cliff pressure.</p><p><strong>The CLO&#8217;s specific role:</strong> before any activism campaign is launched, the CLO should have advised the board on the strategic alternatives analysis that the activist will demand. A board that has considered and documented its analysis of strategic alternatives &#8212; including M&amp;A, licensing, divestitures, and standalone execution &#8212; is a board that can respond to an activist&#8217;s demand for a strategic review with a substantive answer rather than an agreement to do something it should have already done.</p><p><strong>IRA Maximum Fair Price Pressure</strong></p><p>The IRA&#8217;s MFP program creates a specific vulnerability for any company with a large-population small molecule whose Medicare pricing will be compressed beginning within the next 3-5 years. An activist who can model the MFP impact on the company&#8217;s revenue projections and identify a gap between the board&#8217;s public guidance and the MFP-adjusted financial reality has a specific, quantified campaign thesis. Parvus Asset Management&#8217;s engagement with Novo Nordisk &#8212; building a stake amid concerns that the company may be losing its early lead in the weight-loss drug market &#8212; is a version of this thesis applied to the GLP-1 franchise.</p><p><strong>Operational Performance and Cost Structure</strong></p><p>Operational and margin pressure creates activism vulnerability independently of patent cliff and IRA exposure. Charles River Laboratories reached an agreement with Elliott in May 2025 to add four directors and conduct a strategic review. Avantor came under pressure from Engine Capital to bring in new directors, cut costs, and evaluate strategic options including a potential sale. Medtronic appointed two new directors in response to Elliott&#8217;s engagement. Becton Dickinson&#8217;s Starboard engagement produced a $17.5 billion Reverse Morris Trust separation of its life sciences division. Each of these campaigns followed a pattern: identifiable performance gap, specific remediation demand, cooperation agreement or proxy contest. The CLO&#8217;s governance posture should anticipate this pattern rather than respond to it.</p><p><strong><span data-color="#0000ff" style="color: rgb(0, 0, 255);">The Defensive Framework: What the Board Should Have in Place</span></strong></p><p><strong>Advance Notice Bylaws</strong></p><p><strong>Advance notice bylaws are the most basic structural defense against a proxy contest.</strong> They require a shareholder who intends to nominate a director or present a proposal at the annual meeting to provide written notice within a specified window &#8212; typically 60-90 days before the anniversary of the prior year&#8217;s annual meeting. The advance notice window gives the board time to evaluate the shareholder&#8217;s nominees, engage advisors, and prepare a response before the proxy season begins.</p><p>Delaware courts have consistently upheld advance notice bylaws when they are reasonable and not used to disenfranchise shareholders. The specific drafting considerations in 2026: the advance notice bylaw should require the nominating shareholder to provide detailed disclosure about its economic interest in the company (including derivatives, swaps, and other instruments that create economic exposure without voting rights &#8212; the &#8216;wolf pack&#8217; disclosure concern); the background and qualifications of any director nominees; and any agreement or arrangement between the nominating shareholder and its nominees. Advance notice bylaws that were last updated before 2020 are likely inadequate against the disclosure sophistication of the 2026 activist.</p><p><strong>Shareholder Rights Plan (Poison Pill) &#8212; Current Delaware Status</strong></p><p>A shareholder rights plan &#8212; the poison pill &#8212; is a defensive mechanism that dilutes the ownership of any shareholder who acquires above a specified threshold (typically 15-20%) without board approval. Delaware courts upheld the use of poison pills in the pandemic era and have continued to uphold them when they are adopted with a legitimate defensive purpose and not used to entrench management against a fully priced acquisition offer.</p><p><strong>The 2026 consideration:</strong> a poison pill that has not been reviewed by current outside counsel in the prior 12 months may have structural provisions that current Delaware case law has made less defensible. The &#8216;morning-in-America&#8217; provision, the grandfathering threshold, the definition of acting in concert, and the passive investor exemption for index funds are the specific provisions that should be reviewed annually against current Delaware precedent. The CLO should confirm the company has a current poison pill review on file, not a plan adopted in 2019 that has never been updated.</p><p><strong>The Cooperation Agreement: Negotiating the Alternative to a Proxy Contest</strong></p><p>Most activism campaigns in 2026 end in a cooperation agreement rather than a proxy contest. A cooperation agreement typically provides: the activist receives one or more board seats (either from its own nominees or from a mutually agreed independent director); the activist agrees to standstill provisions that limit its ability to acquire additional shares, make additional public demands, or support competing proposals for a specified period; the company commits to certain governance changes or process reviews requested by the activist; and both parties agree to keep the terms of the cooperation confidential.</p><p><strong>The specific negotiation points that protect the board:</strong> the information-sharing agreement embedded in the cooperation agreement (what financial and strategic information does the activist director receive in their capacity as a director, and what fiduciary duties does that create?); the standstill provisions (how long does the activist agree not to launch additional campaigns?); and the scope of any strategic review commitment &#8212; a commitment to &#8216;evaluate strategic alternatives&#8217; that has no defined scope, timeline, or outcome criteria is an open-ended obligation that the activist will use as leverage for additional demands.</p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong>Conduct the Activism Vulnerability Assessment Before the Proxy Season</strong></p><p>The activism vulnerability assessment is the CLO&#8217;s annual contribution to the board&#8217;s governance preparation. It answers four questions: does the company have an identifiable performance gap relative to its sector peers that an activist could quantify and present to institutional shareholders? Does the company&#8217;s current LOE timeline, IRA exposure, or pipeline status create a M&amp;A thesis &#8212; the argument that the board should have pursued M&amp;A and has not, or that the board should explore a sale? Are the company&#8217;s advance notice bylaws current against 2026 Delaware precedent and adequate to protect the board&#8217;s ability to respond to a campaign with appropriate preparation time? Does the company have a current poison pill reviewed against current Delaware case law, or an outdated plan that provides less structural protection than the board believes? The assessment is completed by the CLO and outside M&amp;A and corporate governance counsel before November each year, ahead of the January-February proxy season.</p><p><strong>BUSINESS IMPACT: </strong><em>A board that receives an activist&#8217;s public letter without a current vulnerability assessment, an updated advance notice bylaw, and a reviewed poison pill is a board that is responding to governance pressure in real time. The boards in the Kenvue, Becton Dickinson, and Charles River situations that ended in major structural changes did not have the luxury of a governance framework they had built in advance.</em></p><p><strong><span data-color="#38761d" style="color: rgb(56, 118, 29);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong>Update the Advance Notice Bylaw and Confirm the Poison Pill Status</strong></p><p>Before the next proxy season, confirm the advance notice bylaw has been reviewed by outside governance counsel against current Delaware precedent and the 2026 activist information-request practices. The specific provisions to update: the disclosure requirement for economic interests (including derivatives and instruments without voting rights); the background and qualification disclosure requirement for director nominees; and the acting-in-concert definition (which must capture the wolf pack aggregation of activist positions held through related entities). Separately, confirm the poison pill status: is there a current pill in place, and when was it last reviewed? If the pill was adopted more than three years ago and has not been reviewed against current Delaware case law, commission a review by outside counsel. A pill that contains outdated structural provisions may not provide the board with the protective trigger at the threshold the board believes it does.</p><p><strong>BUSINESS IMPACT: </strong><em>The advance notice bylaw and the poison pill are the structural defenses that determine whether an activist can mount a proxy campaign on their own timeline or must proceed on the company&#8217;s timeline. The company whose governance documents give the board adequate preparation time negotiates from a position of relative strength. The one whose documents are outdated does not.</em></p><p><strong><span data-color="#f1c232" style="color: rgb(241, 194, 50);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong>Build the First-Response Protocol for an Activist Communication</strong></p><p>The first 48 hours after receipt of an activist&#8217;s letter or public demand determine the tone and trajectory of the campaign. Build the first-response protocol before any activist communication arrives. The protocol covers: who at the company is authorized to communicate with the activist and on what timeline; who is authorized to communicate with the media, investment community, and institutional shareholders; the engagement of outside M&amp;A counsel and proxy advisory specialists (ISS and Glass Lewis relationships matter in a campaign, and the proxy advisors should be identified and a relationship established in advance, not in response to a campaign); the board notification protocol and the special committee consideration (should a special committee of disinterested directors manage the response?); and the first written response &#8212; is it a no-comment, an engagement offer, or a substantive rebuttal, and who approves it? The first-response protocol should be a two-to-three page document reviewed annually and updated for any material change in the company&#8217;s governance or strategic position.</p><p><strong>BUSINESS IMPACT: </strong><em>The activist&#8217;s first letter is designed to be made public immediately if the company does not respond quickly and credibly. The company that has a response protocol ready produces a coherent, coordinated response within 24 hours. The company that does not spends those 24 hours in an improvised internal debate while the activist&#8217;s narrative sets the public frame.</em></p><p style="text-align: center;"><em>&#8220;M&amp;A activism accounts for 64% of all Q4 2025 campaigns &#8212; the highest proportion in five years. The pharma board that has not built its pre-campaign governance framework is operating without the tools it will need when the activist&#8217;s letter arrives.&#8221;</em></p><p style="text-align: center;"><strong>For interested readers, I have created a Shareholder Activism Defense Protocol. It can be found at laroccaadvisory.gumroad.com/</strong></p><p><strong>ABOUT THE AUTHOR</strong></p><p><strong>John LaRocca </strong>is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of <strong>LaRocca Advisory Group</strong>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The GC Playbook! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[PE's Durability Play: Four Categories of Durable Pharma Assets, How They're Underwritten, and What the CLO Owns]]></title><description><![CDATA[The durability play changes what the CLO owns.]]></description><link>https://www.thegcplaybook.law/p/pes-durability-play-four-categories</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/pes-durability-play-four-categories</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 23 Sep 2026 11:31:46 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!bfgA!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong><span>FROM THE EDITOR</span></strong></p><p><span>The PwC mid-year analysis stated the current PE investment thesis in pharma with unusual directness: &#8216;private equity seeks durability in specialty pharma and life sciences services.&#8217; Not pipeline upside. Not Phase 3 binary bets. Durability. The analysis identified the scarce resource in the current market as differentiated assets with near-term commercial potential &#8212; and PE is specifically not competing for those assets against large-cap strategic pharma. PE is buying the assets that generate durable revenue while those strategic buyers fight over the next clinical blockbuster.</span></p><p><span>The durability thesis is a specific answer to a specific market condition. In 2024 and 2025, PE funds chased pipeline assets alongside strategic buyers &#8212; bidding on Phase 2 programs at valuations that reflected speculative clinical upside. That strategy produced inconsistent returns when Phase 3 data was negative and an increasingly competitive acquisition process when data was positive. The durability play is structurally different: acquire a commercial-stage specialty pharma company or a pharma services platform with established revenue, known margins, and identifiable moats &#8212; then exit to a strategic buyer who wants the revenue or the infrastructure.</span></p><p><span>Bain&#8217;s 2026 Global Healthcare Private Equity report identified four categories of durable pharma assets attracting PE capital: orphan and rare disease commercial franchises, complex generic and 505(b)(2) specialty products, commercial-stage specialty pharma platforms, and CDMO/pharma services businesses. Each has a distinct legal architecture, a distinct set of diligence risks, and a distinct exit pathway.</span></p><p><strong><span>The durability play changes what the CLO owns. The legal work at a pipeline acquisition is about clinical program risk, IP chain of title, and CVR design. The legal work at a durability acquisition is about commercial contract durability, IRA MFP exposure, payor access architecture, and the exit conditions that make the strategic sale attractive.</span></strong></p><p><em><span>&#8212; John LaRocca</span></em></p><p><span>Founding Editor | LaRocca Advisory Group</span></p><p></p><p><strong><span>What &#8216;Durability&#8217; Means as an Investment Thesis</span></strong></p><p><span>In PE underwriting, a durable asset is one whose revenue can be projected with reasonable confidence over the investment horizon without depending on binary clinical outcomes. A pipeline asset&#8217;s NPV depends on whether the drug works. A durable commercial asset&#8217;s NPV depends on whether patients keep buying the drug that already works, whether payors keep covering it, and whether the competitive landscape remains favorable.</span></p><p><span>Durability does not mean zero risk. It means quantifiable risk that the PE sponsor can underwrite at deal entry &#8212; and that produces a more predictable return profile than the binary outcomes of clinical-stage investing. The Bain analysis confirmed this: &#8216;specialty pharmaceuticals, neurology, nephrology, and plastic surgery are areas where greater scale offers the most durability for PE investment. Pharma services investments have long benefited from consistent demand.&#8217; The durability thesis is specifically the inverse of the speculative market cap thesis covered in this newsletter&#8217;s September analysis &#8212; rather than buying future value at a probability discount, PE is buying current value at an EBITDA multiple.</span></p><p><strong><span>The legal risk profile of a durability acquisition is specific.</span></strong><span> The pipeline acquisition requires clinical program diligence, regulatory transfer analysis, CVR design, and FDA relationship assessment. The durability acquisition requires commercial contract durability analysis, IRA MFP exposure modeling, payor access architecture review, change-of-control risk mapping across all commercial relationships, and the Section 232 tariff exposure assessment for any product with API import exposure. These are not the same diligence workstreams, and the CLO who applies pipeline diligence protocols to a durability acquisition is missing the things that matter most.</span></p><p></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!bfgA!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!bfgA!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 424w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 848w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 1272w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!bfgA!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png" width="622" height="373" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:373,&quot;width&quot;:622,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:162946,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/216335137?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!bfgA!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 424w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 848w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 1272w, https://substackcdn.com/image/fetch/$s_!bfgA!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F32e0e448-4d33-4841-a870-7cc42df1034f_622x373.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong><span>The IRA&#8217;s Impact on the Durability Thesis</span></strong></p><p><span>The IRA&#8217;s Maximum Fair Price program directly affects the durability thesis for three of the four categories &#8212; orphan/rare disease, 505(b)(2) specialty, and commercial platforms. The fourth category (CDMO/pharma services) is not affected by MFP because CDMOs are not Medicare Part D products.</span></p><p><strong><span>Orphan Drug and the MFP Carve-Out</span></strong></p><p><strong><span>Orphan drugs with an indication covering fewer than 200,000 patients are exempt from MFP selection</span></strong><span> under the IRA&#8217;s small population carve-out. This is one of the most significant structural advantages of the orphan drug durability thesis: the seven-year orphan exclusivity, the pricing power, and the patient registry moat persist without the MFP compression that applies to large-population drugs. The PE fund acquiring a rare disease commercial franchise with orphan designation and MFP exemption is acquiring a revenue stream that is structurally protected from the IRA&#8217;s most direct pricing mechanism. For drugs with multiple orphan indications, each indication&#8217;s status must be analyzed separately &#8212; a drug with an orphan indication in one population and a non-orphan indication in a second population may face MFP selection on the non-orphan indication even while the orphan indication remains exempt.</span></p><p><strong><span>505(b)(2) and Complex Generic &#8212; the Small Molecule Pill Penalty</span></strong></p><p><span>The IRA&#8217;s nine-year eligibility clock for small molecules (versus thirteen years for biologics) hits 505(b)(2) specialty products with the same force it hits NCEs. A 505(b)(2) product approved in 2018 reached IRA selection eligibility in 2025. If the product has significant Medicare Part D volume, it is a candidate for negotiation in the next selection cohort. The PE underwriting model for a 505(b)(2) specialty pharma acquisition must incorporate MFP ceiling pricing at each age tier &#8212; 75% of non-federal AMP at year nine, 65% at year twelve, 40% at year sixteen. A 505(b)(2) product with $300 million in Medicare Part D revenue at year fourteen of commercial life, subject to the 35% MFP ceiling discount, faces a revenue reduction of $105 million annually. That reduction must be in the EBITDA model before LOI.</span></p><p><strong><span>Commercial Platform &#8212; Payor Contract Durability Under MFP</span></strong></p><p><span>A commercial specialty pharma platform&#8217;s payor access architecture &#8212; the formulary placements, prior authorization criteria, and specialty pharmacy contracts that determine patient access to the product &#8212; has historically been the most durable element of the commercial franchise. A product in a preferred formulary position with established payor relationships and a specialty pharmacy hub network has a commercial moat that takes years for a competitor to displace. The IRA complicates this durability thesis in a specific way: the MFP creates a Medicare reference price that payors and PBMs use as a benchmark in commercial negotiations even for non-Medicare patients. A product whose Medicare price drops 40% under MFP may face commercial pricing pressure from payors who cite the MFP as evidence that the product can be priced lower across the book of business. The CLO&#8217;s payor contract audit must assess which agreements include MFP reference pricing provisions and what their commercial implications are.</span></p><p><strong><span>Section 232 in the Durability Thesis</span></strong></p><p><span>The Section 232 pharmaceutical tariff adds a cost-of-goods dimension to the durability acquisition that did not exist before April 2026. A commercial-stage specialty pharma company with API sourced from a non-exempt country is carrying ongoing tariff exposure that compounds against its EBITDA margin. The specific categories to assess:</span></p><p><span>&#8226; </span><strong><span>HTSUS classification of all API and key starting materials</span></strong><span>: Is the API classifiable under a specialty product exemption (orphan, CGT, ADC, plasma-derived, nuclear medicine)? If yes, the 0% rate may apply with proper documentation.</span></p><p><span>&#8226; </span><strong><span>API sourcing geography</span></strong><span>: API sourced from a non-exempt country with existing most-favored-nation pricing agreements may qualify for the reduced rate under the tariff&#8217;s MFN onshoring carve-out. Document the basis for any reduced rate claimed.</span></p><p><span>&#8226; </span><strong><span>Cost of goods model</span></strong><span>: The floating rate mechanism means the tariff is applied so the total cumulative duty rate equals 100% &#8212; not the Section 232 rate added on top. Confirm the cost of goods model applies the correct calculation before closing.</span></p><p><span>&#8226; </span><strong><span>CDMO agreement tariff passthrough provisions</span></strong><span>: Does the manufacturing agreement specify who bears the tariff cost on API procured by the CDMO on the company&#8217;s behalf? This is the most commonly overlooked contractual gap in specialty pharma commercial operations.</span></p><p><strong><span>The Exit to Strategic Buyer: What Makes the Durability Play Attractive at Year 4-5</span></strong></p><p><span>The PE durability thesis depends on a strategic buyer acquiring the platform or product at a meaningful EBITDA multiple premium over the entry price. The exit multiple arbitrage &#8212; buying at 8-12x and selling at 14-18x &#8212; is the financial architecture of the trade. What makes the strategic buyer pay that premium:</span></p><p><span>&#8226; </span><strong><span>Commercial infrastructure scarcity</span></strong><span>: A specialty pharma commercial platform with established payor relationships, specialty pharmacy contracts, and a patient services hub is exactly the commercial infrastructure that a mid-market specialty pharma company or a large pharma company seeking a new commercial channel cannot build from scratch in the relevant therapeutic area.</span></p><p><span>&#8226; </span><strong><span>Orphan drug franchise completeness</span></strong><span>: A rare disease commercial franchise with multiple orphan designations, a patient registry, and a global named patient program is significantly more difficult to replicate than it is to acquire. The strategic buyer pays a premium for the registry moat and the regulatory exclusivity stack.</span></p><p><span>&#8226; </span><strong><span>CDMO capacity constraints</span></strong><span>: In the current post-Section 232 environment, FDA-inspected U.S. manufacturing capacity is genuinely scarce. A CDMO with U.S.-based API or formulation capacity commands strategic premiums from pharma companies seeking to reduce their Section 232 tariff exposure or reduce their supply chain concentration risk.</span></p><p><strong><span>The CLO&#8217;s role in the exit preparation:</span></strong><span> The exit-ready legal file for a durability acquisition has the same five elements as any PE portfolio company exit &#8212; IP chain of title, commercial contract change-of-control audit, regulatory compliance file, litigation log, and equity documentation. But the durability acquisition adds two elements that the pipeline acquisition does not: the MFP exposure analysis with a current eligibility calendar for every product, and the payor access architecture documentation showing the transferability of the commercial relationships that justified the premium.</span></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span>Build the MFP Eligibility Calendar Into the Durability Acquisition Model Before LOI</span></strong></p><p><span>The MFP eligibility calendar is the most critical piece of financial analysis in a durability acquisition and the one most commonly absent from the preliminary deal model. Before any letter of intent is executed on a commercial-stage specialty pharma acquisition: build the MFP eligibility calendar for every marketed product; calculate the ceiling price at each age tier for each product with significant Medicare Part D volume; model the revenue impact at the point of MFP effectuation; and confirm whether any product qualifies for the orphan drug MFP exemption. For a product within five years of MFP eligibility, the revenue impact should be incorporated into the acquisition EBITDA multiple &#8212; not treated as a risk factor with a probability discount. The MFP is a scheduled event, not a contingency. The deal model that treats it as a contingency is a deal model built on inaccurate assumptions.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>A durability acquisition closed without an MFP eligibility calendar is a durability acquisition whose most significant revenue risk is not in the model. The PE sponsor whose board approved the acquisition without that analysis owns the gap at Year 3 when the first MFP selection affects the portfolio company&#8217;s commercial operations.</span></em></p><p><strong><span data-color="#ff9900" style="color: rgb(255, 153, 0);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span>Audit the Commercial Contract Architecture for Durability and Change-of-Control Risk</span></strong></p><p><span>The commercial contract architecture at a specialty pharma platform is what makes the durability thesis real. The payor contracts, the specialty pharmacy hub agreements, the co-pay assistance program, the patient support program, and the group purchasing organization relationships are the infrastructure that keeps revenue flowing. Each of these relationships has a change-of-control provision, a term and renewal structure, and a notice and consent requirement that the PE acquisition will trigger. The commercial contract audit &#8212; conducted before closing and integrated into the transition planning process &#8212; identifies which relationships require counterparty consent, which require notice only, and which auto-renew under their existing terms. A commercial platform whose three largest payor contracts all have change-of-control termination rights is a platform whose commercial durability has a closing-date cliff. Identify it before closing, not after.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>The payor relationships that took years to build at the right formulary tier do not automatically transfer to a new owner on closing day. The CLO who mapped the change-of-control provisions before closing has a remediation plan. The one who discovers them post-close is managing a commercial disruption that the investment thesis did not contemplate.</span></em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong><span>Structure the Exit Documentation Package 18 Months Before the Target Exit Date</span></strong></p><p><span>The exit documentation package for a durability acquisition has two elements beyond the standard PE portfolio company exit file. First, the MFP exposure analysis with a current eligibility calendar: the strategic buyer acquiring a commercial specialty pharma platform in Year 4-5 of a PE hold will request the MFP exposure analysis as a standard diligence item. Have it prepared and updated annually rather than assembled in response to the data room request. Second, the payor access architecture documentation: a structured description of each significant payor relationship, the formulary position, the prior authorization criteria, the contract term and renewal status, and the historical revenue contribution. This documentation is what the strategic buyer uses to evaluate the commercial durability that justified the acquisition premium in the first place. The strategic buyer paying 14-18x EBITDA for a specialty pharma platform is paying for the commercial infrastructure as much as the products on it. That infrastructure needs to be documented in a way that a diligence team can evaluate in three weeks.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>The strategic buyer who does not understand the durability of the commercial platform at the point of exclusivity grant reprices the acquisition. The PE sponsor who built the documentation package before the exit process began negotiated from a position of demonstrated value, not asserted value.</span></em></p><p><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested practitioners, I have created a Durability Acquisition Protocol and made it available on Gumroad (https://laroccaadvisory.gumroad.com). It contains five sections covering the specific diligence dimensions that standard pipeline acquisition protocols miss. </span></em></p><p style="text-align: center;"><em><span>&#8220;Private equity is not competing for the next clinical blockbuster. It is buying the revenue that already exists, the commercial infrastructure that is genuinely scarce, and the regulatory moat that protects both. The durability thesis is the most disciplined trade in the current pharma market.&#8221;</span></em></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!9-KB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!9-KB!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!9-KB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/216335137?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!9-KB!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!9-KB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0a84b019-70e4-4899-8a2c-af2ab7a2ee9c_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"></p>]]></content:encoded></item><item><title><![CDATA[Asset Scarcity Is Reshaping Deal Terms: What the Shortage of Near-Term Commercial Assets Has Done to the Merger Agreement]]></title><description><![CDATA[The terms are where the leverage actually lives.]]></description><link>https://www.thegcplaybook.law/p/asset-scarcity-is-reshaping-deal</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/asset-scarcity-is-reshaping-deal</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 20 Sep 2026 11:29:47 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!7TZc!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong><span>FROM THE EDITOR</span></strong></p><p><span>Argenx acquired Forte Biosciences in July 2026 at an 86% premium to the volume-weighted average share price in the 30 days following Forte&#8217;s vitiligo readout. Eighty-six percent. The BioPharm International analysis of that transaction described the premium as &#8216;unusually large.&#8217; It is. It is also a data point, not an anomaly. When an asset is genuinely scarce &#8212; when there are three or four buyers who need it and one seller who has it &#8212; the premium reflects competitive necessity, and the deal terms that surround the premium reflect the seller&#8217;s leverage in a way that most deal lawyers have not seen at this frequency.</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p><span>The PwC mid-year analysis named it directly: &#8216;the scarce resource is differentiated assets with near-term commercial potential in the right therapeutic areas.&#8217; Capital is abundant. Buyer appetite is abundant. The de-risked, near-term commercial assets in cardiometabolic, CNS, oncology, and rare disease are not. The market has cleared much of the available inventory in those categories through the H1 2026 deal wave. What remains commands the terms that scarcity creates.</span></p><p><span>This article covers how scarcity has changed six specific deal terms &#8212; and what the CLO at a company with a scarce asset needs to know about negotiating each of them. The analysis runs in both directions: the CLO advising the seller needs to know when the asset&#8217;s scarcity creates leverage to extract terms that a routine M&amp;A process would not produce. The CLO advising the buyer needs to know which concessions are worth making to close the scarce asset and which ones create ongoing exposure that the transaction economics do not justify.</span></p><p><strong><span>Asset scarcity has moved from a valuation concept to a deal terms concept. The premium is the number. The terms are where the leverage actually lives.</span></strong></p><p><em><span>&#8212; John LaRocca</span></em></p><p><span>Founding Editor | LaRocca Advisory Group</span></p><p></p><p><strong><span>The Scarcity Condition: What Creates Leverage in the Merger Agreement</span></strong></p><p><span>Every deal term in a merger agreement reflects a negotiated allocation of risk between buyer and seller. In a routine M&amp;A process, where the seller is one of many available targets, where the buyer has reasonable alternatives, and where neither party has disproportionate time pressure, the risk is allocated roughly symmetrically. The MAC definition protects the buyer against genuine material changes. The reverse termination fee compensates the seller if the buyer walks without cause. The termination fee compensates the buyer if the board takes a superior offer. These terms are roughly in balance because leverage is roughly in balance.</span></p><p><span>Asset scarcity breaks that balance. When a seller has a late-stage clinical program, an approved product, or a commercial franchise that multiple sophisticated buyers need for competitive reasons &#8212; and when there are genuinely few or no comparable alternatives &#8212; the seller&#8217;s leverage increases on every term simultaneously. The seller can negotiate a higher Reverse Termination Fee (RTF) because the buyer cannot afford to lose the asset to a competing bidder. The seller can narrow the Material Adverse Condition (MAC) because the buyer&#8217;s need for the asset is not materially affected by the business conditions that a broad MAC is designed to capture. The seller can insist on specific performance because the asset&#8217;s irreplaceability means the RTF alone is not an adequate remedy.</span></p><p><strong><span>The CLO&#8217;s first task in any deal negotiation is to assess where the asset sits on the scarcity spectrum.</span></strong><span> A Phase 3 readout in a mechanism where three other programs are six months behind is not a scarce asset &#8212; the buyer has credible alternatives and will use them as negotiating leverage. A de-risked Phase 3 program in a mechanism where no other company has clinical data, in a therapeutic area where a $50 billion patent cliff is approaching, is a scarce asset &#8212; and the deal terms should reflect that reality.</span></p><p><strong><span>The Six Deal Terms That Scarcity Has Changed</span></strong></p><p><span>The following table maps the six deal terms most directly affected by asset scarcity &#8212; comparing the pre-scarcity standard (2022-2024) with the current standard for genuinely scarce assets in the 2026 market.</span></p><p></p><div class="captioned-image-container"><figure><div class="image-link image2" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Pc01!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 424w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 848w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 1272w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!Pc01!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png" width="628" height="157" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/08744925-40bc-464a-936d-eb287dc90a2c_628x157.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:157,&quot;width&quot;:628,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:56935,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/216331632?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Pc01!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 424w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 848w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 1272w, https://substackcdn.com/image/fetch/$s_!Pc01!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F08744925-40bc-464a-936d-eb287dc90a2c_628x157.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></div></figure></div><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!7TZc!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!7TZc!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 424w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 848w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 1272w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!7TZc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png" width="624" height="364" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:364,&quot;width&quot;:624,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:136225,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/216331632?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!7TZc!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 424w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 848w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 1272w, https://substackcdn.com/image/fetch/$s_!7TZc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F114c1275-e7f5-473f-8aac-900231fc9a83_624x364.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong><span>The Bidding War Dynamic: What Happens After the Deal Is Announced</span></strong></p><p><span>A signed merger agreement reveals something the bidder competition did not have during private negotiations: the exact price and all material terms. BioSpace identified this dynamic explicitly in its March 2026 analysis: &#8216;an announced deal reveals the exact price and terms, giving a party that lost out all the details they didn&#8217;t have during private negotiations to top the bid.&#8217; The result is that unsolicited, public bidding wars in biopharma are expected to increase.</span></p><p><span>The Pfizer/Metsera/Novo Nordisk triangle illustrates the mechanics. Pfizer had a signed agreement. Novo Nordisk&#8217;s bid emerged after the announcement. Had Novo ultimately secured the company, the termination fee payable to Pfizer would have been $190 million. The $190 million is not just Pfizer&#8217;s consolation prize &#8212; it is the structural cost that Novo had to incorporate into its bid economics before deciding whether to move. An acquirer evaluating whether to make a competing bid must pay the original buyer&#8217;s termination fee, finance the acquisition at a higher price, and close the process on an even more compressed timeline. The termination fee is a structural barrier to competition, not merely a contractual protection.</span></p><p><strong><span>The CLO&#8217;s role when a competing bid emerges post-announcement:</span></strong><span> The board must evaluate whether the competing offer is a &#8216;superior proposal&#8217; under the merger agreement&#8217;s fiduciary out provisions. That evaluation requires a careful reading of the superior proposal definition &#8212; which is typically specific about the threshold improvement in financial terms required, the certainty of closing required, and the financing condition status required. A competing offer that appears financially superior on headline economics may not satisfy the superior proposal definition if it comes with financing risk, regulatory uncertainty, or a timeline that the board cannot evaluate with confidence. The CLO advising the board in this analysis is doing the most consequential governance work of the entire deal process.</span></p><p><strong><span>The Seller-Side CLO&#8217;s Leverage Assessment Protocol</span></strong></p><p><span>Before engaging in any merger agreement negotiation, the CLO advising the seller should complete a written leverage assessment. The assessment answers four questions whose answers determine which deal terms the seller can realistically move:</span></p><p><strong><span>1. How many credible buyers exist for this specific asset?</span></strong></p><p><span>Not the number of potential acquirers who might theoretically be interested. The number who have the strategic logic, the balance sheet or financing capacity, and the near-term urgency to close a transaction. A cardiometabolic program with Phase 3 data in 2026 might have credible buyer interest from four large-cap pharma companies. A rare disease program with orphan designation in a small indication might have credible buyer interest from two. The number defines the auction&#8217;s competitiveness and therefore the seller&#8217;s leverage on each term.</span></p><p><strong><span>2. What is the buyer&#8217;s time pressure?</span></strong></p><p><span>A buyer whose largest product faces LOE in 2028 has different time pressure than a buyer whose pipeline is well-stocked. The LOE timeline creates urgency that the seller can leverage for better terms. A buyer under time pressure accepts shorter exclusivity, higher RTF, and narrower MAC conditions rather than lose the asset to a competitor with the same urgency.</span></p><p><strong><span>3. Does the asset have a credible IPO alternative?</span></strong></p><p><span>The IPO market&#8217;s strength in H1 2026 &#8212; 13 offerings raising $5 billion, topping every full-year total from 2022 through 2025 &#8212; means that the dual-track is a genuine alternative for many late-stage biotech companies. A seller who can credibly file an S-1 and has a bank relationship supporting the IPO process has a walk-away option that disciplines the buyer&#8217;s terms. A seller who has no realistic IPO path has less leverage on every term and should negotiate accordingly.</span></p><p><strong><span>4. What is the specific term the seller needs most?</span></strong></p><p><span>The leverage assessment should produce a prioritized list of terms. The seller who tries to win every negotiating point typically wins fewer of them than the seller who identifies the two or three terms that matter most and trades concessions on the others to get them. For a seller whose primary concern is deal certainty &#8212; that the transaction closes &#8212; the priority order is specific performance, RTF adequacy, and MAC narrowing. For a seller whose primary concern is value maximization, the priority order is a higher RTF (which improves the seller&#8217;s walk-away economics if the buyer withdraws), a broader fiduciary out (which maximizes the seller&#8217;s ability to take a competing offer), and a go-shop.</span></p><p><strong><span>THE BIO-TECHNE/MERCK KGAA PROXY: A CURRENT DATA POINT ON RTF SIZE</span></strong></p><p><span>The Bio-Techne proxy statement (filed 2026) provides a current reference point on RTF sizing in a large strategic acquisition. The merger agreement in the Merck KGaA / Bio-Techne transaction included a termination fee equal to 2.0% of equity value and a reverse termination fee equal to 10.0% of equity value. The 10% RTF &#8212; five times the seller&#8217;s termination fee &#8212; reflects the Bio-Techne board&#8217;s leverage in a transaction where the seller was a highly differentiated life science tools platform with limited direct comparables. For pharma CLOs benchmarking RTF negotiation, the 10% figure is at the high end of current market practice but within the range that sophisticated sellers are extracting for genuinely differentiated assets.</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span>Complete the Leverage Assessment Before the First Term Sheet</span></strong></p><p><span>The leverage assessment is the CLO&#8217;s contribution to the seller&#8217;s negotiating position before any financial terms are proposed or accepted. The four-question framework above &#8212; credible buyer count, buyer time pressure, IPO alternative credibility, and priority term ranking &#8212; produces a written document that the CEO, CFO, and investment banker can align on before the first draft term sheet is shared. Without it, the negotiating team is making term-by-term decisions without a strategic framework, which typically produces worse outcomes than a coordinated approach to the two or three terms that matter most. The written leverage assessment also creates a board record of the strategic rationale for accepting specific terms &#8212; the same record that a Corwin-cleansed stockholder vote or a post-closing Delaware litigation will examine.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>A board that accepted below-market RTF terms because &#8216;that&#8217;s what the banker said was market&#8217; has accepted a worse outcome than it needed to. The CLO who wrote the leverage assessment, put the range of outcomes on paper, and helped the board evaluate which terms were worth trading away created the governance record that protects the decision in retrospect.</span></em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span>Build the MAC Definition That Matches the Scarcity Profile</span></strong></p><p><span>The MAC definition in a merger agreement is a long list of included and excluded conditions. For a scarce asset seller, the negotiation goal is to limit the MAC to events that specifically impair the fundamental value of the asset &#8212; not to broad business deterioration that the buyer knew about when it made the offer. The standard exclusions that scarce asset sellers should insist on: general economic and market conditions; conditions affecting the pharmaceutical industry generally; changes in the financial markets or interest rates; changes in law or regulation that apply to the industry generally; acts of God, natural disasters, or geopolitical events; and the announcement of the transaction itself (including any customer or employee reaction to the announcement). What the MAC should cover: a clinical hold by FDA specific to the program; a Complete Response Letter for a pending NDA/BLA; a material adverse finding in the clinical data that was not previously known; or the failure of a material regulatory milestone specifically identified in the merger agreement. A MAC this narrow gives the buyer only a regulatory failure walk right &#8212; not a market conditions walk right.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>An acquirer who walks from a scarce asset acquisition citing a MAC that the seller&#8217;s CLO could have negotiated away is an acquirer who found an exit the seller left open. Every MAC carve-out that the CLO closes is a walk-away option the buyer no longer has.</span></em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 3 NEAR-TERM</span></strong></p><p><strong><span>Get Specific Performance Into the Agreement for Every Scarce Asset Deal</span></strong></p><p><span>For any acquisition where the asset is genuinely irreplaceable &#8212; where the seller&#8217;s board has concluded that no comparable asset is available at any price &#8212; specific performance is the term that converts the RTF from a financial remedy into a genuine closing commitment. The specific performance right is the contractual right to seek a court injunction compelling the buyer to close, rather than electing to pay the RTF and walk. When specific performance is available with no MAC walk right and regulatory-only closing conditions, the buyer cannot exit except through a genuine regulatory failure. The procedure for including specific performance: ensure it is bilateral (both sides can seek it), available immediately upon satisfaction of closing conditions, and not contingent on the seller having waived the RTF as an alternative remedy. The most defensible structure gives the seller the choice between specific performance and the RTF &#8212; not one or the other.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>The reverse termination fee is the price of walking. Specific performance eliminates the option to walk. For a truly irreplaceable asset, those are different instruments protecting different interests. The seller who accepts the RTF alone has accepted a price on the buyer&#8217;s discretion to exit. The seller with specific performance has eliminated that discretion.</span></em></p><p><em><span data-color="#0000ff" style="color: rgb(0, 0, 255);">For interested practitioners, I have created a Scarce Asset Deal Term Negotiation Protocol and made it available on Gumroad (https://laroccaadvisory.gumroad.com). It contains six sections, designed to be completed in sequence before any deal term is proposed or accepted.</span></em></p><p style="text-align: center;"><em><span>&#8220;Asset scarcity has moved from a valuation concept to a deal terms concept. The premium is the number. The MAC definition, the RTF, and specific performance are where the leverage actually lives.&#8221;</span></em></p><p style="text-align: center;"></p><p><strong><span>ABOUT THE AUTHOR</span></strong></p><p><strong><span>John LaRocca </span></strong><span>is a pharma and biotech attorney with 26 years of</span></p><p><span> in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of </span><strong><span>LaRocca Advisory Group</span></strong><span>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</span></p><p><span>&#169; 2026 The GC Playbook | All rights reserved | Not for redistribution without permission</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!oIes!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!oIes!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!oIes!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!oIes!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!oIes!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!oIes!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/efd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1479365,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/216331632?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!oIes!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!oIes!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!oIes!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!oIes!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fefd11399-f18f-4d18-a517-fb3f7c020d39_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Carve-Out Is Now Central: Acquiring Programs from Major Pharma Integrations — the CLO's Playbook ]]></title><description><![CDATA[The carve-out opportunity is real. The legal complexity of executing it is specific.]]></description><link>https://www.thegcplaybook.law/p/the-carve-out-is-now-central-acquiring</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/the-carve-out-is-now-central-acquiring</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Wed, 16 Sep 2026 11:31:30 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!ngFk!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong><span>FROM THE EDITOR</span></strong></p><p><span>The five $10 billion-plus pharma acquisitions that closed in Q2 2026 are now in integration. Merck is integrating Terns. Biogen is integrating Apellis. Lilly is integrating Centessa. Each of those acquisitions absorbed companies with multiple programs, multiple CDMO relationships, multiple clinical teams, and multiple commercial commitments. Not everything acquired was intended to be kept. Not everything kept will be prioritized at the same level.</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p><span>This is the dynamic that creates the H2 2026 opportunity for PE-backed specialty pharma platforms and mid-market acquirers. The programs that go from &#8216;actively advancing&#8217; to &#8216;evaluating strategic options&#8217; in the acquirer&#8217;s next pipeline update are the assets that are available &#8212; not yet in a banker-run process, not yet repriced by a formal sale, and not yet competing against every other buyer who reads the same announcement at the same time. The bilateral conversation that happens three weeks before the process is formally launched is where PE pharma platforms build competitive advantage in this market.</span></p><p><span>Seventy-one percent of private equity firms are actively evaluating carve-out transactions in 2026. Fifty-seven percent of corporations are open to or actively exploring divestitures. PwC forecasts additional PE-led carve-outs from large pharma integrations in H2. The carve-out has moved from opportunistic to central as a deal sourcing strategy. What makes pharma carve-outs different from generic corporate carve-outs is the legal architecture &#8212; and that is where the CLO&#8217;s preparation determines whether the deal gets done on the right terms.</span></p><p><strong><span>The carve-out opportunity is real. The legal complexity of executing it is specific.</span></strong></p><p><em><span>&#8212; John LaRocca</span></em></p><p><span>Founding Editor | LaRocca Advisory Group</span></p><p><strong><span>The Carve-Out Is Now Central: Acquiring Programs from Major Pharma Integrations &#8212; the CLO&#8217;s Playbook</span></strong></p><p><strong><span>Why the Carve-Out Is Different in Pharma</span></strong></p><p><span>A non-pharma corporate carve-out separates a business unit from its parent &#8212; a division, a brand portfolio, a commercial franchise. The assets being carved out are primarily commercial: customer relationships, revenue streams, contracts, and employees. The legal work is primarily about separation &#8212; creating standalone versions of shared services, transitioning contracts, and ensuring the carved-out business can operate independently.</span></p><p><span>A pharma carve-out separates a development program from its parent. The assets being carved out are primarily regulatory and scientific: IND applications, clinical trial data, FDA meeting correspondence, CDMO relationships, manufacturing process documentation, and clinical team expertise. The legal work is not primarily about commercial separation. It is about regulatory transfer, data ownership, IP chain of title, and the manufacturing supply bridge that keeps the program operational through the transition.</span></p><p><strong><span>The CLO who approaches a pharma carve-out with a generic M&amp;A carve-out framework will miss the things that matter most.</span></strong><span> This article covers five legal domains that are specific to pharma carve-outs and absent from standard carve-out legal work.</span></p><p><strong><span>The Carve-Out Pipeline: Where to Look in H2 2026</span></strong></p><p><span>The specific programs to watch are not yet in public carve-out announcements. They are visible in the acquirers&#8217; pipeline prioritization language.</span></p><p><strong><span>Signals to Monitor</span></strong></p><p><span>&#8226; </span><strong><span>A program moves from &#8216;Phase X advancing&#8217; to &#8216;Phase X &#8212; under review&#8217; in the acquirer&#8217;s quarterly pipeline update</span></strong></p><p><span>&#8226; </span><strong><span>A therapeutic area is described as &#8216;not a strategic priority&#8217; or &#8216;outside the core focus&#8217; following the acquisition</span></strong></p><p><span>&#8226; </span><strong><span>The acquired company&#8217;s leadership in a specific area is described as &#8216;evaluating their next role&#8217; in press coverage</span></strong></p><p><span>&#8226; </span><strong><span>A clinical trial for an acquired program posts a status change to &#8216;suspended&#8217; or &#8216;terminated&#8217; on ClinicalTrials.gov</span></strong></p><p><span>&#8226; </span><strong><span>Business development contacts at the acquiring company begin responding to inquiries about specific programs that were previously described as internally prioritized</span></strong></p><p><span>These signals typically appear 60-180 days after a transaction closes. The Biogen/Apellis integration closed May 14. The Merck/Terns integration closed May 5. The Lilly/Centessa integration closed June 24. The 60-180 day window for visible deprioritization signals runs from July through December 2026. The PE platform whose business development team is monitoring these signals systematically has a structural sourcing advantage over the acquirer who responds to the banker&#8217;s call when the formal process launches.</span></p><p><strong><span>The Legal Architecture of a Pharma Carve-Out</span></strong></p><p><strong><span>Domain 1: Regulatory Asset Transfer</span></strong></p><p><strong><span>An IND cannot simply be assigned.</span></strong><span> The holder of an IND is the sponsor &#8212; the party responsible to FDA for the conduct of the clinical investigation. Transferring sponsorship requires written notification to FDA, FDA&#8217;s acknowledgment, and a period during which both the transferor and transferee are coordinating their respective FDA relationships. The acquirer must be ready to assume the sponsor responsibilities on Day 1 of the transfer: IND amendments, safety reporting, site correspondence, and protocol submissions.</span></p><p><span>The regulatory transfer due diligence must cover: the complete IND file and all amendments; every Type A, Type B, and Type C meeting summary; every clinical hold and company response; every DSMB/DMC report; and every study protocol submission and FDA response. These documents are the regulatory relationship with FDA. The acquirer who does not have them cannot manage that relationship.</span></p><p><span>NDA and BLA transfers, where the acquired program has reached regulatory submission, are more complex: FDA requires the prior holder to formally withdraw or relinquish the application and the new holder to file a new application or an amendment reflecting the change in applicant. The transition period &#8212; during which the product is technically marketed but the regulatory relationship is in transition &#8212; requires detailed coordination with FDA and is a CLO workstream that begins at signing, not at closing.</span></p><p><strong><span>Domain 2: IP Chain of Title</span></strong></p><p><span>The IP in a pharma carve-out has almost certainly been assigned, licensed, and amended multiple times before the carve-out. The compound may have originated at a university or research institution, been exclusively licensed to the target company, been sublicensed to a CDMO for manufacturing, and been the subject of a co-development agreement with a prior partner. Each layer of that chain must be traced and confirmed before the carve-out closes.</span></p><p><strong><span>The specific IP chain of title questions in a pharma carve-out:</span></strong></p><p><span>&#8226; Does the carve-out agreement transfer ownership of the compound IP, or just a license to use it? Ownership and exclusive license are not the same thing in a carve-out &#8212; the form of the transfer determines what the acquirer can do with the asset, including sublicensing, partnering, and enforcement.</span></p><p><span>&#8226; Are there upstream licenses from academic institutions, research collaborations, or prior development partners that encumber the transferred IP? Every upstream license survives the carve-out unless it is explicitly terminated or assigned. The acquirer inherits the obligations.</span></p><p><span>&#8226; Are there patent prosecution obligations &#8212; maintenance fees, continuation decisions, foreign filing deadlines &#8212; that are currently managed by the parent and must be transferred to the acquirer&#8217;s IP management systems with no gap?</span></p><p><span>&#8226; Are there co-inventors at universities or research institutions whose assignments were obtained at the time of the original invention disclosure, and have those assignments been maintained in the patent prosecution record?</span></p><p><span>&#8226; Does the parent retain any IP license-back rights post-carve-out &#8212; rights to use the transferred technology in the parent&#8217;s own programs? If so, those rights must be defined with precision in the carve-out agreement, because they determine the exclusivity of what the acquirer is buying.</span></p><p><strong><span>Domain 3: CDMO and Supply Agreement Transfer</span></strong></p><p><span>Every clinical-stage program has a CDMO providing drug substance and drug product for clinical supply. The CDMO agreement governs the relationship with the manufacturer who keeps the program operational. In a pharma carve-out, that CDMO agreement must be either assigned to the acquirer or a new agreement must be negotiated before closing.</span></p><p><strong><span>Change-of-control provisions in CDMO agreements are a very common source of post-closing operational disruption in pharma carve-outs.</span></strong><span> A CDMO agreement that permits the CDMO to terminate upon a change of control of the customer gives the CDMO leverage to renegotiate the pricing terms at the worst possible moment &#8212; when the carve-out has just closed and the acquirer has no alternative manufacturing relationship ready. The CLO&#8217;s pre-signing diligence must include a review of every CDMO agreement for change-of-control provisions, and the carve-out agreement must include a condition or covenant requiring the CDMO&#8217;s consent to the assignment before closing.</span></p><p><span>Section 232 tariff exposure adds a layer that did not exist before April 2026. A carve-out program whose API is sourced from a non-exempt country may carry ongoing tariff exposure that the acquirer is assuming. The HTSUS classification of the API and key starting materials must be completed before the carve-out diligence is finished, and the cost of goods model must reflect the tariff exposure at each pricing tier.</span></p><p><strong><span>Domain 4: Clinical Trial Transfer</span></strong></p><p><span>Active clinical trials in a carved-out program must continue without interruption through the carve-out process. The transition from one sponsor to another, managed incorrectly, can constitute a protocol deviation at every active site. Sites must be notified of the sponsor change; IRB/Ethics Committee approvals must be updated; site contracts must be novated or reassigned; and the safety reporting obligations must be continuous from the moment the transfer begins.</span></p><p><span>The transition services agreement (discussed below) must include explicit provisions for the period between signing and closing during which the program continues to be run by the parent company on behalf of the eventual acquirer. The clinical trial data must be transferred to the acquirer&#8217;s data management systems with full audit trail integrity. Any gap in the audit trail is a GxP data integrity issue.</span></p><p><strong><span>Domain 5: The Transition Services Agreement</span></strong></p><p><span>The Transition Services Agreement (TSA) is the contract that governs how the parent company continues to provide services to the carved-out program after closing, until the acquirer has stood up its own capabilities. In a generic corporate carve-out, TSA services are typically back-office: IT, HR, finance, payroll. In a pharma carve-out, the TSA services also include clinical and regulatory: clinical trial management, pharmacovigilance, regulatory affairs, CDMO relationship management, and quality management.</span></p><p><strong><span>The pharma TSA is vital and yet is the most commonly underbuilt document in a pharma carve-out.</span></strong><span> The specific risks: the TSA services are provided by the parent&#8217;s employees, who owe their primary employment obligation to the parent, not to the carved-out program; those employees will be transitioned, terminated, or reassigned on the parent&#8217;s timeline, not the acquirer&#8217;s; and the quality of the TSA services degrades as the parent&#8217;s integration proceeds and the employees who knew the carved-out program are absorbed into different roles. The CLO must negotiate TSA service levels (i.e., minimum staffing, minimum quality metrics, escalation procedures) and TSA duration terms that reflect the realistic time it takes to stand up independent clinical and regulatory operations.</span></p><p><strong><span>THE BILATERAL SOURCING ADVANTAGE</span></strong></p><p><span>The carve-out opportunity that produces the best acquisition economics is the one identified before the formal process is launched. A PE platform that approaches the acquiring company&#8217;s business development team, meaning not through a banker or through a public process, and expresses specific, knowledgeable interest in a specific deprioritized program before any formal sale decision has been made is the potential acquirer best positioned to negotiate bilateral terms. The complexity of separating a clinical-stage program from its parent tends to thin the field of potential buyers which is the entry pricing advantage the carve-out market provides. That advantage is largest before the process is formalized.</span></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">Build the Carve-Out Monitor and Start Running It</span></strong></p><p><span>The carve-out monitor is a systematic tracking system for the integration announcements, pipeline updates, and business development communications from the five largest Q2 2026 acquirers: Biogen, Merck, Lilly, Sanofi (Blueprint Medicines close), and Vertex (Crinetics acquisition). The monitor tracks: quarterly pipeline updates for each acquirer, with changes in program status flagged; ClinicalTrials.gov status changes for programs associated with the acquired companies; press coverage and business development team communications referencing the acquired pipeline; and any conference presentations by the acquired companies&#8217; scientific leadership post-close. The monitor runs on a biweekly cycle. Any signal that a program has moved from &#8216;actively advancing&#8217; to &#8216;under review&#8217; or &#8216;evaluating strategic options&#8217; triggers a business development outreach to the acquirer&#8217;s relevant team within two weeks. Two weeks is the window between when a deprioritization decision is internal and when a formal sale process is launched.</span></p><p><strong><span data-color="#ff0000" style="color: rgb(255, 0, 0);">BUSINESS IMPACT</span><span>: </span></strong><em><span>The PE platform that identifies a carve-out opportunity before the banker is engaged negotiates bilaterally. The PE platform that responds to the banker&#8217;s call negotiates in an auction. These are different markets, at different prices, with different CLO workstreams.</span></em></p><p><strong><span data-color="#ff9900" style="color: rgb(255, 153, 0);">WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span data-color="#ff9900" style="color: rgb(255, 153, 0);">Build the Pharma Carve-Out Diligence Protocol</span></strong></p><p><span>The standard M&amp;A diligence protocol does not cover the five pharma-specific domains identified in this article: regulatory asset transfer, IP chain of title in a layered licensing structure, CDMO change-of-control provisions, clinical trial transfer continuity, and TSA adequacy. Build the pharma carve-out diligence protocol as a standing document &#8212; a checklist of the 40-50 diligence items specific to a clinical-stage program carve-out &#8212; before the specific deal is identified. When the carve-out opportunity surfaces, the protocol is ready to deploy in days, not weeks. The protocol should be built with the same expertise structure as the speculative asset diligence protocol described in the August 2026 GC Playbook analysis: regulatory affairs counsel for the IND transfer assessment, CMC subject matter experts for the CDMO and manufacturing questions, clinical operations expertise for the trial transfer, and IP chain of title specialists for the licensing structure review.</span></p><p><strong><span data-color="#ff9900" style="color: rgb(255, 153, 0);">BUSINESS IMPACT</span><span>: </span></strong><em><span>A PE platform that deploys a complete pharma carve-out diligence protocol in three weeks signals to the seller that it knows what it is buying. A platform that spends six weeks discovering the legal architecture of the carve-out signals that it does not. Sellers reward speed and expertise with fewer conditions and better terms.</span></em></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">WORKSTREAM 3 STRATEGIC</span></strong></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">Negotiate the TSA Before Closing, Not After</span></strong></p><p><span>The TSA negotiation is the most consequential part of a pharma carve-out that most buyers treat as an afterthought. The parent company&#8217;s incentive in the TSA is to provide services for the shortest possible time at the minimum service level required to avoid breach. The buyer&#8217;s need is for clinical and regulatory continuity until it has built the independent capability to manage the program without the parent. Those incentives do not align, and the TSA is where the gap shows up. Negotiate the TSA as a primary document alongside the carve-out agreement, not as a schedule to be finalized after signing. Specific terms to insist on: named key personnel for each TSA service (not just &#8216;qualified personnel&#8217;); minimum quality metrics for clinical trial management and pharmacovigila</span></p><p><span>nce; a notification requirement if any named key person changes their role or employment status; and a right to step in and assume TSA services directly if the parent fails to meet service level requirements within a defined cure period. The TSA duration should reflect the realistic buildup timeline, which for clinical and regulatory operations is 12-18 months, not 6.</span></p><p><strong><span data-color="#6aa84f" style="color: rgb(106, 168, 79);">BUSINESS IMPACT</span><span>: </span></strong><em><span>A TSA that expires before the acquirer has built its own clinical operations capability leaves the program without sponsor management at the worst possible time. That gap produces protocol deviations at active clinical sites, potential FDA findings, and recruiting pressure as the parent&#8217;s employees who were managing the program are no longer available.</span></em></p><p style="text-align: center;"><em><span>&#8220;The carve-out opportunity in H2 2026 is real, and the PE platform that has built the carve-out monitor and the diligence protocol before the specific opportunity surfaces will close the bilateral deal that everyone else bids on in an auction.&#8221;</span></em></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!ngFk!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!ngFk!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!ngFk!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/f957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:830074,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/215267185?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!ngFk!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ngFk!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff957f7fe-626c-4f1f-b08a-b17868790d82_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[Before the Offer Arrives: The CLO's Corporate Governance Protocol for a Company in the M&A Market]]></title><description><![CDATA[The board that was ready before the offer arrived negotiates the deal. The board that was not negotiates its governance.]]></description><link>https://www.thegcplaybook.law/p/before-the-offer-arrives-the-clos</link><guid isPermaLink="false">https://www.thegcplaybook.law/p/before-the-offer-arrives-the-clos</guid><dc:creator><![CDATA[John LaRocca]]></dc:creator><pubDate>Sun, 13 Sep 2026 11:31:15 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!wFfa!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><strong><span>FROM THE EDITOR</span></strong></p><p><span>On June 15, 2026, the Delaware Court of Chancery issued the first decision interpreting the 2024 amendments to DGCL Section 144 &#8212; the statute governing conflicted transactions and special committee procedural safeguards. The decision, Ayers v. Fidelity National Financial, gave boards greater certainty that incidental and immaterial director relationships will not undermine an otherwise careful and independent process. That clarity is useful. What the decision also confirms is that the foundation of M&amp;A governance in Delaware remains what it has always been: the board that has done its preparation before the offer arrives is the board that manages the process on its own terms.</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p><span>Most biotech and specialty pharma boards have not done that preparation. The 2026 M&amp;A market &#8212; $130 billion in H1, five $10 billion-plus transactions in Q2, an IPO window that has made the dual-track a genuine alternative &#8212; has created conditions in which an unsolicited acquisition approach can arrive without warning for any company in the relevant therapeutic categories. The board that receives that approach without a governance framework in place is improvising its fiduciary duties in real time, under time pressure, against a counterparty whose deal team has been preparing for weeks.</span></p><p><span>The CLO&#8217;s role in board governance is more than corporate secretary and minute-taker. The CLO is the person who builds the framework that the board relies on when the pressure arrives. This article covers what that framework looks like &#8212; before any offer comes in, before any investment banker is engaged, and before any special committee is formed.</span></p><p><strong><span>The board that was ready before the offer arrived negotiates the deal. The board that was not negotiates its governance.</span></strong></p><p><em><span>&#8212; John LaRocca</span></em></p><p><span>Founding Editor | LaRocca Advisory Group</span></p><p></p><p><strong><span>Before the Offer Arrives: The CLO&#8217;s Corporate Governance Protocol for a Company in the M&amp;A Market</span></strong></p><p></p><p><strong><span>The Delaware Framework: What the Board Owes and When</span></strong></p><p><span>Delaware corporate law governs the fiduciary obligations of directors at the overwhelming majority of publicly traded pharma and biotech companies. Understanding the framework is the CLO&#8217;s prerequisite for advising the board &#8212; not as a legal tutorial, but as the practical map of what conduct is required, what conduct is protected, and what conduct creates exposure.</span></p><p><strong><span>Business Judgment Rule</span></strong></p><p><span>Most board decisions in M&amp;A receive Business Judgment Rule (BJR) deference from Delaware courts: the court presumes the directors acted on an informed basis, in good faith, and in the honest belief that the action was in the best interest of the company. To receive BJR protection, the board must be: disinterested (no material financial interest in the transaction outcome), independent (no material relationship with a person who has a material interest), and informed (the directors reviewed material information reasonably available to them). A fully informed, uncoerced vote of a majority of disinterested shareholders approving the transaction extends BJR deference under the Corwin doctrine even where process questions exist.</span></p><p><strong><span>Entire Fairness</span></strong></p><p><span>When the transaction involves a controlling stockholder on both sides, or when a majority of the board is interested or not independent, the court applies the Entire Fairness standard &#8212; the most demanding standard in Delaware corporate law. To satisfy Entire Fairness, the board must demonstrate both fair dealing (a fair process) and fair price. The MFW framework &#8212; named for the Delaware Supreme Court&#8217;s 2014 Kahn v. M&amp;F Worldwide decision &#8212; allows a controlling stockholder transaction to receive BJR review if it is conditioned from the outset on both independent special committee approval and a majority-of-the-minority shareholder vote. The June 2026 DGCL Section 144 amendments codified and clarified this framework.</span></p><p><strong><span>The June 2026 Section 144 Decision: What Changed</span></strong></p><p><span>The June 15, 2026 Ayers decision interpreted the 2024 DGCL Section 144 amendments for the first time. The Delaware Court of Chancery confirmed that the amendments provide greater certainty for disinterested boards invoking the business judgment rule and for navigating conflicted transactions through special committees. Specifically: incidental and immaterial director relationships &#8212; the kinds of relationships that plaintiff&#8217;s counsel had used to challenge director independence in prior cases &#8212; will not automatically disqualify a director from participating in a special committee. The test remains materiality. The decision clears procedural uncertainty that had accumulated around director independence challenges and strengthens the defensive value of a well-designed special committee.</span></p><p><span>What the decision does not change: the foundational obligation to run a process that is independent, informed, and genuinely focused on maximizing stockholder value. Procedural fortification substitutes for none of that.</span></p><p><strong><span>The Special Committee: Design Before You Need It</span></strong></p><p><span>The single most consequential governance decision in a change-of-control transaction is whether to form a special committee, and if so, how to design it. Most boards make this decision under time pressure, after an offer has arrived. The CLO should have the design framework ready before any offer exists.</span></p><p><strong><span>When to Form a Special Committee</span></strong></p><p><span>A special committee is warranted whenever a majority of the full board cannot be considered disinterested and independent with respect to the transaction &#8212; because of their relationship with the potential acquirer, because of their equity interests in the transaction outcome, or because of any other material interest that distinguishes them from a disinterested stockholder. A special committee is also warranted in controlling stockholder situations even where the full board is disinterested, because the MFW framework requires it to achieve BJR review. Outside those clear cases, forming a special committee in a transaction where the full board is disinterested and independent can be a defensive choice &#8212; the clarity of a defined committee with an explicit mandate and independent advisors is more defensible than a full board process if the transaction is later challenged.</span></p><p><strong><span>A common CLO mistake: waiting to assess whether a special committee is needed until after the offer arrives.</span></strong><span> By the time the offer is on the table, the board is operating under information that may be material and non-public, time pressure from the counterparty, and the need to respond without appearing to ignore its fiduciary duties. The pre-M&amp;A readiness protocol should include a written director independence assessment, updated annually, that identifies which directors would be disinterested and independent in a hypothetical change-of-control transaction. That document is the starting point for the special committee design when an offer arrives.</span></p><p><strong><span>Who Sits on the Special Committee</span></strong></p><p><span>Special committee members must be independent &#8212; they cannot have a material relationship with the counterparty, with management who would benefit from the transaction, or with any other party whose interests diverge from those of the disinterested stockholders. Post-Section 144, incidental relationships are not disqualifying. Material ones are. The committee should have at least two members, and three is better &#8212; not for voting mechanics, but because a two-person committee whose members disagree produces a governance impasse at the worst possible time.</span></p><p><span>The committee members should have, between them, the expertise to evaluate the transaction substantively &#8212; M&amp;A experience, familiarity with the therapeutic area, and the financial sophistication to engage meaningfully with the fairness opinion. A committee whose members have no independent view of the transaction&#8217;s merits is a committee that is entirely dependent on its advisors, which is a weaker governance structure than one that can interrogate the advisors&#8217; work.</span></p><p><strong><span>The Committee&#8217;s Mandate and Authority</span></strong></p><p><span>The special committee&#8217;s mandate &#8212; the resolution establishing it &#8212; must give it full board authority to negotiate, reject, and recommend on the transaction. A committee that can only recommend and not negotiate is a process committee, not a decision committee, and Delaware courts have given less deference to process committees whose authority was constrained. The mandate should also give the committee the authority to retain its own independent legal and financial advisors &#8212; separate from those serving management or the full board &#8212; and to have those advisors report directly to the committee, not through management.</span></p><p><strong><span>The Fairness Opinion</span></strong></p><p><span>The fairness opinion &#8212; an investment bank&#8217;s opinion that the consideration offered is fair, from a financial point of view, to the company&#8217;s unaffiliated stockholders &#8212; is a standard element of M&amp;A governance in pharmaceutical and biotech transactions. It addresses the duty of care element of the board&#8217;s analysis by providing expert support for the price determination. The CLO should understand what a fairness opinion does and does not do: it opines on financial fairness, not on whether the transaction is the best strategic outcome for the company, not on whether a higher price was available, and not on whether the process was adequate. The board&#8217;s process is separate from the fairness opinion.</span></p><p><strong><span>The CLO&#8217;s Pre-M&amp;A Board Governance Checklist</span></strong></p><p><span>The following checklist should be completed and updated annually, regardless of whether any acquisition discussion is underway. Its purpose: to ensure the board is prepared to respond to an unsolicited approach with a governance framework already in place rather than being constructed in real time.</span></p><p><strong><span>Director Independence Assessment</span></strong></p><p><span>&#8226; Current mapping of every director&#8217;s relationships with potential acquirers (strategic and PE) in the company&#8217;s relevant therapeutic category</span></p><p><span>&#8226; Documentation of all director equity holdings, including unvested equity that would accelerate on a change of control</span></p><p><span>&#8226; Documentation of all director relationships with management, including compensation committee members&#8217; roles in setting executive compensation</span></p><p><span>&#8226; Identification of the two or three directors who would be disinterested and independent in any transaction with any plausible acquirer &#8212; the pre-selected special committee pool</span></p><p><span>&#8226; Annual update of this assessment, with the CLO signing off on the independence conclusions</span></p><p><strong><span>Board Education on Fiduciary Duties in M&amp;A</span></strong></p><p><span>&#8226; Annual board session &#8212; separate from ordinary board meeting &#8212; on Delaware M&amp;A fiduciary duty framework: Business Judgment Rule, Entire Fairness, Corwin, MFW, and the Section 144 DGCL amendments</span></p><p><span>&#8226; Board materials explaining what happens when an unsolicited offer arrives: who the offer goes to, who is notified, what the timeline looks like, and what the board&#8217;s obligations are in the first 24-48 hours</span></p><p><span>&#8226; Written policy on how the board handles preliminary inquiries: who can communicate with potential acquirers, what can be said, and when the full board must be convened</span></p><p><span>&#8226; Director education on Regulation FD and insider trading obligations in the M&amp;A context &#8212; who is in the information barrier and from what point</span></p><p><strong><span>D&amp;O Insurance Adequacy Review</span></strong></p><p><span>&#8226; Annual review of D&amp;O policy limits against the transaction sizes at which the company could realistically be acquired &#8212; the policy that was adequate at a $200 million market cap is inadequate at $2 billion</span></p><p><span>&#8226; Confirmation that the D&amp;O policy includes run-off coverage (the &#8216;tail&#8217;) that protects directors post-closing for pre-closing acts &#8212; standard in acquisition transactions but must be confirmed and sized correctly</span></p><p><span>&#8226; Identification of the exclusions that would limit coverage in a challenged transaction &#8212; including the conduct exclusion (intentional wrongdoing), the insured-versus-insured exclusion, and any M&amp;A-specific exclusions</span></p><p><span>&#8226; Understanding of the policy&#8217;s treatment of derivative claims versus direct claims &#8212; derivative claims typically require shareholder demand, direct claims do not</span></p><p><strong><span>Books and Records Readiness</span></strong></p><p><span>&#8226; Board minutes current and complete &#8212; the minutes of every meeting at which the company&#8217;s strategic direction, M&amp;A activity, or any unsolicited inquiry was discussed are the evidentiary record of the board&#8217;s process</span></p><p><span>&#8226; Written record of any prior discussions with investment bankers about the company&#8217;s strategic alternatives, including any informal discussions</span></p><p><span>&#8226; Retention policy for board materials current and confirmed &#8212; board packages, presentations, and supporting materials must be preserved and retrievable</span></p><p><strong><span>THE AUGUST 2026 PBC DECISION: A NOTE FOR LIFE SCIENCES COMPANIES WITH DUAL MISSIONS</span></strong></p><p><span>On July 29, 2026, the Delaware Court of Chancery issued the first decision addressing PBC (public benefit corporation) director fiduciary duties in a change-of-control transaction. The court confirmed that PBC directors must balance the interests of stockholders, other stakeholders, and the company&#8217;s public benefit &#8212; but found that this balance does not require PBC directors to prioritize the benefit mission over stockholder value in a change-of-control context. The decision is significant for the growing number of life sciences companies that have adopted PBC status, many of which are in the rare disease and global health space. CLOs at PBC biotech companies should review the decision and confirm that board education on fiduciary duties reflects the PBC&#8217;s specific statutory framework under DGCL Section 365.</span></p><p><strong><span>WORKSTREAM 1 IMMEDIATE</span></strong></p><p><strong><span>Conduct the Director Independence Assessment and Document It</span></strong></p><p><span>The director independence assessment is the governance foundation for every other element of M&amp;A readiness. Without it, the CLO cannot answer the basic question that determines the entire process architecture: who on this board could sit on a special committee in a transaction with Acquirer X? The assessment must be current &#8212; meaning updated within the last 12 months &#8212; and must cover the full universe of plausible acquirers, not just the ones currently in deal discussions. For a specialty pharma company in cardiovascular disease, the plausible acquirer universe includes every large cap pharma with a CVD gap, every PE fund with a cardiovascular platform, and every China-origin licensor with U.S. commercialization ambitions. Map each director against each plausible acquirer category. Document the independence conclusion for each. Sign off on the document as CLO. Put it in the board file with a date. Update it annually.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>An offer arrives on a Tuesday morning. The board chair calls the CLO before calling anyone else. The CLO&#8217;s first answer needs to be: here are the three directors who are disinterested and independent for purposes of a special committee. Without the assessment, that answer requires legal analysis under time pressure that produces worse results than analysis done in advance.</span></em></p><p><strong><span>WORKSTREAM 2 NEAR-TERM</span></strong></p><p><strong><span>Run the Annual Board Fiduciary Duty Education Session</span></strong></p><p><span>The annual board fiduciary duty session is not a compliance exercise. It is the CLO&#8217;s investment in the board&#8217;s ability to function correctly under pressure. A board that has never discussed what happens when an unsolicited offer arrives will make procedural mistakes in the first 48 hours &#8212; communicating selectively with the counterparty in ways that create Reg FD exposure, discussing the offer in a setting that is not a properly convened board meeting, or taking actions that appear responsive to the offer before a governance structure is in place. The session should cover: the Business Judgment Rule and what is required to maintain it; the Corwin doctrine and why the shareholder vote matters for litigation purposes; the special committee design questions and what the committee needs to function properly; Reg FD obligations from the moment material non-public information is shared; and the director&#8217;s personal D&amp;O insurance protection and its limits. The session should be conducted by the CLO with outside M&amp;A counsel presenting. It should be minuted. It should occur in the fall of each year &#8212; before the JPMorgan Healthcare Conference in January, when deal discussions that have been developing since Q3 often surface publicly.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>A board that has never discussed its M&amp;A fiduciary duties before a specific transaction arises will discuss them for the first time under time pressure, with a potential counterparty waiting for a response. The board that has done the education advances the deal on its own terms.</span></em></p><p><strong><span>WORKSTREAM 3 NEAR-TERM</span></strong></p><p><strong><span>Review and Right-Size the D&amp;O Insurance Program</span></strong></p><p><span>The D&amp;O insurance adequacy review is the governance workstream most commonly deferred until after the transaction is already in process &#8212; which is too late. The specific questions for the annual review: What are the current policy limits, and do they reflect the company&#8217;s current market cap and the transaction sizes at which it could realistically be acquired? Does the policy include D&amp;O run-off coverage (the tail policy) that protects directors post-closing for pre-closing acts, and is the tail period adequate? Most tail policies run three to six years. For a transaction that results in securities litigation, three years may not be enough. What are the policy&#8217;s primary exclusions, and are there M&amp;A-specific exclusions that would limit coverage in a transaction that is later challenged? The CLO should review the D&amp;O policy with the company&#8217;s insurance broker annually, not just at renewal. The broker sees what is happening in the D&amp;O market; the CLO brings the governance context.</span></p><p><strong><span>BUSINESS IMPACT: </span></strong><em><span>A director who serves on a special committee in a transaction that is later challenged in Delaware Court of Chancery is a defendant in that litigation regardless of the merits. The D&amp;O policy is their defense fund. An inadequate policy at the time the claim arises is not a problem that can be fixed retroactively.</span></em></p><p style="text-align: center;"><em><span>&#8220;The board that was ready before the offer arrived negotiates the deal. The board that was not negotiates its governance.&#8221;</span></em></p><p style="text-align: center;"><strong><span>THE GC PLAYBOOK &#8212; COMING NEXT</span></strong></p><p style="text-align: center;"><strong><span>PE Pharma Playbook</span></strong></p><p style="text-align: center;"><em><span>The Carve-Out Is Now Central: Acquiring Programs from Major Pharma Integrations</span></em></p><p style="text-align: center;"><strong><span>laroccaj.substack.com | Subscribe: $40/month or $400/year</span></strong></p><p><strong><span>ABOUT THE AUTHOR</span></strong></p><p><strong><span>John LaRocca </span></strong><span>is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of </span><strong><span>LaRocca Advisory Group</span></strong><span>, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.</span></p><p style="text-align: center;"><span>&#169; 2026 The GC Playbook | All rights reserved | Not for redistribution without permission</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!wFfa!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!wFfa!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!wFfa!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg" width="1456" height="1768" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1768,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1030731,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://laroccaj.substack.com/i/215261433?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!wFfa!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 424w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 848w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!wFfa!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9876ab24-0b53-49aa-b107-3ff03b807183_1856x2254.jpeg 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p style="text-align: center;"></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.thegcplaybook.law/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">The GC Playbook is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item></channel></rss>